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Chapter 1 
1 General introduction 
 
1.1 Transport across cell membranes 
Every cell is enclosed by a selectively permeable membrane to guarantee the homeostasis 
of essential cellular constituents depending on the requirements and functions of the 
respective cell type. In addition to its physiological function, biological membranes are an 
effective barrier for xenobiotics. Consequently, the ability to pass these membranes is 
essential for the efficacy of administered therapeutic agents (Rees et al., 2009). The 
majority of drugs are small, lipophilic and often planar molecules that predominantly enter 
cells via passive diffusion (Higgins, 2007). In order to estimate the passive permeability 
(and solubility) of a given compound considering its physico-chemical properties, empirical 
guidelines have been established (Lipinski et al., 2001). 
Despite the indisputable significance of passive diffusion for the absorption and distribution 
of orally administered drugs, it must not be forgotten that there is a vast number of 
alternative routes (Mehdipour and Hamidi, 2009). Endogenous macromolecules such as 
peptides and proteins are shuttled via absorptive-mediated transcytosis (e.g. albumin, 
histones) and receptor-mediated transport (e.g. transferrin, insulin) across cell 
membranes. Inorganic ions as well as charged (e.g. amino acids) and uncharged (e.g. 
sugars) polar compounds rely on selective membrane transport proteins to enter and leave 
cells. In E. coli, approximately 10 % of the total genome encodes for membrane proteins 
like ion channels, carriers and ATP-powered pumps (Blattner et al., 1997). These proteins 
enable cells to maintain the exact conditions needed to fulfill diverse functions such as the 
generation of energy, the processing of information or the storage of nutrients. It has been 
suggested that the uptake (and the excretion) of drugs by membrane transport proteins is 
a common rule rather than an exception (Dobson and Kell, 2008). Indeed, for a substantial 
number of drugs, the ability to cross cell membranes cannot satisfactorily be explained by 
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passive diffusion. Whereas solute carriers (SLC) enhance uptake, efflux is mediated by 
members of the ABC transporter superfamily. 
 
1.2 ATP-binding cassette (ABC) transporters 
ABC transporters belong to one of the four classes of ATP-powered transport proteins that 
use the energy of ATP hydrolysis to translocate various compounds against their 
concentration gradients across cell membranes (Lodish et al., 2003). Substrates of 
representatives of the other classes (V-, F- and P-class (e.g. the Na+/K+ ATPase, the 
H+/K+ ATPase and the Ca2+ ATPase) pumps) are invariably inorganic ions. In contrast, 
members of the ABC transporter superfamily are capable to transport structurally diverse 
substrates such as amino acids, lipids, polypeptides and small hydrophobic molecules 
(Higgins, 2007). They are named after their characteristic, highly conserved intracellular 
ATP-binding cassette domains and are distributed ubiquitously over all species (and cells). 
The human genome encodes 48 different ABC transporters. Depending on their sequence, 
they were categorized by the HUGO Gene Nomenclature Committee into seven 
subfamilies termed A - G. The functional unit consists of four distinctive domains: two 
transmembrane domains (TMDs), containing 6 alpha helices each, and two intracellular 
nucleotide binding domains (NBDs). Detailed information regarding the structural 
organization and the mechanism of transport is presented in chapter 7. While individual 
members of the various subfamilies are specific for a certain substrate (e.g. ABCB4 for 
phosphatidyl choline), some expel a broad variety of hydrophobic compounds (see below). 
Furthermore, dysfunctions of particular transporters are associated with diseases such as 
cystic fibrosis, Dubin-Johnson syndrome, adrenoleukodystrophy et cetera (Higgins and 
Linton, 2001). 
More important with regard to pharmacological aspects are a number of multispecific efflux 
pumps. These ABC transporters greatly influence the absorption, distribution (e.g. across 
the blood-brain barrier, BBB), excretion and the toxicity of many commonly prescribed 
drugs (Ecker et al., 2008; Szakacs et al., 2008). Additionally, approximately one third of all 
malignancies in the periphery develop resistance against various chemotherapeutic agents 
(MDR, multidrug resistance) due to the (over)expression of ABC transporters (Gillet and 
Gottesman, 2010; Mellor and Callaghan, 2008). The significance of multidrug transporters 
in this field as well as the therapeutic approach to improve cancer chemotherapy by 
inhibition of these efflux pumps is discussed in chapter 5. 
Beyond the three most important transporters listed in Table 1.1, ABCB11 and ABCC2-5 
(MRP2-5) also influence drug distribution and resistance. The role in protecting the 
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organism against xenobiotics is underlined by the fact that these transporters are 
preferentially expressed in excretory organs as liver (Chandra and Brouwer, 2004) or 
kidney (Thiebaut et al., 1987) and at important pharmacological barriers. The presence of 
ABCB1/ABCG2 at the brush border membrane of intestinal cells limits the oral bio-
availability of drugs that are substrates of the respective transporters. This has been 
shown for paclitaxel and topotecan in experiments with Abcb1a/b double knockout mice or 
by concomitant application of the ABCB1/ABCG2 modulator elacridar (Breedveld et al., 
2006; Koolen et al., 2010). During lactation, in particular BCRP plays an important role in 
the excretion of xenobiotics into the milk (Jonker et al., 2005). In contrast, due to its high 
expression at the placenta, BCRP protects the fetus against potential harmful compounds 
present in the general circulation (Maliepaard et al., 2001; van Herwaarden and Schinkel, 
2006). 
Table 1.1: Overview of the most important ABC transporters at the blood-brain barrier and with 
regard to multidrug resistance in cancera 
Gene 
term  
Protein name 
(abbreviations; 
synonyms) 
Substrates Modulators / inhibitors 
ABCB1  
Multidrug Resistance 
Protein 1 
(MDR1; P-gp; 
P-glycoprotein) 
taxanes, epi-
podophyllotoxines 
vinca alkaloids, 
anthracyclines 
verapamil, cyclosporin, 
valspodar, 
elacridar, tariquidar 
ABCC1  
Multidrug Resistance 
Associated Protein 1 
(MRP1) 
doxorubicin, 
folic acid 
quinidine, 
tricyclic isooxazoles 
ABCG2  
Breast Cancer 
Resistance Protein 
(BCRP; Mitoxantrone 
Resistance Protein, 
MXR) 
mitoxantrone, 
methotrexate, 
topotecan 
fumitremorgin C, 
Ko143, 
elacridar, ME22-1 
a Common synonyms are listed in parentheses. With modifications according to Szakacs et al. 
(2006) 
Since many substrates are toxic natural products from plants and microorganisms (or 
derivatives thereof), the presence of such transporters is an essential evolutionary 
advantage that could explain the above mentioned ubiquitous distribution (Higgins, 2007). 
Due to its morphological properties, the high level of P-glycoprotein expression and the 
presence of multiple other efflux transporters, the blood-brain barrier is presumably the 
most important pharmacological barrier (Cooray et al., 2002; Dombrowski et al., 2001). 
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1.3 The blood-brain barrier and malignant brain tumors 
The BBB is formed by the endothelial cells of brain capillary microvessels. These vessels 
are estimated to have the substantial length of 600 km (and a surface area of 
approximately 20 m2) to meet the immense demand of the brain with regard to oxygen, 
glucose and other nutrients (Pardridge, 2003). 
By contrast, the CNS has to be protected from immunological risks (bacteria, viruses), 
endogenous constituents (that may disturb neuronal signal transmission; e.g. epinephrine, 
potassium) and potential harmful xenobiotics present in the general circulation. In order to 
fulfill this function, brain capillaries show, opposite to vessels of the periphery, some 
distinct characteristics such as low pinocytic activity, an additional basal membrane as well 
as a 90 % coverage with astrocyte end feet (Deeken and Löscher, 2007). While all these 
factors limit transcellular permeation, the lacking fenestration and, especially the formation 
of tight junctions, restrict paracellular transport (Rubin and Staddon, 1999). 
Additionally, the entry of pharmacologically active compounds into brain tissue is severely 
limited due to the expression of ABC transporters. The main subject of the present work, 
P-glycoprotein, is the most prominent member of these efflux pumps. The high transport 
capacity and the broad substrate specifity make it the major obstacle for drug delivery into 
the brain (Miller et al., 2008). 
Due to their physico-chemical properties, highly hydrophobic agents should be able to 
cross the BBB. However, the recognition by P-gp is responsible for the efflux back into the 
blood circulation. This problem severely limits the treatment options of CNS disorders. 
Since many substrates of P-glycoprotein are integral parts of most chemotherapeutic 
regimens (Szakacs et al., 2006), in particular the treatment of CNS malignancies is 
affected. 
Malignancies of the brain can be categorized into primary and secondary tumors. While 
secondary tumors are metastases originating from malignant tumors outside the CNS, 
primary tumors descend from brain tissue. The majority (approximately 80 % in adult 
patients) of the latter arises from the supportive tissue of the brain (the glial cells) and is 
subsumed under the term gliomas. Within this heterogeneous group of neoplasm, 80 % 
are astrocytomas (malignant forms of astrocytes). According to histological characteristics 
of malignancy, the World Health Organization (WHO) categorizes astrocytomas into four 
grades (Louis et al., 2007). 
High-grade gliomas (WHO grades III/IV) and especially glioblastomas have an unfavorable 
prognosis due to the high risk of tumor recurrence (Hou et al., 2006). The median survival 
time of patients under maximal treatment is estimated to be between 12 and 18 month. A 
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multidisciplinary treatment approach is recommended comprising maximal feasible tumor 
resection, postoperative external-beam radiotherapy and multimodal chemotherapy 
(Mason et al., 2007). In particular, alkylating agents (see Figure 1.1) that are no substrates 
of P-glycoprotein and therefore reach adequate concentrations in brain tissue are in use 
(Fadul et al., 2008). Combination of the p.o. bioavailable temozolomide with radiotherapy 
is the best treatment currently available (Stupp et al., 2005). Nevertheless, the median 
survival time of 14.6 month after prognosis is still disillusioning. 
 
 
Figure 1.1: Chemical structures of chemotherapeutic agents used in the therapy of malignant (or 
high-grade) gliomas. 
As discussed above, the efficacy of many otherwise active anticancer agents (e.g. 
paclitaxel) is severely restricted because they are substrates of the ABCB1 transporter. 
Consequently, the inhibition of P-glycoprotein by selective modulators is an attractive 
strategy to improve the limited therapeutic options in both, the treatment of malignant 
gliomas and multidrug resistant tumors in the periphery. Intense research efforts over the 
past decades yielded potent ABCB1 modulators such as tariquidar (cf. Figure 2.1) with 
superior characteristics compared to previous generations of inhibitors (Lee, 2010). The 
investigation of the therapeutic potential of new tariquidar-like modulators in preclinical 
in vivo tumor models is the central part of this thesis. 
 
1.4 In vitro screening assays to determine ABC transporter 
interactions 
Considering the enormous impact of ABC transporters on the items discussed in the 
previous sections, reliable in vitro test systems for the screening of potential substrates 
and inhibitors are indispensable. Beside the identification of potent inhibitors of ABC 
transporters, such assays are of general interest for the evaluation of new lead structures 
at early stages of the drug development process since ABC transporters can be 
considered as off-targets (anti-targets). 
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The in vitro models can be categorized into two main classes, cell based and 
membrane/protein-based test systems. Assays of the first class use cells (preferentially 
mammalian, but also bacterial, insect cells etc.) expressing the respective transporter due 
to the exposure to cytostatic agents or the transfection with the gene(s) of interest. Protein-
based test systems normally utilize membranes prepared from that kind of cells. 
Additionally, models using isolated organs are described. 
As measuring vesicular transport (Szakacs et al., 2008) and micro-pH (Landwojtowicz et 
al., 2002) are of no or of minor relevance for P-glycoprotein, these methods are only 
mentioned and not considered in detail. The subsequent discussion of the most important 
assays to examine drug interactions with ABC transporters is essentially based on the 
following literature: Szakacs et al. (2008), Varma et al. (2003) and Xia et al. (2007). 
 
1.4.1 ATPase activity assays 
According to Callaghan et al. (2006), the complex translocation process of P-glycoprotein 
(and other ABC transporters) comprises four distinct stages: the loading of P-gp with 
substrate and nucleotide (1), reorientation of TMDs combined with the transition of the 
binding site from the high to the low affinity state (2), release of substrate followed by the 
hydrolysis of ATP (3) and the resetting of TMDs (4). The energy to power the vast 
conformational changes required for substrate transport (cf. chapter 7) is provided by the 
hydrolysis of the nucleotide. The correlation between ATPase activity and transport 
function allows the characterization of substrates or modulators by quantifying the release 
of phosphate/ADP or the amount of ATP. The liberation of inorganic phosphate can easily 
be monitored by a simple colorimetric reaction using ammonium molybdate (Polli et al., 
2001). In contrast, the quantification of nucleotides requires more elaborate methods such 
as luciferase-mediated bioluminescence, ion-exchange HPLC or ion-pairing reverse phase 
HPLC (Meyer et al., 1999; Varma et al., 2003). 
The assay is usually performed with membranes prepared from cells expressing the 
respective transporter (cultured cells are also suitable). In order to eliminate the effect of 
mitochondrial and Ca2+ ATPases, sodium azide and ethylene glycol tetraacetic acid 
(EGTA) are included in the assay systems. After one cycle of ATP-hydrolysis, released 
phosphate is replaced by inorganic vanadate (Vi) and the resulting complex traps the 
investigated ABC transporter in an intermediate state. Consequently, the difference in the 
amount of ATP consumed (or phosphate released) in the presence or absence of Vi 
represents ABC transporter-mediated ATPase activity (Xia et al., 2007). 
Normally, the addition of substrates increases the extent of ATP hydrolysis, whereas 
modulators (inhibitors or slowly transported compounds) decrease substrate stimulated 
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ATPase activity. Constitutive ATPase activity, most likely caused by the transportation of 
endogenous substrates (e.g. membrane lipids), is characteristic for most ABC transporters. 
Consequently, false negative results are possible for substrates (e.g. reported for 
vincristine, colchicine or digoxin) that do not further stimulate ATP hydrolysis (Litman et al., 
1997; Schwab et al., 2003). Additionally, the basal ATPase activity can be influenced by 
the composition of the utilized membrane and the experimental set-up (Telbisz et al., 
2007). A further limitation is the low reproducibility (high inter-day variability). In contrast, 
the utilized membranes are easily prepared and maintained (or even commercially 
available). Combined with a compound independent, practicable colorimetric 
quantification, the assay is suitable for high throughput screening. 
 
1.4.2 Photoaffinity labeling assays 
This technique requires photolabeling agents (substrates/inhibitors of the respective 
transport) e.g. [125I]iodoaryl-azidoprazosin (Pouliot et al., 1997) or [3H]azidopine (Safa et 
al., 1987). These agents are incubated with transporter enriched membranes at various 
concentrations of the test compound. After UV-irradiation, the transporter is isolated by 
SDS gel electrophoresis. Test compounds that interact with the protein should significantly 
reduce the amount of labeled transporter (quantified by autoradiography). Moderate 
reliability due to low labeling efficacy is the major limitation of this time consuming 
procedure. Additionally, different (or only partially overlapping) binding sites of test 
compound and photolabeling agents (cf. chapter 7) as well as the indefinite mechanism of 
transport have to be considered. 
 
1.4.3 Chemosensitivity assays 
In this assay type, the chemosensitivity of cells is a surrogate parameter for the cellular 
accumulation of cytostatic agents. In order to identify substrates, cells expressing the 
respective transporter and the parental (transporter negative) cell line are incubated in the 
presence of increasing concentrations of the test compound. After a certain incubation 
period (or after various incubation times; cf. the kinetic crystal violet assay described in 
section 3.2.5) the amount of viable cells is determined and IC50-values are calculated. 
Methods to quantify the number of surviving cells are manifold. Commonly used 
colorimetric techniques are to measure the activity of reductive enzymes (e.g. the 
conversion of [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]; MTT) 
(Mosmann, 1983) or the mass of viable cells with special dyes (Bernhardt et al., 1992). 
More recent approaches also utilize the detection of luciferase-mediated light signals 
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(Niles et al., 2007). Significant differences in the obtained IC50-values (i.e. unequal 
chemosensitivity) are observed if the drug is extruded by the transporter-expressing cells. 
Limitations are a mandatory antiproliferative activity of the test compound as well as a 
restricted comparability of data obtained with different cell lines (depending on the 
expression level and/or pattern of ABC transporter(s)). 
With a modified approach, it is also feasible to identify non-toxic modulators/inhibitors. The 
combination of a known (cytostatic) substrate of the transporter of interest with the test 
compound should reverse the efflux transporter-mediated multidrug resistance. Virtually all 
first and second generation P-gp modulators (Gottesman and Ling, 2006) as well the 
fumitremorgin C analog and selective BCRP inhibitor Ko143 were identified using this type 
of assay (Allen et al., 2002). 
 
1.4.4 Transcellular transport assays 
Before drugs can exert a pharmacological action by interacting with the respective cellular 
targets, they have to overcome various epithelial barriers (e.g. in the intestine, the liver and 
at the BBB). Transcellular transport assays simulate the physiological situation and allow 
the direct determination of the permeability as well as the evaluation of the interaction with 
transport proteins. Normally, cells expressing the transporter of interest are cultured on 
porous membranes that are mounted on multi-well plates (cf. Figure 1.2). Having reached 
confluency, the test compound is added either to the apical or the basolateral reservoir. 
After different periods of incubation, the concentration of the test compound in the 
receiving compartment is quantified by sensitive analytical methods (see below). The 
apparent permeability is calculated (flux rate corrected to the surface area and the initial 
concentration) separately for the basolateral-to-apical direction (Papp B-A) and the apical-to-
basolateral direction (Papp A-B). If the test compound is not a substrate of the present 
transporter (or the efflux transporter is inhibited by a modulator), the ratio of both values 
equals unity. In contrast, if the compound is recognized by P-gp or BCRP (expressed in 
the apical membrane), Papp B-A will significantly exceed Papp A-B. Additionally, active transport 
(saturable) can be discriminated from passive diffusion (linear increase) if the apparent 
permeability is determined at varying concentrations of the test compound. In an indirect 
setting, inhibitory properties can be identified by comparing the permeability ratios of know 
substrates in the presence and the absence of the test compound. 
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Figure 1.2: Schematic illustration of the 
experimental set-up of a characteristic trans-
cellular transport assay to evaluate the activity of 
efflux transporter. The ABC transporters are 
represented by black circles. Illustration adapted 
from the Corning® HTS Transwell® - 96 Tissue 
Culture System. 
 
Suitable cells must be polarized, i. e. express the transporter of interest at a defined side of 
the membrane and form tight junctions. Commonly used cell lines are Caco-2 (human 
colonic adenocarcinoma; simulation of the absorption process in the intestine), LLC-PK1 
(epithelial porcine kidney cells) and MDCK (Madin-Darby canine kidney cells). In contrast 
to LLC-PK1 and MDCK cells (3 - 4 days), Caco-2 cells have to be cultured 3 weeks on the 
filter membranes until the studies can be initiated. Additionally, it has to be taken into 
consideration that numerous different transporters are expressed in this cell type. 
Further general problems are varying levels of transporter expression as well as the 
possibility of misinterpretations due to membrane leakage (toxicity of the substrate or 
insufficient confluence). False negative results (with regard to the identification of 
substrates) are caused if the investigated compound shows a high passive permeability 
(Doppenschmitt et al., 1999). In this case it is assumed that the high intrinsic permeability 
levels the ABC transporter mediated efflux (Lentz et al., 2000). Moreover, the substrates 
have to be available radioactively labeled or show fluorescent properties. If a high number 
of compounds has to be screened, the quantification necessitates elaborate analytical 
methods such as liquid chromatography with tandem mass spectrometry (Polli et al., 
2001). 
 
1.4.5 Cellular accumulation assays 
In contrast to chemosensitivity investigations, the accumulation of transporter substrates in 
ABC transporter expressing cells is measured directly. If the test compound shows 
inherent fluorescence or is radioactively labeled, substrate properties as well as 
characteristic pharmacological parameters (e.g. Km or Vmax) can be determined 
straightforward. Since the majority of agents lacks these properties, mostly indirect 
methods utilizing fluorescent indicators are applied. In this set-up, the concentration 
dependent inhibition of the respective transporter can be quantified by the successively 
increased cellular fluorescence. As becomes obvious, the method is especially suitable for 
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the identification of modulators. Nevertheless, due to the competitive inhibition of dye efflux 
in higher concentrations, the assay is not able to discriminate between substrates and 
inhibitors. 
Commonly used fluorescent indicators are rhodamine 123 (P-gp) (Eytan et al., 1997), 
pheophorbide a (BCRP) (Henrich et al., 2006), Hoechst 33342 (P-gp and BCRP) (Seigel 
and Campbell, 2004) and calcein-AM (P-gp and MRP1) (Homolya et al., 1993). The latter 
has become the preferred fluorescent dye for the evaluation of ABCB1 mediated efflux due 
to its unique activation mechanism (cf. section 3.2.3). Nevertheless, a suitable fluorescent 
probe has to be selected with regard to the ABC transporter expression pattern of the used 
cell line and the protein of interest. Alternatively, selectivity for an individual protein can be 
achieved by utilizing cells that express solely (genetically engineered) or preferentially the 
respective ABC transporter. 
In the indirect set-up, the fluorescent indicator assays are suitable for the screening of 
large compound libraries and were recommended for investigations in early stages of drug 
discovery (Rautio et al., 2006; Schwab et al., 2003). Despite a generally high reliability, 
false negative results are possible due to an inherent toxicity or lacking completion of the 
test compound and the fluorescent probe. For example, colchicine inhibited 
Hoechst 33342 transport whereas rhodamine 123 transport was stimulated (Shapiro and 
Ling, 1998). Responsible for this and similar observations are most likely different 
interaction sites for the various substrates and modulators (Martin et al., 2000). A 
combination with ATPase and/or transcellular transport assays circumvents these 
problems and facilitates the differentiation of substrates and inhibitors (Polli et al., 2001). 
 
1.4.6 Isolated organ preparations 
The perfusion technique stands at the interface between in vitro assays and more time 
consuming and cost intensive in vivo investigations. Isolated organs are perfused with 
solutions containing the test compound (ABC transporter substrate) at a certain 
concentration. Determination of the substrate concentrations in the perfusate and the 
organ enables the estimation of transporter activity in the respective tissue. This technique 
has been successfully applied for the evaluation of the significance of ABC transporters in 
liver (Lau et al., 2004), kidney (Hori et al., 1993) or intestine (Adachi et al., 2003). With 
regard to the role of P-gp at the BBB, perfusion studies showed that the uptake of 
colchicine and vinblastine into the brain of mdr1a deficient mice was three times higher 
compared to wild type animals. Pre-administration of the P-glycoprotein modulators 
valspodar or elacridar increased the apparent brain transport of the respective compounds 
to the level observed with P-gp deficient animals (Cisternino et al., 2001). Due to the intact 
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organ structure, these models may provide data of high predictive value and contribute to 
reduce the number of animal experiments. Nevertheless, compared to the assays 
discussed above, the organ preparations are elaborate and time consuming. Additionally, 
handling errors due to the complex methodology as well as tissue injuries may cause 
misleading results. 
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2 Scope and objectives 
 
ABCB1 transporter mediated efflux is the most important cause of multidrug resistance 
(MDR) in cancer (Szakacs et al., 2006). Furthermore, as an essential component of the 
blood-brain barrier, P-glycoprotein compromises the efficacy of many otherwise potent 
drugs in the central nervous system (Deeken and Löscher, 2007). Within the plethora of 
drugs (antidepressants, hormones, antibiotics etc.), in particular many clinically used anti-
cancer agents (taxanes, anthracyclines, vinca alkaloids etc.) are transported by 
P-glycoprotein. This results in low concentrations of the cytostatics in the CNS and is 
arguably the main cause for the disillusioning prognosis of malignant brain tumors. 
In previous studies with nude mice bearing intracerebral human U-118 MG glioblastomas, 
the brain levels of paclitaxel were significantly increased when the cytostatic was 
combined with the second generation modulator valspodar (Fellner et al., 2002). While the 
elevated brain concentration of paclitaxel resulted in a reduction of tumor volume by 90 %, 
valspodar also increased the concentration (and hence the toxicity) of the cytostatic agent 
in the periphery. By contrast, studies performed with the (in vitro even more potent) third 
generation modulator tariquidar, showed no influence on the plasma concentration of 
paclitaxel (Hubensack et al., 2008). Compared to co-administered valspodar, tariquidar 
significantly elevated the paclitaxel brain levels as well, but to a lesser extent than 
expected. Considering the high in vitro potency of tariquidar, the discrepancy to the in vivo 
results was attributed to poor drug-like properties, for instance high lipophilicity 
(accumulation in adipose tissue) and low solubility. Consequently, it was hypothesized that 
more hydrophilic tariquidar-like modulators will be more effective in vivo. 
In order to investigate this hypothesis, a series of tariquidar-like modulators with 
pronounced differences in lipophilicity was synthesized in the group of Prof. Dr. Burkhard 
König (Egger et al., 2007). With substantial different octanol-water partition coefficients 
(covering the range of two orders of magnitude), the three derivatives ME27-4, ME30-1 
and ME33-1 were identified as potent inhibitors of P-glycoprotein (cf. Figure 2.1). 
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Figure 2.1: Chemical structures of tariquidar and the three new ABCB1 modulators selected for 
in vitro and in vivo studies 
Accordingly, these compounds were considered suitable to test the aforementioned 
hypothesis by the tumor pharmacological and bio-analytical investigations described in this 
thesis. The objectives of this work are summarized in the following. 
- Firstly, a series of experiments aimed at the in vitro characterization of the selected 
modulators to assess their suitability for further in vivo studies. Especially bio-
pharmaceutical issues such as stability, toxicity, plasma albumin binding properties etc. 
should be addressed. To assure inhibition of the murine ABCB1 transporter subtypes, 
a cellular model with predictive value for the intended experiments in nude mice had to 
be established. Moreover, to facilitate the rapid screening of test compounds with 
putative activity at the ABCB1 transporter, there was a need for a fluorescence-based 
inhibition assay in the microtiter plate format. 
- Subsequently, bio-distribution studies in NMRI mice should confirm sufficient 
bioavailability and metabolic stability of the modulators prior to pharmacodynamic 
in vivo studies. Hence, a reliable method to determine the concentration in brain and 
plasma samples had to be installed. Quantification of co-administered paclitaxel should 
assure the desired increase of the cytostatic drug in the brain. With regard to the 
increased toxicity observed in previous studies with valspodar, the new tariquidar-like 
modulators should not affect paclitaxel plasma levels. 
- To elucidate, if the putative increase in the CNS concentration of paclitaxel is of clinical 
significance for the treatment of malignant gliomas, a third approach was intended. 
Previous studies (using intracerebral tumor xenografts) were limited to a single 
endpoint evaluation of tumor load by time consuming histological serial sections of the 
brain. Fluorescence- and luminescence-based in vivo imaging methods were 
considered appropriate to facilitate the non-invasive determination of tumor burden at 
the beginning as well as during the therapy. For this purpose, U-118 MG glioblastoma 
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cells had to be transfected with genes encoding for various fluorescent proteins or the 
luciferase2 enzyme. Following the in vitro characterization, the transfectants should be 
used to optimize the existing orthotopic brain tumor model. Ultimately, the refined 
model should be utilized to study the therapeutic value of the most promising ABCB1 
modulators in combination with paclitaxel. 
- In an analogous therapeutic approach, the effect on MDR tumors in the periphery 
should be assessed. Consequently, an ABCB1 transporter expressing subcutaneous 
tumor model had to be established in nude mice. Therefore, P-glycoprotein expressing 
Kb-V1 cells as well as the resulting xenografts should be characterized concerning 
malignancy, growth kinetics and maintenance of transporter expression. 
- Work in a different subject of this thesis was inspired by the recent publication of the 
first high resolution x-ray structure of a mammalian ABC transporter (Aller et al., 2009). 
Based on experimental data from the literature, docking experiments should localize 
the binding region of the tariquidar-like modulators at P-glycoprotein and identify 
important interacting residues. The obtained results could in turn contribute to the 
structure based design of improved ABCB1 modulators in the future. 
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3 The ABCB1 transporter: modulation, spe-
cies differences and in vitro character-
ization of tariquidar-like compounds 
 
3.1 Introduction 
The (over)expression of ABCB1 transporters in MDR tumors and at the blood-brain barrier 
has prompted the search for potent inhibitors over the past decades (Lee, 2010). The first 
modulators identified (e.g. verapamil or quinidine) were approved drugs already used for 
other indications (the so called first generation modulators). The low affinity of these 
compounds required high therapeutic doses that resulted in toxic side effects due to 
lacking specificity. Second generation modulators such as the cyclosporine D analogue 
valspodar showed higher affinity for P-glycoprotein at per se nontoxic doses (Fox and 
Bates, 2007). However, pharmacokinetic interactions increased the concentration and 
hence the toxicity of the administered cytostatic drug (cf. chapter 4). 
Intense research efforts have yielded potent and specific third generation ABCB1 
modulators (e.g. tariquidar) lacking the aforementioned shortcomings. Indeed, tariquidar 
was well tolerated in clinical studies with healthy volunteers at a dosage of 2 mg/kg i.v. (or 
750 mg p.o.) (Stewart et al., 2000) as well as in combination with the cytotoxic drug 
vinorelbine (Abraham et al., 2009). By contrast, whereas tariquidar was considerably more 
potent than valspodar on human ABCB1 transporters in vitro, both compounds were 
approximately equipotent in inhibiting P-gp at the blood-brain barrier in vivo (Fellner et al., 
2002; Hubensack et al., 2008). These discrepancies could result from species dependent 
peculiarities of the nude mouse model as well as poor drug-like properties (as low solubility 
and high lipophilicity) of tariquidar. Accordingly, the first objective of this study was to 
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establish a cellular model to compare the activities of selected P-glycoprotein modulators 
at both, the human and the murine transporter. 
Additionally, it was speculated that less hydrophobic and better water soluble tariquidar-
like modulators may be more suitable for in vivo studies. Consequently, a series of more 
hydrophilic tariquidar-like ABCB1 modulators was synthesized (Egger et al., 2007). The 
most promising modulators ME27-4, ME30-1 and ME33-1 (cf. Figure 2.1) were selected 
for further in vitro characterization. During these biopharmaceutical studies, issues 
regarding stability (see section 4.3.5), drug-like properties, toxicity, antiproliferative activity 
against MDR Kb-V1 cells and human glioblastoma cells (cf. sections 5.3.1.6 / 6.3.3.1) as 
well as potential pharmacokinetic interactions should be investigated. The studies should 
also help to assess the suitability of the modulators for the intended in vivo studies. 
A third series of experiments aimed at the adaptation of the established flow cytometric 
assay to the microtiter plate format. Though calcein-AM proved to be the supreme 
reference substrate for ABCB1 mediated transport (Szakacs et al., 2008), the flow 
cytometric assay has disadvantages with regard to cost-intensity and moderate 
throughput. Moreover, another series of tariquidar analogs (with the hetarylcarboxamide 
moiety in meta position to the benzamide core, cf. chapter 7) turned out to be among the 
most potent and selective inhibitors of ABCG2 mediated efflux (Kühnle et al., 2009). To 
evaluate the selectivity of future modulators for the ABCG2 transporter, a fast and reliable 
assay would be of additional advantage. 
 
3.2 Materials and methods 
3.2.1 Drugs and chemicals 
Elacridar (GF 120918) and valspodar (SDZ PSC 833) were kindly provided by GSK 
(Research Triangle Park, NC) and Novartis (Nürnberg, Germany), respectively. The 
tariquidar-like modulators were synthesized (Egger et al., 2007) in the workgroup of Prof. 
König (Institute of Organic Chemistry, University of Regensburg, Germany). Tariquidar 
was synthesized in our laboratory according to the literature (Dodic et al., 1995; Roe et al., 
1999) with slight modifications (Hubensack, 2005). Vinblastine, doxorubicin and paclitaxel 
were purchased from Sigma (Munich, Germany). Calcein-AM (4 mM in anhydrous DMSO) 
as well as pluronic F127 were obtained from Biotium (Hayward, CA). All stock solutions 
(made in DMSO or 70 % ethanol depending on the solubility of the compounds) as well as 
the solid substances were stored at -20 °C. 
Phosphate buffered saline (PBS) contained 8.0 g/L NaCl, 1.0 g/L Na2HPO4·2 H2O, 0.20 g/L 
KCl, 0.20 g/L KH2PO4 and 0.15 g/L NaH2PO4·H2O and was adjusted to pH 7.4 with 
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1 M NaOH. If not otherwise stated, chemicals (p.a. quality) were obtained from Merck 
(Darmstadt, Germany). Purified water (Milli-Q system, Millipore, Eschborn, Germany) was 
used throughout. 
 
3.2.2 Cell lines and culture conditions 
Human Kb-V1 cells were cultured in DMEM containing 10 % FCS (Biochrom, Berlin, 
Germany) and 330 nM vinblastine to maintain ABCB1 transporter expression. 
Murine P388D1 cells (CCL-46, murine lymphoid neoplasm with macrophage-like 
morphology) were maintained as suspension culture in DMEM supplemented with 10 % 
FCS (Biochrom). The ABCB1 transporter expressing subclone P388D1Doxo was obtained 
by subculturing of wild type cells with increasing concentrations of doxorubicin. The 
characterization of modulators was performed with cells propagated in the presence of 
1.25 µM doxorubicin. 
The human glioblastoma cell line U-118 MG (HTB-15) was maintained in DMEM 
containing 5 % FCS (Biochrom). 
Wild type cells were obtained from the American Type Culture Collection (Rockville, MD) 
and were cultured in water-saturated atmosphere (95 % air/5 % CO2) at 37 °C in cell 
culture flasks purchased from Nunc (Wiesbaden, Germany). Dulbecco´s Minimum 
Essential Medium (DMEM; Sigma, Munich, Germany) was supplemented with 3.7 g/L 
sodium hydrogen carbonate and 110 mg/L sodium pyruvate. Subculturing of adherently 
growing cells was performed after trypsinization (0.05 % trypsin/0.02 % EDTA, Roche 
Diagnostics, Mannheim, Germany). Cell were routinely monitored for mycoplasma 
contamination by PCR (Venor® GeM, Minerva Biolabs GmbH, Berlin) and only 
mycoplasma negative cultures were used. 
 
3.2.3 Calcein-AM efflux assay 
Since calcein-AM (cf. Figure 3.1) is a substrate of P-glycoprotein, ABCB1 transporter 
expressing cells show lower intracellular levels of the compound compared to P-gp 
negative cells. Inside the cell, endogenous esterases cleave the ester bonds and the 
fluorescent calcein is formed. Consequently, inhibition of ABCB1 transporters can be 
quantified by the determination of calcein-mediated fluorescence (Homolya et al., 1993). 
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Figure 3.1: Chemical structures of the P-gp substrate calcein-AM and the intracellularly generated 
fluorescent calcein 
 
In all assays, tariquidar served as positive control at a final concentration of 1 µM 
corresponding to 100 % inhibition of calcein-AM efflux. IC50-values were calculated with 
SigmaPlot 9.0 using the Hill equation. 
3.2.3.1 Flow cytometry 
3.2.3.1.1 Kb-V1 cells 
The assays were performed as described previously (Müller et al., 2007). 
3.2.3.1.2 P388D1Doxo cells 
The protocol was adopted from the flow cytometric assay using Kb-V1 cells (Müller et al., 
2007). In brief: having reached a sufficient density, P388D1Doxo cells were harvested and 
washed with PBS. After centrifugation, the supernatant was discarded, and the cell density 
was adjusted to 1 · 106 cells per 0.75 mL with loading buffer (120 mM NaCl, 5 mM KCl, 
2 mM MgCl2 · 6 H2O, 1.5 mM CaCl2 · 2 H2O, 25 mM HEPES, 10 mM glucose, pH 7.4). 
Additionally, 0.25 mL loading suspension (loading buffer, 20 mg/mL BSA, 5 µL/mL 
pluronic F127 (20 % in DMSO)) were added to reach a final density of 1 · 106 cells/mL. 
Subsequent to a pre-incubation period with various concentrations of test compounds for 
15 min at 37 °C/5 % CO2, calcein-AM solution was added to achieve a final concentration 
of 0.75 µM and samples were incubated for 10 min at 37 °C/5 % CO2. After centrifugation 
the supernatant was discarded, cells were washed once with ice cold PBS and re-
suspended in 0.5 mL loading buffer per sample. Calcein fluorescence was determined with 
a FACS CaliburTM flow cytometer (Becton Dickinson, Heidelberg, Germany) in the FL1-H 
channel. In each measurement 20,000 gated events were evaluated. The geometric 
means were calculated from the fluorescence intensity histograms, related to the controls 
and plotted against the various concentrations of test compounds. The photomultiplier 
settings were as follows: E-1 for FSC, 270 for SSC and 345 for FL1-H. Data analysis was 
performed by the WinMDI 2.9 software. 
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3.2.3.2 Microtiter plate format 
Human Kb-V1 cells were seeded into flat-bottomed 96-well plates (Greiner, Fricken-
hausen, Germany) at a density of 20,000 cells per well. On the following day, cells were 
washed with loading buffer (120 mM NaCl, 5 mM KCl, 2 mM MgCl2 · 6 H2O, 1.5 mM 
CaCl2 · 2 H2O, 25 mM HEPES, 10 mM glucose, pH 7.4) in order to remove unspecific 
serum esterases. Afterwards, cells were incubated with loading suspension (loading buffer, 
5 mg/mL BSA, 1.25 µL/mL pluronic F127 (20 % in DMSO)) containing 0.5 µM calcein-AM 
and the test compound at increasing concentrations for 10 min (37 °C/5 % CO2). In 
general, test compounds were investigated as triplicates, controls as sextets, respectively. 
Subsequently, the loading suspension was discarded and cells were fixed with 4 % 
paraformaldehyde (PFA) solution in PBS for 20 min. After three washing circles (loading 
buffer), fixed cells were overlaid with loading buffer and relative fluorescence intensities 
were determined at 535/25 nm at a GENios Pro microplate reader (Tecan Deutschland 
GmbH, Crailsheim, Germany) after excitation at 485/20 nm. The obtained mean 
fluorescence intensities were related to the controls and plotted against the various 
concentrations of test compounds. 
The validation of the relevant assay parameters was performed according to the published 
literature (Bauer et al., 2003; Bubik et al., 2006; Polli et al., 2001) and is presented in 
section 3.3.3.1. 
 
3.2.4 Plasma albumin binding 
10 µM solutions of tariquidar and the tariquidar-like modulators were prepared in PBS 
containing 40 mg/mL bovine serum albumin (BSA, Serva, Heidelberg, Germany). In order 
to reach equilibrium between bound and unbound ligand, the respective solutions were 
incubated for 30 min at 37 °C. Subsequently, the samples were ultra-filtrated by an 
Microcon centrifugal filter device with a nominal molecular weight limit of 10,000 Da 
(Millipore, Eschborn, Germany) at 10,700 g for 16 min (15 °C). Aliquots of the filtrates were 
combined with two parts of ice-cold acetonitrile and stored at 4 °C for 1 h. Afterwards, 
samples were centrifuged at 10,700 g for 8 min and the supernatant was transferred to 
glass vials and an equal volume of 0.05 % TFA (aq.) was added. 
The subsequent RP-HPLC analysis was performed as described in section 4.2.3 (cf. 
conditions of the recovery analysis) immediately, or after a storage period ≤ 24 h at -78 °C. 
The free filtratable fractions were determined by comparison of peak areas to the 
respective areas of not ultra-filtrated samples prepared in PBS without BSA by an 
otherwise identical procedure. 
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3.2.5 Chemosensitivity assay 
The assay was performed as described previously (Bernhardt et al., 1992). In brief: tumor 
cells were seeded into flat-bottomed 96-well plates (Greiner) at a density of 10 - 15 cells 
per microscopic field (magnification: 320-fold). After an incubation period of 48 - 72 h at 
37 °C/5 % CO2, the medium was replaced by fresh culture medium containing the test 
compounds at various concentrations. Growth of untreated cells (respective solvent of the 
test compound in a dilution of 1:1000) served as control. After different incubation periods, 
growth was stopped by fixation with glutardialdehyde. The mass of viable cells was 
determined by simultaneous staining of all plates with 0.02 % aqueous crystal violet 
(Serva, Heidelberg, Germany) solution. After removal of excess dye with water, cell-bound 
crystal violet was re-dissolved with 70 % ethanol under agitation for 2 - 3 h. Absorbance 
was measured at 578 nm (BioTek 309 Autoreader, Tecnomara, Fernwald, Germany) or at 
580 nm (GENios Pro microplate reader, Tecan Deutschland GmbH, Crailsheim, Germany), 
respectively. 
The effects of test compounds on the investigated cells were expressed as corrected 
T/C values according to 
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where T is the mean absorbance of treated cells, C the mean absorbance of controls and 
C0 the mean absorbance at the time when test compounds were added (t = 0). 
If the absorbance of treated cells T was less than the absorbance at t = 0 (cytocidal drug 
effect), the extent of killed cells was calculated as 
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3.2.6 Determination of cell membrane integrity 
HEL cells were transferred into 8 chamber BD Falcon Culture Slides (BD Biosciences, 
Heidelberg, Germany) and test compounds were added to the cell culture medium at 
various concentrations. After different exposure times a mixture of ethidium bromide and 
acridine orange (50 mg of ethidium bromide and 15 mg of acridine orange dissolved in 
50 mL of Millipore water containing 2 % ethanol) was added as 400-fold concentrated 
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stock solutions to each chamber. Digitonin at a concentration of 0.25 mg/mL served as 
positive control. 
Microscopic images were acquired with a Carl Zeiss Axiovert 200M LSM510 confocal 
laser-scanning microscope equipped with a Carl Zeiss AxioCam HR. At every investigated 
concentration, 200 cells were evaluated concerning to their viability (see section 3.3.2.3). 
 
3.2.7 Immunocytochemistry and confocal laser-scanning microscopy 
Labeling of α-tubulin was essentially performed as described elsewhere (Gross, 2006). 
Briefly: Kb-V1 cells were seeded into 8 chamber BD Falcon Culture Slides (BD 
Biosciences, Heidelberg, Germany). 48 h later, the medium was replaced with culture 
medium containing the test compounds at various concentrations (prepared by dilution of 
the 1000-fold concentrated DMSO stock solution). 
After an incubation period of 3 h at 37 °C/5 % CO2, paraformaldehyde solution in PBS was 
added to achieve a final concentration of 4 % PFA and cells were fixed for 20 min at room 
temperature. Subsequently, cells were washed three times with 0.5 % BSA in PBS. 
Permeabilisation of cells was achieved by incubation with PBS containing 0.5 % BSA and 
1 % Triton X-100 (Sigma, Munich, Germany) for 10 min, followed by three washing steps 
with 0.5 % BSA in PBS. 
Microtubules were labeled by incubation with the mouse anti-human α-tubulin primary 
antibody DLN-09992 (Dianova, Hamburg, Germany) for 1 hour followed by 3 washing 
steps with 0.5 % BSA in PBS. Subsequently, cells were simultaneously treated with Cy5TM-
conjugated anti-mouse secondary antibody (Dianova) and 1 µM of the nucleic acid staining 
dye SYTOXGreen® (Molecular Probes, Eugene, OR) for 40 min. The primary and 
secondary antibodies were used as a 1:200 dilution in PBS, containing 0.5 % BSA. After 
three washing steps, object slides where dried and embedded in Konfokal-matrix® (Micro 
Tec Lab, Graz, Austria). 
Picture acquisition was performed with a Carl Zeiss Axiovert 200M LSM510 confocal laser-
scanning microscope equipped with a Carl Zeiss AxioCam HR. Multifluorescence images 
were acquired in the multitrack acquisition mode and the following instrument settings: 
SYTOXGreen®, 488 nm Argon laser, 505 nm longpass filter; Cy5TM-conjugated secondary 
antibody, 633 nm HeNe laser, 650 nm longpass filter. 
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3.2.8 Inhibition of cytochrome P450 isoenzymes 
3.2.8.1 Preparation of rat liver microsomes 
In order to isolate rodent microsomes, male CD rats were killed by cervical dislocation, 
livers were excised and immediately placed on ice. After dissection with scissors, tissue 
was transferred to a Potter-Elvehjem homogenizer tube. Homogenization was performed 
in 0.15 M phosphate buffer (pH 7.4) under ice cooling by 25 heaves at 100 RPM. After 
5 heaves, a break of 30 seconds allowed the tube to cool down. Subsequently, a first 
centrifugation was performed for 30 min at 9000 g (4 °C). The supernatant was removed 
and centrifuged for 1 hour at 105,000 g (4 °C). The resulting microsome pellet was 
suspended in 83 mM phosphate buffer (pH 7.4) containing 17 mM KCl and stored at 
-78 °C. 
The amount of microsomal protein in the respective samples was determined according to 
the method of Bradford (1976). 95 µL of Millipore water were added to 5 µL of the various 
dilutions of the microsome suspension (in 0.1 M Tris buffer, pH 7.4) and incubated with 
1000 µL of Bradford´s dye reagent (Bio Rad Laboratories, Munich, Germany) for 10 min. 
Subsequently, the absorbance at 595 nm was measured with an Uvikon 930 
spectrophotometer (Kontron, Düsseldorf, Germany). The protein concentrations were 
calculated from a standard calibration curve of bovine serum albumin (Serva, Heidelberg, 
Germany) in the range of 1 - 12 µg protein per sample. 
3.2.8.2 CYP3A4 and CYP2C8 inhibition assay using bioluminescence 
based methods 
10 µL of the respective inhibitor (1:100 dilution in Millipore filtered water) or Millipore water 
containing 1 % DMSO (for the background control) were pipetted into white Lumitrac 200 
96-well plates (Greiner Bio-One, Frickenhausen, Germany). As positive controls for 
CYP3A4 inhibition, 25 µM terfenadine (Decker et al., 1998), for CYP2C8 inhibition 25 µM 
trimethoprim (Wen et al., 2002), respectively, were used. Afterwards, 10 µL of ice-cold 
0.1 mM Tris buffer (pH 7.4) containing 6.7 µg microsomal protein (or 1 pM CYP2C8) and 
100 µM luciferin-PPXE (CYP3A4) or 600 µM luciferin-ME (CYP2C8) were added (mixture 
prepared immediately prior to use). In the respective background control wells, heat 
inactivated (10 min at 100 °C) microsomal protein was used. After careful vortexing, the 
plate was pre-incubated for 10 min at 37 °C. Subsequently, 20 µL of the two-fold 
concentrated NADPH regeneration system (Promega, Mannheim, Germany) was added 
and the plate was incubated at 37 °C for 15 min (luciferin-PPXE) or 35 min (luciferin-ME), 
respectively. Afterwards, addition of 40 µL of the reconstituted Luciferin Detection Reagent 
(Promega, Mannheim, Germany) started the luciferase-mediated light emission. After a 
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stabilization period (20 min in assays using microsomes and 10 min when CYP2C8 
bactosomes were utilized), luminescence was determined with a GENios Pro microplate 
reader (Tecan Deutschland GmbH, Crailsheim, Germany) at 25 °C (1000 ms integration 
time, no attenuation). 
 
3.3 Results and discussion 
3.3.1 Species dependent differences in P-glycoprotein inhibition 
3.3.1.1 Induction of P-gp overexpression in murine P388D1 cells and 
optimization of assay parameters 
By analogy with the method used to generate ABCB1 transporter expressing human 
Kb-V1 cells, murine P388D1 cells were subcultured with increasing concentrations of 
doxorubicin over a period of approximately 4 months. The increase in functional 
P-glycoprotein was monitored after different periods of time by means of the calcein-AM 
efflux assay (see Figure 3.2). Total inhibition of transporter function was achieved by 
addition of tariquidar at a final concentration of 1 µM. The difference between the 
geometrical mean values of the fluorescence intensities (GeoMean) of untreated (100 % 
function) versus tariquidar treated cells corresponds to the amount of functional efflux 
transporter (cf. also section 5.3.1.7 and Figure 5.10 A). 
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Figure 3.2: Relative increase 
in P-glycoprotein activity in 
murine P388D1 cells depending 
on doxorubicin exposure. The 
calcein-AM incubation time had 
no significant influence on the 
relative activity: 10 min (black 
bars) and 20 min (grey bars). 
At a concentration of 120 nM 
doxorubicin, the GeoMean 
value of the wild type was com-
pared to that of doxorubicin 
induced cells (mean values 
± SEM, n = 2 - 4). 
 
The activity of P-glycoprotein did not increase significantly at concentrations higher than 
1 µM. Additionally, an approximately 11-fold increase (at a doxorubicin concentration of 
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1,055 nM) in the signal ratio of positive control and background is by far sufficient for the 
performance of inhibition studies. Consequently, the characterization of modulators was 
performed with cells propagated in the presence of 1.25 µM doxorubicin. 
Since a different cell line was utilized, it was investigated if assay parameters such as 
incubation time or temperature of calcein-AM had to be adopted. Fortunately, this was 
unnecessary (data not shown). Nevertheless, the calcein-AM concentration was slightly 
reduced to 0.75 µM (1 µM with Kb-V1 cells), since at this concentration the observed shift 
of the GeoMean value was also sufficient for the planned investigations. Additionally, the 
number of gated events in each measurement was reduced to 20,000 (30,000 with Kb-V1 
cells) to increase the throughput of the assay. All other factors that could influence the 
results of the assay were kept constant for reasons of comparability. 
3.3.1.2 Inhibitory activity of ABCB1 modulators on the murine transporter 
The inhibitory activity of selected modulators on the murine transporter was determined 
with the newly established calcein-AM efflux assay at the flow cytometer. Determination of 
calcein-mediated cellular fluorescence revealed that P388D1Doxo cells responded in a 
concentration-dependent manner. This allowed the construction of sigmoidal concentration 
response curves (see Figure 3.3) and the calculation of IC50-values. All investigated 
modulators, except for ME27-4 (IC50: 199 nM), were active in the double-digit nanomolar 
range at the murine transporter. 
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response curves for P-glyco-
protein inhibition by the in-
vestigated modulators in the 
calcein-AM assay on 
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(filled triangles), ME33-1 (open 
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squares), ME27-4 (open 
circles) and valspodar (filled 
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The obtained data were compared with results of the calcein-AM efflux assay performed 
with human Kb-V1 cells (see Table 3.1 and Figure 3.4). At the murine cells, all 
investigated compounds were more potent compared to human Kb-V1 cells. Whereas the 
 ABCB1-transporter - in vitro characterization of tariquidar-like modulators 29 
ratio of IC50-values ranged from 8 to 16 in the case of elacridar and the tariquidar 
(analogs), valspodar was 46 times more active on the murine transporter. 
Table 3.1: Comparison of P-glycoprotein inhibition (IC50-values and maximal effects) of the selected 
modulators in the calcein-AM assay on human Kb-V1 and murine P388D1Doxo cells 
P-gp 
modulator 
 Human 
Kb-V1 cells  
Murine 
P388D1Doxo cells 
 IC50-ratioa 
 
Kb-V1/ 
P388D1Doxo 
 IC50 
[nM]a 
 Emax 
(%)a 
 IC50 
[nM]a 
 Emax 
(%)a 
 
Elacridar  193 ± 24  106 ± 6  20 ± 2  91 ± 2  9.7 ± 2.2 
Tariquidar  223 ± 8  103 ± 2  14 ± 1  119 ± 3  15.9 ± 1.7 
ME33-1  256 ± 14  121 ± 3  28 ± 6  125 ± 5  9.1 ± 2.5 
ME30-1  798 ± 42  120 ± 4  93 ± 4  119 ± 2  8.6 ± 0.8 
ME27-4  1775 ± 155  120 ± 6  199 ± 15  125 ± 3  8.9 ± 1.0 
Valspodar  2648 ± 331  113 ± 9  58 ± 9  128 ± 5  45.7 ± 13.0 
a Mean values ± SEM, n = 3 
Figure 3.4 visualizes the higher relative activity of valspodar at the murine transporter 
compared to the third generation modulators. These compounds (all with a similar 
chemical structure; cf. Figures 2.1 and 7.4) showed nearly the same increase in affinity at 
the murine compared to the human transporter. This can be explained with the 
experimental set-up using a different cell type or by species differences in the affinity of 
P-glycoprotein. In particular the significantly higher relative activity of valspodar is most 
plausible explained by the latter. It can be speculated that valspodar occupies a binding 
site different from that of the structurally very similar tariquidar analogs (cf. section 7.4). 
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The cell line dependent shift in the concentration response curves of valspodar is shown in 
Figure 3.5. The higher activity in P388D1Doxo cells becomes obvious. 
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Figure 3.5: Concentration 
response curves for 
P-glycoprotein inhibition by 
valspodar in the calcein-AM 
assay on human Kb-V1 
(squares) and murine 
P388D1Doxo cells (circles); at 
the murine transporter, val-
spodar was 46 times more 
potent (mean values ± SEM, 
n = 3). 
 
The results suggest that the previously reported (Fellner et al., 2002; Hubensack et al., 
2008) discrepancies between the in vitro potency and the activity in nude mice reflect, at 
least in part, species differences in the affinities of modulators to P-gp. Consequently, the 
cellular models presented in this work should be of predictive value for the activity of 
P-glycoprotein modulators in further preclinical in vivo studies (see chapters 4, 5 and 6). 
 
3.3.2 In vitro characterization of tariquidar-like ABCB1 modulators 
With regard to future in vivo studies, the most promising new tariquidar-like ABCB1 
modulators ME27-4, ME30-1 and ME33-1 (see Figure 2.1) were selected and further 
characterized in vitro. 
3.3.2.1 Binding to serum albumin 
In order to estimate the fraction of modulators bound to serum albumin, ME27-4, ME30-1, 
ME33-1 and tariquidar were incubated with PBS containing 40 mg/mL BSA. Subsequently, 
the amounts of modulators found after ultra-filtration (free filtratable fraction, FFF) were 
determined (see Figure 3.6). 
As expected, the adsorption to albumin correlated with the lipophilicity of the compounds. 
Nevertheless, it has to be kept in mind that the lipophilicity also influences the adsorption 
to boundary surfaces such as the filter membrane. When the ultra-filtrate of compounds 
incubated in BSA-free PBS was investigated, the determined FFF of the various 
modulators was ≤ 35 % (data not shown). Since the presence of BSA (in the previously 
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described experiment) could in turn have reduced the adsorption to the filter membrane 
(and vessel material) it is complicated to discriminate between adsorption to albumin and 
boundary surfaces. 
ME27-
4
ME30-
1
tariqu
idar
fr
ee
 fi
ltr
at
ab
le
 fr
ac
tio
n 
(%
)
0
2
4
6
8
10
Figure 3.6: Percental amounts of the 
various modulators found in the ultra-
filtrate; the FFF of ME33-1 could not be 
determined due to an interfering peak (a 
compound most likely eluted from the 
filter membrane). Mean values ± SEM, 
n = 3 
Nevertheless, the percental amount of ABCB1 modulators not bound to serum albumin 
has to be considerably higher than the determined FFF. Therefore, the serum albumin 
binding is lower than that observed for many clinically established drugs. 
3.3.2.2 Effect on the proliferation of U-118 MG and Kb-V1 cells 
Prior to in vivo studies, the toxicity of ME27-4, ME30-1 and ME33-1 on two different cell 
lines was investigated by means of the crystal violet chemosensitivity assay (see Figure 
3.7 and Figure 3.8). 
On proliferating human U-118 MG glioblastoma cells solely ME27-4 showed a strong 
cytocidal effect at a concentration of 10 µM. At a concentration of 20 µM, the respective 
compound exerted also a cytocidal effect on quiescent U-373 MG cells (Müller, 2007). 
When proliferating Kb-V1 cells were incubated with the new ABCB1 modulators, the three 
compounds showed a cytotoxic drug action at a concentration of 5 µM. The sensitivity at 
this high concentration decreased according to the following order: 
ME27-4 > ME33-1 > ME30-1. The observed effect on cell growth resulted from long-term 
exposure of the cells to the modulators for several days, whereas the residence time is 
significantly shorter under in vivo conditions (see chapter 4). Despite this, the suitability of 
ME27-4 is compromised with respect to therapeutic in vivo studies. 
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Figure 3.7: Effect of ME27-4 (squares), ME30-1 (triangles) and ME33-1 (diamonds) on proliferating 
U-118 MG cells (passage 481) upon long-term exposure; positive control: 30 nM paclitaxel (inverted 
triangles); investigated concentrations of the ABCB1 modulators: A) 1 µM, B) 10 µM 
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Figure 3.8: Effect of ME27-4 (squares), ME30-1 (triangles) and ME33-1 (diamonds) on proliferating 
Kb-V1 cells (passage 49) upon long-term exposure; positive control: 1 µM vinblastine (inverted 
triangles); investigated concentrations of the ABCB1 modulators: A) 1 µM B) 5 µM 
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3.3.2.3 Effect of ME27-4 and tariquidar on the integrity of the cell 
membrane 
A potentially harmful effect of the ABCB1 modulators on the integrity of the cell membrane 
is detectable by this method, since the used fluorescent dyes differ with regard to their 
membrane permeability. In contrast to ethidium bromide, acridine orange is cell-permeable 
and viable cells with normal membrane function show a green color. If compounds 
increase permeability or damage the cell membrane, ethidium bromide is able to penetrate 
into the cell, resulting in a yellow to orange color (of the nuclei) of dead cells. 
At a concentration of 20 µM, ME27-4 showed a cytocidal effect on quiescent U-373 MG 
glioblastoma cells (Müller, 2007). Since this is an indication of unspecific toxicity, ME27-4 
and tariquidar (for comparison) were investigated concerning an unspecific effect on the 
permeability of the cell membrane (see Table 3.2). As becomes obvious, the cytotoxicity of 
ME27-4 is probably not caused by membrane damage, whereas tariquidar showed a 
pronounced effect on the viability of HEL cells, especially upon long-term incubation at a 
concentration of 10 µM. 
 
Concent-
ration 
[µM] 
 Percentage of dead cells 
Table 3.2: Fraction of dead HEL 
cells after different periods of 
incubation with ME27-4 or 
tariquidara 
 ME27-4  Tariquidar 
 4.5 h 
 
20 h 
 
4.5 h 
 
20 h 
0.1  n.d. 1.0 n.d. 3.5 
1.0  n.d. 1.5 n.d. 8.5 
10  2.5 1.5 11.0 38.0 
a Treatment of cells with 0.25 mg/mL of digitonin resulted in 100 % cell death, whereas the fraction 
of harmed cells was ≤ 2.5 % upon incubation with the respective solvents. 
 
3.3.2.4 Effect of tariquidar on the tubulin architecture 
In order to investigate if a synergistic cytostatic effect of epothilones in combination with 
the ABCB1 modulators (cf. appendix A) resulted from alteration in microtubule 
organization, α-tubulin was visualized by immunodetection. These investigations revealed 
an impact of tariquidar (100 nM) on the cytoskeleton of Kb-V1 cells (see Figure 3.9). Since 
tariquidar alone did not affect the growth of Kb-V1 cells even during long-term incubation 
and at concentrations up to 500 nM (Hubensack, 2005), the effect on tubulin seems not to 
correlate with cytotoxicity. 
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Figure 3.9: Impact of tariquidar on the tubulin architecture of Kb-V1 cells (passage 59); 
A) Untreated cells; B) After incubation with 100 nM tariquidar for 3 h; primary AB: mouse anti-
human α-tubulin AB (dilution 1:200); secondary AB: Cy5TM-conjugated anti mouse AB (dilution 
1:200); nuclei were stained with SYTOXGreen®. Microscopic images were acquired with a Carl 
Zeiss Axiovert 200M LSMM510 confocal laser-scanning microscope. 
 
3.3.2.5 Interaction of the modulators with cytochrome P450 isoenzymes 
A further objective was to exclude interactions of the new tariquidar-like modulators with 
the metabolism of paclitaxel. Since paclitaxel is preferentially metabolized by CYP3A4 and 
CYP2C8 (Fischer et al., 1998; Jamis-Dow et al., 1995), the investigation of the inhibitory 
properties of the modulators concentrated on these isoenzymes. For comparison, elacridar 
and valspodar were included into these investigations. 
Figure 3.10 shows the chemical structures of the utilized proluciferin substrates. Whereas 
luciferin-PPXE is solely metabolized by CYP3A4, -3A5 and -3A7, luciferin-ME is converted 
by a number of isoenzymes (CYP2C8, CYP1A2, CYP2C9, CYP2J2, CYP4A11, CYP4F3 
and CYP19) to luciferin. After addition of luciferase, the emission of light can be measured 
and correlates with the amount of produced luciferin. 
 
 
Figure 3.10: Chemical structures of used proluciferin substrates. Selectivity for 
certain cytochrome P450 isoenzymes is mediated by the residue R. 
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As part of the assay validation, among other things, the linearity and the stability of the 
light signal was investigated (see Figure 3.11). 
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Figure 3.11: Direct correlation 
of the luminescence signal with 
the amount of microsomal 
protein. Time after addition of 
the enzyme: 14 (open circles), 
20 (filled circles), 30 (open 
squares) and 40 min (filled 
triangles); mean values ± SEM, 
n = 3 
 
In the following experiments, 6.7 µg protein per well and a stabilization time of 20 min after 
addition of luciferase enzyme was used. 
Figure 3.12 illustrates the impact of the modulators on the activity of CYP3A4, CYP3A5 
and CYP3A7. Due to the lacking specificity of the substrate, it cannot be differentiated 
between effects on individual isoenzymes. At a concentration of 2.5 µM, no investigated 
modulator significantly inhibited the aforementioned cytochromes. In contrast, at 12.5 µM 
the various compounds reduced cytochrome P450 mediated generation of luciferin in the 
range between 20 and 50 %. Due to the comparatively high concentrations and the fact 
that protein binding is not considered (see section 3.3.2.1), the observed effect should 
presumably be irrelevant under clinical conditions (cf. also chapter 4). 
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Figure 3.12: Impact of the 
various compounds at 2.5 µM 
(light grey bars) and 12.5 µM 
(black bars) on the activity of 
CYP3A4, CYP3A5 and 
CYP3A7. Luciferin-PPXE medi-
ated luminescence was measu-
red 20 min after addition of the 
enzyme. The CYP3A4 inhibitor 
terfenadine (25 µM) served as 
positive control (mean values 
± SEM, n = 3). 
 
Interestingly, in this assay the inhibition of CYP3A4 by valspodar reported in the literature 
(Fischer et al., 1998) was not observed. Since CYP3A4 is involved in the metabolism of 
paclitaxel (Jamis-Dow et al., 1995), higher toxicity of the cytostatic (Fellner et al., 2002; 
Kemper et al., 2003) after co-administration with valspodar is commonly attributed to 
increased systemic exposure due to the inhibition of cytochrome P450 enzymes (Fox and 
Bates, 2007). A possible explanation why no CYP3A4 inhibition was observed in the 
present investigation could be that Luciferin-PPXE is also metabolized by CYP3A5 and 
CYP3A7. Consequently, selective inhibition of CYP3A4 can hardly be detected, when 
microsomes are utilized (see below for CYP2C8). Furthermore, it is conceivable that 
valspodar accumulates in the liver at concentrations above those investigated in this study. 
In the corresponding assay using luciferin-ME and rat liver microsomes, the generation of 
luciferin could not be suppressed by 25 µM of the CYP2C8 inhibitor trimethoprim (data not 
shown). This was attributed to the vast number of isoenzymes capable to convert luciferin-
ME. If a compound selectively modulates CYP3A4, the educt is metabolized by other iso-
enzymes present in the rat liver microsomes and the light intensity is comparable to the 
untreated control. To circumvent that problem, human CYP3A4 bactosomes were utilized 
for further investigations. Since preliminary experiments revealed a limited stability of the 
luminescent signal (data not shown), the stabilization period was reduced to 10 min. 
Figure 3.13 shows the effect of the modulators on the activity of human CYP2C8 
bactosomes. As becomes obvious, even at a concentration of 2.5 µM all compounds 
moderately inhibit CYP2C8 activity. Nevertheless, it is important to emphasize the higher 
significance of CYP3A4 for the metabolism of paclitaxel. 
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Figure 3.13: Impact of the 
various compounds at 2.5 µM 
(light grey bars) and 12.5 µM 
(black bars) on the activity of 
CYP2C8 bactosomes; 
Luciferin-ME mediated 
luminescence was measured 
10 min after addition of the 
enzyme. The CYP2C8 inhibitor 
trimethoprim (25 µM) served as 
positive control (mean values 
± SEM, n = 3). 
 
Investigations on the relevance of the observed modulation of CYP2C8 with respect to 
pharmacokinetics and toxicity are described in chapter 4 and chapter 5, respectively. 
 
3.3.3 Adaptation of the calcein-AM efflux assay to the microtiter plate 
format 
3.3.3.1 Establishment of assay parameters 
3.3.3.1.1 Impact of cell number and calcein-AM concentration 
In order to determine the linearity of calcein-AM uptake and to optimize the number of cells 
per well, Kb-V1 cells were investigated (cf. section 3.2.3.2) at various cell densities (see 
Figure 3.14) in 96-well plates. A first attempt revealed a nonlinear relationship between 
the number of seeded cells and the relative fluorescence intensity (RFI) especially at 
higher cell densities. 
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after pre-incubation of Kb-V1 
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concentrations of calcein-AM 
and 1.0 µM tariquidar; 
calcein-AM combined with 
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inverted triangles) and 1.0 µM 
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Since the lacking correlation between cell number and RFI was attributed to a loss of cells 
during the various incubation and washing cycles, a fixation step (4 % PFA in PBS for 
20 min) was implemented after the 10 min incubation period with calcein-AM (see Figure 
3.15). This modification resulted in a linear dye uptake up to 40,000 cells/well. Due to the 
high activity of ABCB1 transporters in Kb-V1 cells, even a dye concentration of 1.5 µM 
produced only a slight increase in RFI at higher cell densities. When cells were pre-
incubated with the ABCB1 modulator tariquidar, a linear and concentration dependent 
increase of fluorescence was observed. 
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Figure 3.15: Correlation of cell 
number with fluorescence after 
fixation of cells with 4 % PFA; 
combination of tariquidar 
(1 µM) with calcein-AM at 
various concentrations: 1.5 µM 
(open diamonds), 1.0 µM (filled 
squares) and 0.5 µM (open 
inverted triangles); negative 
control: 1.5 µM calcein-AM 
without tariquidar (filled circles); 
mean values ± SEM, n = 3 
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3.3.3.1.2 Co-incubation of calcein-AM with the ABCB1 modulator 
All previous experiments were carried out with a pre-incubation period (with the modulator) 
of 15 min as in the calcein-AM assay at the flow cytometer. Figure 3.16 shows the results 
of a second approach, in which the modulators were added in combination with 
calcein-AM. Though the linear increase in the RFI was smaller, the signal-to-noise ratio 
was by far sufficient for quantitative measurement even at a concentration of 0.5 µM 
calcein-AM. 
 
3.3.3.1.3 Normalization of fluorescence intensity by cell mass 
Additionally, aiming at further optimization of the calcein assay, fluorescence was 
normalized by cell mass. For this purpose, the cells in 96-well plates were fixed with 
glutardialdehyde and stained with 0.02 % crystal violet solution (as described in detail in 
section 3.2.5) after measurement of calcein fluorescence. Figure 3.17 A shows the 
correlation of cell mass with the measured RFI. Compared to Figure 3.16, there is no 
distinct advantage of counter-staining with crystal violet. This is also true for the 
constructed concentration response curves (see Figure 3.17 B for tariquidar). The 
calculated IC50-values differed by less than 12 %. 
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Figure 3.16: Correlation of cell 
number with fluorescence after 
co-incubation of Kb-V1 cells 
with tariquidar (1 µM) and 
calcein-AM at various con-
centrations: 1.0 µM (filled 
squares) and 0.5 µM (filled 
circles); negative controls: 
1.0 µM (open diamonds) and 
0.5 µM (open inverted 
triangles) of calcein-AM without 
tariquidar (mean values ± SEM, 
n = 3) 
40 Chapter 3 
absorbance
0.0 0.2 0.4 0.6 0.8
re
la
tiv
e 
flu
or
es
ce
nc
e 
in
te
ns
ity
0
5000
10000
15000
20000 A
concentration [µM]
0.01 0.1 1 10
A
B
C
B
1 
in
hi
bi
tio
n 
(%
)
-20
0
20
40
60
80
100
B
Figure 3.17: A) Correlation of absorbance (cell mass) with fluorescence intensity. 1 µM tariquidar 
combined with calcein-AM at various concentrations: 1.0 µM (filled squares) and 0.5 µM (open 
inverted triangles); calcein-AM at a concentration of 1.5 µM without tariquidar (filled circles); 
B) Concentration response curve of tariquidar with (filled squares) and without (open squares) 
normalization (mean values ± SEM, n = 3) 
In consideration of the aforementioned results, the assay was performed after seeding of 
20,000 cells/well. Modulators were investigated by co-incubation with 0.5 µM calcein-AM 
and after cell fixation with 4 % PFA solution (as described in section 3.2.3.2). 
Compared to the flow cytometric characterization of a test compound (in triplicates), the 
required number of cells could be lowered from 48 to approximately 1 million. Moreover, 
the amount of test compounds, calcein-AM and the expenditure of time were reduced by a 
factor 8, 16 and 6, respectively. 
3.3.3.2 Comparison of microplate assay with flow cytometry 
Investigation of ABCB1 modulators with the established assay protocol at the microplate 
reader allowed the construction of sigmoidal concentration response curves (cf. Figure 
3.18) and the calculation of IC50-values. 
It is important to note that the control samples should be placed in the middle of the plate 
and the solutions of inhibitor/calcein-AM have to be added immediately to avoid any delay 
critically affecting the results (Emax- and IC50-values). This is due to the comparatively short 
co-incubation period of 10 min and the fact that the intensity of calcein fluorescence 
correlates with the incubation period which must be carefully kept constant. 
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Subsequently, the inhibitory activities of 11 modulators with IC50-values ranging from 
0.20 to 12.6 µM as determined at the flow cytometer were investigated in the microplate 
format. In addition to the most potent inhibitors described in section 3.3.1.2, the previously 
characterized (Müller, 2007) modulators ME1-2, ME1-3, ME27-2; ME27-3 and ME32 were 
included in this study. In Figure 3.19 the results are compared with those from the flow 
cytometric calcein-AM efflux assay. A strong correlation between data from the two assay 
types is obvious. 
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On average, the IC50-values determined at the microplate reader were 1.82-fold (SEM: 
± 0.42) higher. The seemingly lower potency in this assay is attributed to the lack of the 
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pre-incubation period which allows modulators to accumulate in the membrane bilayer 
(see chapter 7). By a modified experimental procedure (15 min pre-incubation of the cells 
with test compounds followed by a 30 min calcein-AM incubation period) at the microplate 
reader, valspodar, tariquidar and elacridar were investigated (data not shown). Under 
these conditions, the obtained IC50-values were on the average 4.40-fold (range: 2.81 - 
4.55, SEM: ± 0.88) lower compared to the standard assay at the microplate reader. 
Consequently, the incubation period is a critical parameter that has to be carefully 
controlled. 
 
3.4 Summary and conclusions 
In the present study, the ABCB1 transporter expressing murine P388D1Doxo cells were 
utilized to establish a cellular model with predictive value for the administration of 
P-glycoprotein modulators in preclinical in vivo studies. Subsequently, the inhibitory activity 
of selected modulators at murine P-gp was determined and compared with data from the 
calcein-AM efflux assay performed with human Kb-V1 cells. These investigations revealed 
that the ratio of IC50-values ranged from 8 to 16 in the case of elacridar and the tariquidar-
type compounds, whereas valspodar was 46 times more active on the murine transporter. 
Species differences in the affinities to rodent and human (and/or porcine) P-gp were also 
described for other substrates and modulators such as vinblastine, itraconazole and 
verapamil (Schwab et al., 2003; Tang-Wai et al., 1995). It has to be considered that there 
are two different isoforms of P-glycoprotein in mice (Abcb1a and Abcb1b) that have distinct 
and in part complementary substrate specificities. Since it is unknown which one is 
prevalent (or if both are expressed) in P388D1Doxo cells, it remains unclear if the 
observed higher inhibitory activity of valspodar has to be attributed to one distinct subtype. 
Nevertheless, the significantly higher relative activity of valspodar is in agreement with 
previously reported discrepancies between the potencies of P-glycoprotein modulators 
in vitro (human Kb-V1 cells) and in nude mice (Fellner et al., 2002; Hubensack et al., 
2008). 
In another approach, the established flow cytometric calcein-AM efflux assay was 
successfully adapted to the microtiter plate format. The newly established assay 
enormously reduced the amount of materials (e.g. number of cells, test compounds and 
fluorescent dye) while throughput was substantially increased. Additionally, the assay led 
to comparable and reliable data when compared to the flow cytometric procedure. Due to 
the influence of the incubation period on Emax- and IC50-values (discussed in 
section 3.3.3.2), it is recommended to prolong this period to 30 min for the investigation of 
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future compound libraries. In general, there are further issues that may enormously effect 
the determination of P-gp modulatory activity. Beside plasma protein binding (presence of 
BSA) and species-dependent differences (as discussed above), the utilized substrate may 
affect the inhibition data (Schwab et al., 2003). Such interdependencies have also been 
reported for other promiscuous macromolecular targets such as the cytochrome P450 
enzymes (Korzekwa et al., 1998). Consequently, all above mentioned issues should be 
kept in mind, when comparing data of modulators from different laboratories. 
With respect to intended in vivo studies, in a third series of experiments, the 
biopharmaceutical properties of the most promising new tariquidar-like modulators 
ME27-4, ME30-1 and ME33-1 were investigated. During these studies, the compounds 
were characterized with regard to cytotoxicity, potential pharmacokinetic interactions and 
drug-like properties. In summary, the results of these investigations identified the new 
ABCB1 modulators as candidates for further in vivo experiments which are presented in 
the following chapters. 
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Chapter 4 
4 Tariquidar analogs: quantification by HPLC 
and impact on the distribution of 
co-administered paclitaxel in NMRI mice 
 
4.1 Introduction 
Paclitaxel (Taxol®) is active against a broad variety of clinically relevant malignancies. 
According to the guidelines of the National Institute for Health and Clinical Excellence1 this 
cytostatic drug is recommended for the first and second line therapy of ovarian cancer, 
non-small cell lung cancer and advanced breast cancer. In contrast to the indisputable 
benefit in the treatment of peripheral neoplasms, in the clinics taxol is ineffective against 
primary and secondary brain tumors (Brandes et al., 2000; Glantz et al., 1999) regardless 
of the chemosensitivity of such malignant cells in vitro. This is mainly caused by the 
special location of the tumors in the CNS “behind” the blood-brain barrier (Debinski, 2008). 
Indeed, 98 % of small molecular drugs (Pardridge, 2007) are not able to cross the BBB 
due to its special architecture (see section 1.3) and the presence of ATP-driven drug efflux 
transporters (Glantz et al., 1999; Miller et al., 2000). Among these transporters, 
P-glycoprotein is the major obstacle for drug delivery to the brain due to the high 
expression level, the eminent transport capacity and the broad substrate specificity (Miller 
et al., 2008). 
In previous studies with nude mice bearing intracerebral human glioblastomas, the brain 
levels of paclitaxel, an ABCB1 substrate, were significantly increased when the drug was 
co-administered with the second generation modulator valspodar (Fellner et al., 2002). 
Furthermore, the elevated concentration of paclitaxel in the brain caused a reduction of the 
                                                
1 www.nice.org.uk 
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tumor volume by 90 %. However, concomitant administration of valspodar resulted in 
elevated plasma levels and thereby increased toxic side effects of the cytostatic drug 
(cf. chapter 2). A plausible explanation for this observation is that paclitaxel is metabolized 
by the enzymes CYP3A4 and CYP2C8 (Fachinformation Taxol®, (Jamis-Dow et al., 1995)) 
which are inhibited by valspodar (Fischer et al., 1998). On the other hand, elevated plasma 
levels could result from impaired drug clearance as P-glycoprotein is also present in the 
membranes of epithelia lining excretory organs. However, the latter can be ruled out as 
Kemper et al. (2003) showed that in contrast to valspodar and cyclosporin A, the third 
generation modulator elacridar did not increase brain or plasma AUCs of paclitaxel in both 
wild type and Abcb1a/b double-knockout mice. Moreover, experiments with other 
intravenously administered P-gp substrates and modulators (e.g. digoxin, verapamil, 
vinblastine etc.) in Abcb1a/b double-knockout mice showed no substantial increase in 
plasma levels compared to wild type animals (Mizuno et al., 2003). 
Subsequent pharmacokinetic studies using the third generation inhibitor tariquidar 
confirmed these findings and revealed that the plasma levels of co-adminestered paclitaxel 
were comparable to those achieved by mono-therapy (Hubensack et al., 2008). By 
contrast, the brain levels of paclitaxel, albeit lower than after co-administration of 
valspodar, were significantly elevated. The discrepancy between high in vitro potency of 
tariquidar (by far superior to valspodar) and the in vivo results was attributed to poor drug-
like properties such as high lipophilicity (accumulation in adipose tissue) and poor 
solubility. Consequently, it was hypothesized that more hydrophilic tariquidar-like 
modulators should have improved pharmacokinetic and pharmacodynamic properties. 
In order to investigate this hypothesis, a series of tariquidar like modulators was 
synthesized (Egger et al., 2007). The three most potent compounds were characterized in 
vitro (see chapter 3) and, based on these results, selected for in vivo investigations. 
One objective of this study was to investigate the bioavailability and distribution of these 
new modulators. The second objective was to elucidate the potential to increase the 
concentration of paclitaxel in the CNS to improve brain cancer chemotherapy. Special 
attention was dedicated to answer the question if these new modulators may be superior 
to valspodar with respect to systemic toxicity. 
 
4.2 Materials and methods 
4.2.1 Drugs and chemicals 
The tariquidar-like modulators ME27-4, Me30-1 and ME33-1 were synthesized (Egger et 
al., 2007) by the workgroup of Prof. König (Institute of Organic Chemistry, University of 
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Regensburg, Germany). Tariquidar was synthesized in our laboratory according to the 
literature (Dodic et al., 1995; Roe et al., 1999) with slight modifications (Hubensack, 2005). 
In order to improve solubility with respect to the in vivo experiments, the modulators were 
transferred to the TFA salt in a mixture of acetonitril/water (80:20), and the respective 
solution was freeze-dried subsequently. Drug formulations for in vivo administration 
(ketamine (Ketanest®, WVD, Garbsen, Germany), xylazine (Rompun®, Bayer, Leverkusen, 
Germany) and paclitaxel (6 mg/mL; Bristol-Meyers Squibb; Wien, Austria)) as well as pure 
material (paclitaxel and docetaxel) for HPLC standardization were obtained from the 
Regensburg University Hospital´s pharmacy. Bovine serum albumin was purchased from 
Serva (Heidelberg, Germany), CPD (citrate-phosphate-dextrose) plasma from the 
Bavarian Red Cross (BRK, Regensburg, Germany), respectively. If not stated otherwise, 
chemicals (p.a. quality) were obtained from Merck (Darmstadt, Germany). Millipore filtered 
water was used throughout. 
 
4.2.2 Sample preparation 
Sample preparation by liquid-liquid and solid-phase extraction was performed according to 
the method established by Sparreboom et al. (1995) with modifications described in detail 
previously (Fellner, 2001; Hubensack, 2005). After the elution of paclitaxel and docetaxel, 
the ABCB1 modulators ME27-4, ME30-1, ME33-1 and tariquidar (internal standard) were 
rinsed from the SPE columns with 0.8 mL of tetrahydrofuran and processed as described 
for paclitaxel (Fellner, 2001; Hubensack, 2005). This modification allowed the selective 
detection of the taxanes and the tariquidar-like modulators extracted according to one 
sample preparation protocol. The method yielded very clear extracts, containing no 
interfering substances (see sections 4.3.1 and 4.3.4). 
 
4.2.3 HPLC analysis of ME27-4, ME30-1, ME33-1 and paclitaxel  
The samples obtained after SPE were analyzed immediately (paclitaxel brain extracts) or 
after storage at -78 °C. Subsequent RP-HPLC analysis was performed with a Waters 
(Eschborn, Germany) system composed of a 600S controller and pump, a Waters 
degasser, a temperature control module, a 717 plus autosampler and a 2487 UV-detector. 
A Luna RP-18 (Phenomenex, Aschaffenburg, Germany) analytical column (3 µm, 150 mm 
x 4.6 mm) thermostatted to 30 °C with a flow rate of 0.8 mL/min was used. 100 µL of the 
sample were injected while UV-detection was performed at 227 nm for paclitaxel and at 
210 nm for the analyzed ABCB1 modulators, respectively. During recovery analysis, the 
applied gradient was as following: MeCN/0.05 % TFA (aq.): 0 min: 15/85, 19 min: 60/40, 
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20 min: 95/5, 24.5 min: 95/5, 25 min: 15/85, 38 min: 15/85. For the subsequent in vivo 
investigations the gradient was slightly modified (0 min: 15/85, 21.1 min: 65/45, 22.5 min: 
95/5, 26.5 min: 95/5, 27 min: 15/85, 40 min: 15/85) to optimize paclitaxel analysis without 
affecting the retention time of tariquidar-like modulators. 
For the quantification of plasma and brain samples, at the day of analysis calibration 
curves were constructed by dilution of the respective stock solutions (paclitaxel and 
docetaxel in absolute ethanol; tariquidar and its analogs in anhydrous DMSO; stored at 
-20 °C) with mobile phase (1:100). Depending on the type of tissue, 5 to 6 different 
concentrations between 50 nM and 10 µM were analyzed. Coefficients of determination for 
the various analytes and sample types were higher than 0.995 throughout. 
The method for paclitaxel analysis was validated previously (Fellner, 2001). Recoveries for 
paclitaxel ranged from 69 to 85 % (plasma samples) and 50 to 59 % (brain samples), 
respectively. In the concentration range from 0.13 to 6.67 nmol/g, the method´s accuracy2 
was better than 8 % while precision3 was not more than 9 % CV. 
 
4.2.4 Recovery of tariquidar-like modulators 
By analogy with the protocol for the analysis of paclitaxel, a quantification method for 
ME27-4, ME30-1 and ME33-1 in plasma and brain samples was set up and validated. To 
determine the recoveries, human CPD plasma and porcine brain was used instead of the 
murine tissues. Prior to the extraction routine, 10 µL of the IS (tariquidar, [50 µM]) and the 
respective analyte ([50 µM], [125 µM] and [250 µM]) were added to 250 µL plasma or 
134 mg brain tissue, respectively. 
The density of murine plasma was averaged by exact weighting of 1000 µL (n = 5) murine 
plasma to be 1.048 g/mL. The amount of tissue in the homogenates was 134 mg/mL 
(determined by Fellner (2001)). Quantification was carried out by calibration curves as 
described in section 4.2.3. 
 
4.2.5 Pharmacokinetic studies in NMRI mice 
The in vivo experiments were performed with slight modifications by analogy with previous 
studies (Fellner et al., 2002; Hubensack et al., 2008) and are summarized in Figure 4.1. In 
brief: 24 female six- to eight-week-old NMRI mice were used per treatment group providing 
4 replicates (n = 4) per time point. All modulators were dissolved in a vehicle composed of 
                                                
2 Percental difference between the determined value and the true value (Shah, et al., 1991) 
3 Closeness of replicate determinations of an analyte by an assay expressed as coefficient of 
variation (CV) (Shah, et al., 1991) 
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52.5 g cremophor RH40 (Caelo, Hilden, Germany), 15 g Labrafil M2125CS (Gatefosse, 
Weil am Rhein, Germany), 15 g absolute ethanol, 7.5 g propylene glycol and 0.1 g of D,L-
α-tocopherol (Sigma, Munich, Germany) by sonication at 37 °C. A volume of 5 µL per gram 
of body weight (concentration: 10 mg/mL) was administered by gavage into the stomach. 
Control animals received the respective amount of vehicle. 
After a lag time of 2.5 hours, animals were anesthetized with 30 - 50 µL (depending on the 
body weight) of a mixture of ketamine/xylazine (3:1) and received 8 mg/kg (5 µL per gram 
of body weight) paclitaxel by injection via the retrobulbar plexus. Prior to paclitaxel 
administration, drug solution (6 mg/mL) was diluted with 0.9 % NaCl solution to a 
concentration of 1.6 mg/mL. 
10, 30, 60, 120, 240 and 420 minutes after paclitaxel injection, ketamine/xylazine-
anesthetized mice were killed by cardiac puncture, and heparin-plasma as well as brain 
samples were collected. All samples were immediately stored on ice, and brain tissue was 
subsequently homogenized in 4 % BSA solution with a Potter-Elvehjem homogenizer. 
Within 15 minutes after sampling, plasma and brain homogenates were shock-frozen in 
liquid nitrogen and stored at -78 °C until SPE and RP-HPLC analysis. 
Pharmacokinetic parameters were determined by standard non-compartmental analysis. 
The area under the concentration-time curve (AUC) after intravenous paclitaxel 
administration was calculated by linear trapezoidal rule from t = 0 min (t0) to the last 
quantified concentration. The paclitaxel concentration at t0 was extrapolated by linear 
regression (plasma) or designated to be zero (brain), respectively. 
 
Figure 4.1: Application scheme of the 
tariquidar-like modulators and paclitaxel to 
NMRI mice; the treatment experiments 
with subcutaneously (chapter 5) and intra-
cerebrally (chapter 6) growing tumors in 
nude mice were carried out by analogy 
(with different concentrations of the 
modulator and the cytostatic drug; quod 
vide). 
 
4.3 Results and discussion 
4.3.1 Elaboration of the analytical method 
By means of the modified extraction procedure it became possible to quantitate paclitaxel 
and the tariquidar-like modulators using a single extraction routine, followed by a single, 
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standardized HPLC method. As becomes obvious from Figure 4.2, SPE yielded very pure 
extracts, containing no interfering substances. 
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Figure 4.2: Chromatogram of a CPD plasma 
sample spiked with the tariquidar analogs 
[1 nmol/mL] obtained after sample preparation 
with the modified SPE procedure (blue solid 
line); the respective chromatogram of a blank 
plasma sample (red dotted line) processed by 
the same method shows no interfering peaks 
originating from plasma constituents. HPLC 
conditions: Luna RP-18 (3 µm, 150 mm x 
4.6 mm); gradient mode: MeCN/0.05 % 
TFA (aq.): 0 min: 15/85, 19 min: 60/40, 20 min: 
95/5, 24.5 min: 95/5, 25 min: 15/85, 38 min: 
15/85; flow: 0.8 mL/min; UV-detection at 210 
nm; 30 °C 
 
A major problem of the tariquidar-like compounds was the high affinity to boundary 
surfaces. This property was responsible for low recoveries at the beginning of the 
investigations and impeded precise quantification. Figure 4.3 shows that the adsorption to 
vessel material could be effectively prevented by siliconization. Consequently, for 
subsequent analysis, solely siliconized glass vials were used for the construction of 
calibration curves. 
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Figure 4.3: Influence of vessel 
material on the slope of a 
calibration curve for ME33-1; 
adsorption of the analyte to the 
surface is responsible for the 
outcome. The same effect was 
observed for tariquidar and the 
other modulators (data not 
shown). 
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4.3.2 Specificity of the separation method 
A specific detection of the various analytes is fundamental for accurate quantification. To 
guarantee sufficient separation of the internal standard from the respective analyte, 
resolution4 was determined at different concentrations of the modulators (see Figure 4.4). 
In general, baseline separation is defined as a resolution ≥ 1.5 (provided that peaks are 
symmetrical and areas comparable) (Rücker et al., 2008). The obtained data demonstrate 
that the established HPLC method is by far sufficient for specific analyte detection in the 
investigated concentration range. 
Table 4.1: Resolution of internal standard [2.5 µM] and the different analytes at various 
concentrationsa 
Concentration 
[µM] 
 
Resolution 
ME27-4 
 
ME30-1 
 
ME33-1 
0.25 13.47 6.10 4.91 
2.5 13.28 6.46 4.79 
10.0 13.22 7.20 5.51 
a HPLC conditions as described in section 4.2.3 
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Figure 4.4: Chromatograms of the internal standard (IS) [2.5 µM] and ME33-1 (analyte with the 
lowest resolution to the IS at various concentrations: A) 0.25 µM, B) 2.5 µM and C) 10 µM; HPLC 
conditions as described in section 4.2.3 for the in vivo investigations 
To exclude undesired matrix effects, samples obtained by SPE of CPD plasma spiked with 
ME27-4, ME30-1 and ME33-1 were also analyzed (cf. Table 4.2). Since the extraction 
                                                
4 The resolution as well as the modified signal-to-noise ratio (see section 4.3.4) was determined 
according to European Pharmacopoeia (Ph. Eur., 6th Edition, 2008), section 2.2.46. 
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routine had no influence on the quality of resolution, only a medium concentration of every 
modulator was investigated. 
 
Modulator  Resolution CV (%) Table 4.2: Resolution of the IS 
[2 µM] and the different analytes 
[5 µM] after SPEa 
ME27-4  13.51 0.96 
ME30-1  6.55 0.53 
ME33-1  4.79 1.57 
a HPLC conditions as described in section 4.2.3 for the in vivo investigations, n = 3 
 
4.3.3 Linearity and quantification range 
The linearity of the detector signal was verified for all analytes in the concentration range 
between 30 nM and 10 µM. Figure 4.5 shows the result for ME30-1 and illustrates that the 
instrumental setup is adequate to determine the anticipated very low concentrations in the 
brain as well as high peak plasma levels. 
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Figure 4.5: Linearity of the 
detector signal for ME30-1 
in the concentration range 
between 30 nM and 10 µM 
(injection volume 100 µL); 
for all other analytes the 
coefficient of determination 
was > 0.9999 (data not 
shown). HPLC conditions as 
described in section 4.2.3 
 
4.3.4 Limit of quantification 
To estimate the lowest concentration to be reliably quantified, ME27-4, ME30-1 and 
ME33-1 were analyzed at various concentrations. Since the “noise” of the given analytical 
procedure mainly results from interfering peaks from components of the biological matrix, 
signal intensities were compared to background signals obtained by SPE of the respective 
blank tissue (see Table 4.3 and Figure 4.6). 
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Table 4.3: Ratio of analyte to background signals at various concentrationsa 
Concen
-tration 
[nM] 
 
ME27-4 ME30-1 ME33-1 
Plasma 
 
Brain Plasma Brain Plasma 
 
Brain 
30 - - - - 3.3 3.5 
50 11.5 2.8 3.6 2.2 5.3 5.7 
100 17.0 5.2 6.9 4.2 10.7 11.3 
300 53.0 16.3 19.3 12.0 33.8 35.8 
1000 178.0 54.8 63.6 38.9 - - 
a HPLC conditions as described in section 4.2.3 for the in vivo investigations 
 
Even at the lowest examined concentrations, peak heights of the modulators exceeded 
impurity peaks several times. Additionally, for none of the compounds, background signals 
did interfere (different retention times) with the analyte peaks. 
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Figure 4.6: Chromatogram of ME30-1 at a concentration of 300 nM (A) and the corresponding 
blank brain sample (B); the analyte to background signal ratio for the selected example is 12. HPLC 
conditions as described in section 4.2.3 for the in vivo investigations 
Taken together, the purity of the SPE samples allows a quantification of the various 
analytes in the two-digit nanomolar range. 
 
4.3.5 Stability of the analytes in murine plasma and in mobile phase 
Due to reasons of feasibility, tissue samples were stored at -78 °C (maximum storage 
period 14 days) until subsequent SPE. Owing to the same reason, the extracts obtained by 
SPE were stored under identical conditions for less than 14 days (paclitaxel brain samples 
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were analyzed immediately after the extraction routine). In order to investigate the 
influence of the storage on the concentration of the various modulators, spiked plasma 
samples and analytes in mobile phase were quantified immediately and after a storage 
period of 14 days. Table 4.4 summarizes the obtained results. 
 
Modulator 
 Δ concentration during storage (%) 
Table 4.4: Mean change 
of the concentration of the 
analytes [5 µM] after 
storagea 
 Spiked plasma sample  
Analytes in 
mobile phase 
ME27-4  -5.2  +6.5 
ME30-1  -7.6  -5.7 
ME33-1  -14.0  -15.1 
a storage conditions: 14 days at -78 °C, n = 4 
The observed concentration differences are tolerable and most likely not caused by 
degradation of the analytes (no additional peaks in the respective chromatograms). 
Arguably, the decrease in concentration is caused by adsorption to vessel walls (difference 
increases with the lipophilicity of the modulators). Moreover, the overall accuracy of the 
established method has to be considered (see section 4.3.7). 
 
4.3.6 Recoveries 
The recoveries of ME27-4, ME30-1 and ME33-1 from plasma and brain samples were 
determined at various concentrations (see Table 4.5 for plasma and Table 4.6 for brain 
samples, respectively). The same amount of the internal standard (10 µL of a [50 µM] 
tariquidar solution in DMSO) was added to every sample prior to the extraction procedure. 
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Table 4.5: Plasma recoveries of ME27-4, ME30-1 and ME33-1 at various concentrationsa 
Modulator 
Concen-
tration 
[µM]b 
 Recovery (%) 
CV 
(%) 
Recovery ratio 
(modulator/IS) 
CV 
(%) 
ME27-4 
1  68.8 6.5 0.974 1.5 
5  81.6 3.2 0.935 3.4 
10  84.6 1.7 0.981 1.2 
ME30-1 
1  79.8 2.6 1.122 2.8 
5  79.4 2.8 0.925 2.9 
10  75.0 5.2 0.964 1.6 
ME33-1 
1  79.4 5.4 1.069 2.3 
5  75.1 1.5 0.976 1.3 
10  72.7 2.2 0.932 1.9 
a Prior to sample preparation 10 µL of the respective analyte (25-fold concentrated stock solution) 
and 10 µL of tariquidar stock solution (always 50 µM) were added. 
b For each concentration 5 - 6 samples were analyzed. 
The extraction procedure yielded consistently high recoveries in the range of 69 to 85 % 
for all analytes at the examined concentrations. Even at low concentrations, constant 
recovery ratios around unity were obtained. That indicates that the modulators as well as 
tariquidar are extracted to the same extent, enabling a reliable calculation in the 
subsequent in vivo investigations. Additionally, the precision of the determined recoveries 
and recovery ratios was considerably high (1.5 to 6.5 % and 1.2 to 3.4 %, respectively). 
Table 4.6: Brain recoveries of ME27-4, ME30-1 and ME33-1 at various concentrationsa 
Modulator 
Concen-
tration 
[nM/g]b 
 Recovery (%) 
CV 
(%) 
Recovery ratio 
(modulator/IS) 
CV 
(%) 
ME27-4 
1.87  40.0 14.3 1.018 5.2 
9.24  20.7 19.7 1.007 4.9 
18.66  28.9 14.3 1.142 2.8 
ME30-1 
1.87  30.2 19.9 1.105 2.9 
9.24  42.7 15.2 1.214 4.3 
18.66  37.0 12.2 1.020 0.7 
ME33-1 
1.87  54.9 13.3 1.156 3.6 
9.24  50.2 15.8 1.093 2.3 
18.66  47.1 12.5 1.128 9.0 
a Prior to sample preparation 10 µL of the respective analyte (25-fold concentrated stock solution) 
and 10 µL of tariquidar stock solution (always 50 µM) were added. 
b For each concentration 5 - 6 samples were analyzed. 
58 Chapter 4 
Compared to the results obtained with plasma, the recoveries from brain samples are 
consistently lower (most probably due to additional (insufficient) diethyl ether extraction). 
However, the recovery ratios converged to unity and showed high precision between 
0.7 and 5.2 %. 
 
4.3.7 Accuracy and precision of the established method 
The reliability of the modified SPE method was determined exemplarily for plasma 
samples spiked with ME30-1. Table 4.7 shows that the accuracy ranged between 1.5 and 
7.0 % while precision was not more than 3.1 % CV. 
Table 4.7: Determination of known ME30-1a concentrations in plasma samples to revise accuracy 
and precisionb 
Reference 
concentration [µM]  
Determined 
concentration [µM] 
Accuracy 
(%)  
Precision 
(%)c 
1.0  0.93 -7.0  3.1 
5.0  4.93 -1.5  1.5 
10.0  9.55 -4.5  1.6 
a Modulator with medium lipophilicity; b For each concentration 5 - 6 samples were analyzed. 
c Precision is expressed as coefficient of variation (CV). 
The accuracy of spiked brain samples (ME30-1, 18.7 nmol/g, n = 5) was better than 
16.7 %. In general, an accuracy better than 20 % is demanded for quantitative 
determinations (Shah et al., 1991). The precision (2.5 %) was excellent. 
 
4.3.8 Distribution of tariquidar-like modulators in NMRI mice 
Adequate bioavailability and stability of the ABCB1 modulators is a prerequisite for 
successful tumor pharmacological studies (cf. chapters 5 and 6) on the efficacy of 
combined cancer chemotherapy. Additionally, the modulators should be devoid of inherent 
toxicity and should not increase the toxicity of the co-administered anticancer drug (see 
section 4.3.9). The established and validated method for the quantification of ME27-4, 
ME30-1 and ME33-1 was utilized to assess the bioavailability and stability of these 
compounds. The study design as well as the application scheme is described in 
section 4.2.5. 
Figure 4.7 shows the plasma concentration time curves of tariquidar-like modulators. 
Within the considered period of time, the determined concentrations of the various 
modulators ranged from approximately 4 to 12 µM and were far above the limit of 
quantification. The plasma levels of ME30-1 and ME33-1 were 10 to 285 times higher than 
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the IC50-values obtained in vitro (depending on assay type and used cell line, cf. 
chapter 3). In the case of ME27-4 this ratio (4 to 35 times) was considerably lower. 
ME33-1 was the only modulator that showed an increase in plasma levels over the 
investigation period, possibly due to redistribution from adipose tissue or retarded 
absorption from the gastro-intestinal tract. 
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Figure 4.7: Plasma concentrations of the ABCB1 modulators ME27-4 (circles), ME30-1 (diamonds) 
and ME33-1 (triangles) in NMRI mice (mean values ± SEM, n = 3 - 4) 
The brain concentrations of ME27-4 and ME30-1 (Figure 4.8) ranged in the low 
micromolar level and were remarkably lower than those determined in plasma. By contrast, 
the brain concentrations of the most lipophilic compound (ME33-1) were significantly 
higher and with approximately 2.5 to 8.0 µM comparable to those in plasma (Figure 4.8). 
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Figure 4.8: Brain concentrations of the ABCB1 modulators ME27-4 (circles), ME30-1 (diamonds) 
and ME33-1 (triangles) in NMRI mice (mean values ± SEM, n = 3 - 4) 
Taken together, all investigated modulators showed adequate bioavailability and high 
metabolic stability obvious from the only moderate decrease in concentration over the 
investigation period. Additionally, no acute intrinsic toxicity of the modulators was 
observed. Taking the determined concentrations and the differing in vitro potency of the 
modulators into account, ME30-1 and ME33-1 should be superior to ME27-4. 
 
4.3.9 Effect of tariquidar-like modulators on the distribution of paclitaxel 
The second prerequisite for the efficacy of adjuvant brain cancer chemotherapy is the 
potential of the individual ABCB1 inhibitor to increase the concentration of the cytostatic 
drug (in our study paclitaxel) in the CNS. In addition, with respect to systemic toxicity, the 
modulator should not increase the paclitaxel plasma levels. The latter is also an important 
issue to conclude that elevated CNS levels result exclusively from the inhibition of ABC 
transporters at the BBB. 
The effect of tariquidar-like modulators on the brain levels of co-administered paclitaxel is 
summarized in Figure 4.9. The results correlate with the previously determined in vitro 
potency. With nearly constant paclitaxel levels of approximately 400 nM over 7 hours, 
ME33-1 produced the most pronounced effect. ME30-1 induced brain levels between 400 
and 150 nM, especially in the first two hours. Unless ME27-4 had the lowest effect on the 
brain concentration of paclitaxel, the levels were still about 100 % higher than in the control 
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experiments. It is important to note that against the glioblastoma cells selected for in vivo 
investigations (U-118 MG and U-87 Luc2 clone 3, cf. chapter 6) a cytocidal effect of 
paclitaxel was observed at concentrations of 50 nM and 100 nM, respectively (long-term 
drug exposure). This means that the extent of the increase in brain levels of the anticancer 
drug was sufficient to achieve the therapeutically relevant concentration. 
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Figure 4.9: Effect of ABCB1 modulator co-administration on paclitaxel levels in the brain of NMRI 
mice (mean values ± SEM, n = 3 - 4); ME27-4 (filled circles), ME30-1 (filled diamonds) and ME33-1 
(filled triangles) were used as ABCB1 modulators. Untreated mice served as control (open 
squares). 
The determined paclitaxel plasma concentration time curves presented in Figure 4.10 are 
typical for intravenous drug administration. The concentrations ranged from 5.5 to 7.0 µM 
after 10 minutes and decreased to 2.5 µM within one hour. Four hours and seven hours 
after paclitaxel administration, the concentration decreased to 590 and 270 nM, respec-
tively. It is important to emphasize that none of the modulators affected the paclitaxel 
plasma concentration significantly. 
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Figure 4.10: Effect of ABCB1 modulator co-administration on paclitaxel levels in the plasma of 
NMRI mice (mean values ± SEM, n = 3 - 4); ME27-4 (filled circles), ME30-1 (filled diamonds) and 
ME33-1 (filled triangles) were used as ABCB1 modulators. Untreated mice served as control (open 
squares). 
In Figure 4.11 the area under the paclitaxel concentration-time curves obtained by co-
administration of the respective modulator are compared with the AUC of paclitaxel mono-
therapy (control). Depending on the substance, the brain AUCs were increased to 190, 
230 or 380 %. By contrast, the paclitaxel plasma AUCs remained unchanged, irrespective 
of the concomitant modulator. Therefore, the systemic paclitaxel toxicity should be lower 
compared to previous studies using valspodar as modulator of P-glycoprotein (Fellner et 
al., 2002). Additionally, the data confirm that the enhanced penetration of paclitaxel into 
the brain is not a consequence of an increased plasma/brain concentration gradient of the 
cytostatic drug. 
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Figure 4.11: Effect of ABCB1 modulator co-administration on the AUC of paclitaxel in brain (A) and 
plasma (B) of NMRI mice; the AUC of the control (paclitaxel + vehicle) was defined as 100 %. As 
becomes obvious, every compound had the potency to elevate the brain AUC of paclitaxel. The 
extent of the increase is in agreement with the determined in vitro activity of the ABCB1 modulators. 
In contrast, none of the tariquidar-like modulators has a significant impact on the paclitaxel plasma 
AUC. 
 
4.4 Summary and conclusions 
The P-glycoprotein modulators ME27-4, ME30-1 and ME33-1 were investigated in vivo 
due to encouraging results in vitro (see chapter 3). Furthermore, the hypothesis that more 
hydrophilic ABCB1 inhibitors are superior to tariquidar in terms of pharmacokinetics and 
pharmacodynamics should be evaluated. 
The modified SPE routine yielded very clear extracts, containing no interfering substances. 
Additionally, it became possible to quantitate the modulators and paclitaxel with one 
extraction routine, followed by one consistent RP-HPLC procedure. Validation revealed 
high specificity, reproducibility, accuracy, precision and a low limit of quantification for the 
various modulators. 
Subsequent biodistribution studies in NMRI mice revealed the absence of acute inherent 
toxicity, favorable bioavailability and high metabolic stability of the tariquidar-like 
compounds. Moreover, it should be stressed that all investigated modulators selectively 
elevated the brain paclitaxel levels in accordance with the determined in vitro potency. The 
increase in the paclitaxel brain AUCs by approximately 100 to 300 % was less pronounced 
than that observed previously with co-administered valspodar (Fellner et al., 2002). 
Nevertheless, it has to be taken into consideration that most likely cytochrome P450 
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related pharmacokinetic interactions of valspodar (Fischer et al., 1998; Jamis-Dow et al., 
1995) contributed to the increased penetration of paclitaxel into the brain. This is confirmed 
by experiments done with Abcb1a/b double knockout mice in which valspodar increased 
the plasma as well as the brain levels of paclitaxel (Kemper et al., 2003). Plasma levels 
were elevated 1.6 to 4.4-fold, and brain concentrations 1.4 to 1.8-fold, respectively. In 
contrast to the absorption of orally administered drugs, P-glycoprotein seems not to reduce 
the excretion of substrates. Studies with P-gp knockout mice showed no elevated plasma 
levels of intravenously administered vinblastine, digoxin et cetera (Mizuno et al., 2003), 
whereas the bioavailability of per orally dosed paclitaxel and docetaxel was significantly 
increased (Bardelmeijer et al., 2002; Koolen et al., 2010; Sparreboom et al., 1997). 
Another important finding from the performed in vivo studies is that none of the new 
modulators influenced the paclitaxel plasma AUC. This observation is in agreement with 
data from the literature for the close structural analog tariquidar. In a phase I study using 
tariquidar in patients with a broad variety of tumors (renal cell carcinoma, breast cancer, 
adrenocortical cancer, ovarial cancer etc.), Abraham et al. (2009) found no influence on 
the pharmacokinetics and the toxicity of the P-gp substrate vinorelbin. Moreover, tariquidar 
did also not alter the plasma levels of paclitaxel in NMRI (nu/nu) mice (Hubensack et al., 
2008) or CD rats (Mistry et al., 2001). The absence of effects on the plasma level of 
paclitaxel should result in lower systemic toxicity. As a consequence, the investigated 
modulators are more suitable for co-administration in cancer chemotherapy compared to 
second generation modulators. Indeed, due to toxic side effects in combination with 
valspodar, the paclitaxel dose had to be reduced to 2 mg/kg body weight in the 
subsequent treatment experiments (Fellner et al., 2002). Due to the lacking effect on the 
AUC of paclitaxel in plasma, a dose reduction of the cytostatic agent is not necessary 
when combined with the new modulators in therapeutic studies. 
The discrepancy between the high in vitro potency of tariquidar (and elacridar) and the in 
vivo results led to the assumption that the modulators reach the target at suboptimal 
concentrations due to low solubility, high lipophilicity and, possibly, accumulation in 
adipose tissue (Hubensack et al., 2008). Consequently, it was hypothesized that more 
hydrophilic modulators should show a higher in vivo potency. The investigated tariquidar-
like modulators show pronounced differences (approximately two orders of magnitude) in 
lipophilicity and were suitable to investigate the working hypothesis. However, a decrease 
in lipophilicity was not associated with increased paclitaxel levels in the brain. On the 
contrary, the effect directly correlated with lipophilicity: the most lipophilic inhibitor 
(ME33-1) was most potent, followed by the compound with the medium lipophilicity 
(ME30-1) and the most hydrophilic ABCB1 modulator (ME27-4). A certain degree of 
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hydrophobicity seems to be required for the accumulation in the membrane and to reach 
the binding site of the transporter (see chapter 7, in particular section 7.3.1). It has to be 
taken into consideration that the more hydrophilic modulators had also higher IC50-values 
in vitro. Nevertheless, even the compound with the highest IC50-value investigated in this 
study had a higher in vitro potency than valspodar. 
On the basis of the results of the pharmacokinetic studies, the two modulators with the 
most pronounced effect on the paclitaxel brain AUC were chosen for more detailed tumor 
pharmacological experiments in nude mice. In chapter 5 the effect of concomitant 
paclitaxel administration on subcutaneously growing, ABCB1 transporter over-expressing 
human Kb-V1 tumors (ME30-1 and ME33-1) is evaluated. In chapter 6 an analogous 
approach is used to study the impact of combination treatment on intracerebral human 
glioblastomas (ME33-1). 
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Chapter 5 
5 Reversal of classical multidrug resistance 
by co-administration of ABCB1 modulators 
and paclitaxel in a subcutaneous xenograft 
model 
 
5.1 Introduction 
In the previous 50 years considerable research effort has been devoted to the design and 
the clinical use of innovative chemotherapeutic agents (Mellor and Callaghan, 2008). 
Additionally, substantial advances have been achieved in the fields of molecular biology, 
genetics, tumor biology and immunology. This information has ameliorated our 
understanding of carcinogenesis, development and progression of malignant tumors at a 
molecular level. 
Despite this indisputable progress, the translation of this knowledge into a clinically 
relevant improvement of therapy is still lacking for many tumor types (Gillet and 
Gottesman, 2010). In particular this is true for neoplasms with a special location that 
impedes dissection and/or drug therapy (e.g. in the CNS; cf. chapters 4 and 6) and after 
dissemination. Moreover, a vast number of malignancies in the periphery is also affected, 
since these tumors show inherent and/or developed (approximately 40 % of all cancer 
types) resistance against chemotherapy (Higgins, 2007). Characteristic of the latter is that 
many of the affected patients previously underwent chemotherapy and showed initial 
response followed by relapse (Mellor and Callaghan, 2008). In most cases relapse is 
accompanied by the insensitivity to a broad spectrum of cytostatic agents (including drugs, 
which in the patient initially reduced the tumor size). This phenotype was subsumed under 
the designation multidrug resistance (MDR). Consequently, it is important to consider that 
MDR is a multifactorial phenomenon (see Table 5.1). Although multiple mechanisms play 
70 Chapter 5 
a role, ABC transporter mediated efflux (particular by ABCB1) is the most important and 
the best characterized cause for MDR. 
Table 5.1: Main mechanisms of multidrug resistance observed in tumor cell linesa 
Mechanism  Effect / Examples  
Altered membrane 
transport 
 Decreased uptake of water soluble drugs via carrier systems 
 (e.g. folate antagonists, nucleoside analogs, cisplatin) 
Increased export of mainly lipophilic drugs via efflux transporter 
 (most important are ABCB1, ABCG2 and ABCC1) 
Increased 
detoxification by 
metabolic 
enzymes 
 
Cytochrome P450 enzymes (e.g. cyclophosphamide) 
Glutathion S-transferase (e.g. carmustine, cyclophosphamide)
UDP-glucoronyltransferase (e.g. etoposide, tamoxifen) 
Alterations in 
target molecules  
Increased transcription of the target (e.g. taxanes) 
Mutation of the binding site (e.g. epothilones)
Alterations in 
genes regulation  
Enhanced DNA repair (alkylating agents)
Reduced apoptosis (Bcl2 pathway, p53 protein; e.g. vinorelbine)
Pertubation of cell cycle (p53 protein; e.g. fluorouracil, paclitaxel)
a Modified from Meijerman et al. (2008) and complemented according to Gillet and Gottesman 
(2010), Luqmani (2005) and Szakacs et al. (2006) 
The significance of P-gp, both at the BBB and in classical MDR, as well as the 
encouraging in vitro results of the investigated modulators (see chapter 3 and 
section 5.3.1.6), prompted the development of a predictive in vivo model to investigate the 
therapeutic value of the new ABCB1 modulators in multidrug resistant tumor xenografts. 
 
5.2 Materials and methods 
5.2.1 Drugs and chemicals 
Vinblastine, doxorubicin and cisplatin were purchased from Sigma (Munich, Germany). 
Mitoxantrone and topotecan stock solutions were obtained by diluting Novantron® (Wyeth 
Pharma, Münster, Germany) and Hycamtin® (GlaxoSmithKline, Munich, Germany) with 
70 % ethanol. For tariquidar, ME30-1 and ME33-1 see section 3.2.1. Paclitaxel (6 mg/mL, 
Bristol-Meyers Squibb, Wien, Austria) was obtained from the pharmacy of the University 
Hospital Regensburg. Bovine serum albumin and fetal calf serum were acquired from 
Serva (Heidelberg, Germany) and Biochrom (Berlin, Germany), respectively. Detection of 
P-gp was performed with Mdr C19 purified polyclonal primary antibody raised in goat 
(Santa Cruz Biotechnology, Heidelberg, Germany). The secondary antibody (texas red 
conjugated donkey anti-goat IgG (H+L)) as well as the ImmunoSelect antifading Mounting 
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Medium with DAPI were purchased from Dianova (Hamburg, Germany). If not otherwise 
stated, chemicals (p.a. quality) were obtained from Merck (Darmstadt, Germany). Water 
was purified by a Milli-Q system (Millipore, Eschborn, Germany) 
 
5.2.2 Cell line and culture conditions 
Kb-V1 cells were cultured at 37 °C/5 % CO2 in DMEM (supplemented with 3.7 g/L sodium 
hydrogen carbonate, 110 mg/L sodium pyruvate and 10 % FCS (Biochrom, Berlin, 
Germany)) containing 330 nM vinblastine to maintain ABCB1 transporter expression (cf. 
section 3.2.2). For further general details cf. section 3.2.2. 
 
5.2.3 Determination of chemosensitivity, growth and doubling times 
in vitro 
Chemosensitivity was investigated by means of the kinetic crystal violet assay that was 
performed as described in section 3.2.5. In vitro growth was determined by a similar 
approach. After various periods of incubation (37 °C/5 % CO2) cells were fixed with glutar-
dialdehyde, stained with crystal violet and the absorbance (A580nm) was plotted against the 
cultivation time. Doubling times were calculated using a computer analysis program (Reile 
et al., 1990). 
 
5.2.4 Cytological staining 
Two days after seeding on specially prepared microscopic slides (cf. section 5.2.5), cells 
were fixed for 1 hour with Carnoy´s solution (ethanol/chloroform/glacial acetic acid 6:3:1) 
and stored in PBS containing 0.1 % NaN3. Subsequent staining with Harris` haematoxylin, 
orange G6 and eosin azure 50 was performed by the method of Papanicolaou (Takahashi, 
1987). The stained sections were evaluated with a BH-2 microscope (Olympus, Hamburg, 
Germany) with 40x and 100x Planapo oil immersion objectives (Zeiss, Jena, Germany). 
 
5.2.5 Karyology 
The assay was essentially performed as described previously (Jarzyna, 2007). In brief: 
microscopic slides were prepared (immersion in ethanol/hydrochloric acid (6 mL of 
concentrated hydrochloric acid in 200 mL 70 % ethanol for 24 hours)) according to the 
procedure of Rooney and Czepulkowski (1986). After cells had reached a confluency of 
approximately 15 % on the prepared slides (in Quadriperm lux-multiplates, Greiner 
Bio-One, Frickenhausen, Germany), cell culture medium was replaced with medium 
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containing 0.5 µg/mL of colcemide. After an incubation period of 2.5 hours (37 °C/5 % 
CO2), culture medium was removed and hypotonic potassium chloride solution (75 mM, 
37 °C) was added carefully. After 30 minutes, an equal volume of fixative (ice-cold 
methanol/glacial acetic acid 3:1) was added and removed (by careful suction) immediately. 
The fixation step was repeated twice (last step: 10 minutes fixation period). Subsequently, 
the dried slides were stained with Giemsa dye solution for 8 minutes. (10 mL filtered 
Giemsa solution, 90 mL of 0.025 M KH2PO4, pH 6.8) and mounted with DePeX (EMS, 
Hatfield, PA). Chromosome numbers were determined with a BH-2 microscope (Olympus, 
Hamburg, Germany) using a 100x Planapo oil immersion objective (Zeiss, Jena, 
Germany). For each passage of Kb-V1 cells 50 metaphases were counted. 
 
5.2.6 Immunocytochemical staining 
Kb-V1 cells were seeded into 8 chamber BD Falcon Culture Slides (BD Biosciences, 
Heidelberg, Germany). 24 h later (at approximately 50 % confluency), culture medium was 
replaced with 4 % paraformaldehyde in PBS and cells were fixed for 30 minutes. After a 
washing step (0.5 % BSA in PBS) and two subsequent permeabilisation steps with 0.1% 
Triton X-100 (Sigma, Munich, Germany) in PBS (PBS-T), an additional washing step 
followed. Unspecific binding of the primary AB was blocked by incubation with BSA 
solution (10 % in PBS-T) for 30 minutes. Afterwards, slides were incubated with various 
concentrations of the primary AB (Mdr C19) in PBS (containing 0.5 % BSA) over night at 
4 °C. To the controls, 0.5 % BSA in PBS without primary AB was added. Subsequent to 
three washing steps, samples were incubated with the secondary AB (texas red 
conjugated donkey anti-goat IgG (H+L), 1:200) in the dark for 1.5 hours. Then, the 
secondary AB was removed in 3 washing steps and by rinsing with Millipore water 
(2 seconds) afterwards. Counterstaining of the nuclei was achieved by mounting the slides 
with ImmunoSelect antifading Mounting Medium containing DAPI. Picture acquisition was 
performed as described in section 5.2.7. 
 
5.2.7 Immunohistochemical investigations 
Fixation, cryosectioning, staining and image acquisition were essentially performed 
according to the literature (Gleich and Pina, 2008; Gleich and Strutz, 2002; Gleich et al., 
2004) with some modifications. In brief: a nude mouse, bearing a subcutaneous human 
Kb-V1 tumor (passage 1) was killed by an overdose of narcotic (200 mg/kg ketamine, 
50 mg/kg xylazine; i.p.). To remove the blood and enlarge the vascular system the animal 
was transcardially perfused with 50 mg/L NaNO3 in common salt solution for 1 minute 
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(flow : 8 mL/min). Subsequently, tissue was fixed by perfusion with 0.1 M phosphate buffer 
(pH 7.4) containing 4 % paraformaldehyde/0.1 % glutardialdehyde for 30 minutes. After 
tumor dissection, tissue was cryoprotected with 30 % saccharose in 0.1 M phosphate 
buffer at 4 °C for 24 hours under agitation. 
Subsequently, the tumor was embedded in Tissue Freezing Medium (Jung, Leica 
Instruments GmbH, Nussloch, Germany) and sections of 50 µm were cut by a Leica CM 
1900 cryostat (Leica Mikrosysteme, Bensheim, Germany). Sections were immediately 
transferred into 24 well plates (Nunc, Wiesbaden, Germany) containing phosphate buffer. 
All further washing and staining steps were performed in these 24 well plates under 
agitation at room temperature (unless otherwise noted). 
Sections were washed three times (10 minutes) with PBS-T. Unspecific binding of the 
primary AB was blocked by incubation with 10 % BSA in PBS-T for 1 hour. Thereafter, 
tissue samples were incubated with various concentrations of the primary AB (Mdr C19) in 
PBS-T (containing 0.5 % BSA) for 24 hours at 4 °C. In controls, the respective solution 
without primary AB was added. After three washing steps (10 minutes) with PBS-T, 
secondary AB (texas red conjugated donkey anti-goat IgG (H+L), 1:400) was added and 
samples were stored for 2 hours in the dark. After additional three washing steps with 
PBS-T, sections were transferred to SuperFrost plus microscope slides. Nuclei were 
counterstained by mounting the samples with ImmunoSelect antifading Mounting Medium 
containing DAPI. 
Stained tissue samples were analyzed with a Leica DM RBE microscope (Leica 
Mikrosysteme, Bensheim, Germany). Image acquisition was conducted by using the digital 
high resolution Spot 2000 camera (Diagnostic Instruments, Stirling Heights, MI) under 
software control (Metamorph, Universal Imaging Corporation, West Chester, NY). Optimal 
exposure time for the red channel was determined empirically and kept constant in the 
following. Picture processing was performed with Adobe Photoshop in the same manner 
for all samples. 
 
5.2.8 Flow cytometric determination of functional ABCB1 transporters 
In order to determine the amount of functional P-gp, Kb-V1 cells were split into two 
subgroups. A control group (CG) was propagated with medium containing 330 nM 
vinblastine as before. The test group (TG) was subcultured without vinblastine. After 
various periods of time (with both subgroups) the calcein-AM efflux assay was performed 
at the flow cytometer with slight modifications according to Müller et al. (2007). 100 % 
inhibition of P-gp function was achieved by addition of 1 µM of tariquidar. The difference 
between the geometrical mean values in fluorescence intensity (GeoMean) of untreated 
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(100 % function) versus tariquidar treated cells corresponds to P-gp function. The 
percental amount of functional transporter in the TG in relation to the CG was calculated 
according to the following equation: 
 
100
)(GeoMean_CG)(GeoMean_CG
)(GeoMean_TG)(GeoMean_TG(%) gpP functional ⋅
−−+
−−+
=−         (equation 3) 
 
where (+) indicates treatment with 1 µM tariquidar and (-) addition of the respective volume 
of DMSO. 
 
5.2.9 Subcutaneous injection Kb-V1 cells and serial transplantation of 
solid tumor fragments 
Nude mice, housed under specified pathogen free (SPF) conditions in the central animal 
facility of the University of Regensburg, were used to establish and characterize 
subcutaneous Kb-V1 tumors for subsequent treatment experiments. The mice were kept in 
type III cages from TecniplastTM (Hohenpeißenberg, Germany) at a 12 hours light/dark 
cycle, 26 °C and 70 % relative humidity. Animals took food (Ssniff, Soest, Germany) and 
water (autoclaved tap water) ad libitum. 
For subcutaneous tumor cell implantation, cells were detached from the culture flask with 
trypsin/EDTA and FCS-free DMEM. After a subsequent washing step, cells were re-
suspended with serum-free DMEM and 1·107 cells (100 - 150 µL cell suspension) were 
injected under the thoracic dermis of nude mice. Tumor progression as well as body 
weight was monitored once weekly (all animals were individually identifiable due to 
tattooed pads). In order to maintain tumor growth over various passages a solid tumor was 
excised, pieces of approximately 2 mm3 were prepared in sterile PBS and serially 
transplanted. 
 
5.2.10 Histology 
Excised tumor tissue and organs were fixed for at least three days in Bouin´s solution 
(300 mL aqueous saturated picric acid, 100 mL formaldehyde and 20 mL glacial acetic 
acid) and embedded in paraffin by a standard procedure (cf. section 2.3.9.1 in Müller 
(2007)). Sections of 6 µm were cut by a Leica RM2255 microtome (Leica, Bensheim, 
Germany), transferred to SuperFrost plus microscope slides followed by deparaffinization 
using xylene and rehydration in a descending alcohol series. Subsequently, the samples 
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were stained by the procedure of Masson-Goldner or with haematoxylin-eosin (HE) as 
described elsewhere (Romeis, 1989). 
 
5.2.11 Therapeutic in vivo studies 
Compound preparation and administration was essentially performed as described in 
section 4.2.5. The modulators were dissolved in the vehicle and administered by gavage 
into the stomach (30 mg/kg, 7.5 mg/mL, 4 µL per gram of body weight) 2.5 hours before 
i.v. injection of paclitaxel (concentration range 2.5 - 4.5 mg/kg, 4 µL per gram of body 
weight). For the exact concentration and time regime of the various modulators see 
sections 5.3.3.1, 5.3.3.2 and 5.3.3.3. In the following, the treatment arm receiving this dose 
regime is designated as Pac/Mod-group. 
Animals in the control group received vehicle and 0.9 % common salt solution, whereas 
mice in the modulator group were dosed with the respective modulator alone. In order to 
exclude an impact of components of the vehicle on tumor growth, the lipid carrier was 
administered 2.5 hour prior to injection of the cytostatic agent to animals in the paclitaxel 
group. During and after therapy, tumor progression as well as body weight was monitored 
twice weekly. 
 
5.3 Results and discussion 
5.3.1 In vitro characterization of Kb-V1 cells 
The HeLa derived (cervical carcinoma) human Kb cells were obtained from the American 
Type Culture Collection (ATCC, Rockville, MD). In order to obtain the ABCB1 transporter 
(over)expressing subclone Kb-V1, cells were maintained in the presence of the P-gp 
substrate vinblastine at increasing concentrations (Hubensack, 2005). At a final vinblastine 
concentration of 330 nM, the expression level of the efflux transporter was sufficiently high 
for in vitro investigations on ABCB1 modulators (cf. chapter 3). With respect to the use of 
this subclone for the generation of an ABCB1 transporter expressing subcutaneous tumor 
model in nude mice, the obtained cells had to be characterized in vitro first. 
5.3.1.1 Morphology 
In general, Kb-V1 cells grew tightly adherent to cell culture flasks in monolayers. Figure 
5.1 shows cells stained by the method of Papanicolaou that stains plasma turquoise, 
nuclei blue and nucleoli deep blue. Distinctive features of malignancy as anisomorphic 
cells, an increased nucleocytoplasmic ratio and multiple prominent nucleoli are visible. 
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Further characteristics of the irregularly formed cells are numerous polynucleated cells (cf. 
Figure 5.1 B). 
 
Figure 5.1: Morphology of human Kb-V1 cells (passage 46, Papanicolaou staining); A) The 
anisomorphic cells show mitotic activity, an increased nucleocytoplasmic ratio as well as multiple 
prominent nucleoli (objective: 40x). B) Detail (objective: 100x) of the upper left corner of (A) 
showing a highly malignant tri-nucleated cell. 
No or only minor morphological changes were recognized over the various passages (data 
not shown). 
5.3.1.2 In vitro growth of Kb-V1 cells 
Due to the fact that cancer cell lines are usually polyclonal and genetically instable (cf. 
section 5.3.1.3), long-term culture can result in significantly altered growth parameters. 
Modified growth kinetics can in turn affect the antiproliferative effect of cytostatic drugs as 
well as the in vivo growth of resulting solid tumors. Consequently, to exclude the above 
mentioned issues, the growth kinetics of Kb-V1 cells in various in vitro passages were 
investigated. 
Figure 5.2 compares the growth rates of Kb-V1 cells in the passages 25, 41 and 64. As 
becomes obvious, there were no significant alterations so that doubling times were 
comparable (data not shown). 
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Figure 5.2: Growth kinetics of 
Kb-V1 cells over various 
passages: 25th (open circles), 
41th (filled squares) and 
64th passage (filled circles); 
mean values ± SEM 
 
A minimal doubling time of 20 hours was reached 15 - 20 hours after seeding. Within the 
next 50 hours doubling times slowly (and almost linearly) increased to 40 hours followed 
by a steep ascent afterwards. 
Taken together, growth kinetics did not vary significantly, indicating that chemosensitivity 
and growth rates of resulting solid tumors should not depend on the utilized in vitro 
passage of Kb-V1 cells. 
5.3.1.3 Chromosomal number 
An aneuploidy (abnormal number of chromosomes per cell) is a well known characteristic 
of tumor cells. Additionally, extensiveness and alteration over time can be used to estimate 
malignancy as well as genetic stability. Consequently, various passages of the newly 
generated, ABCB1 transporter expressing Kb-V1 cell line were examined with respect to 
their chromosome distribution. 
Figure 5.3 shows characteristic images (obtained after cell preparation and Giemsa 
staining) used to determine the number of chromosomes in individual cells. 
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Figure 5.3: Representative metaphase chromosomes of Kb-V1 cells (46th passage) stained with 
Giemsa solution; the micrographs demonstrate the broad variety of chromosome numbers from 30 
(cell on the left) over a normal diploid chromosome set (middle) to the prevalent triploid one (right). 
In Figure 5.4 the number of chromosomes is plotted against the frequency in which the 
respective number was observed. In all investigated passages the modal number was 69 
corresponding to the prevalent triploid karyotype. With regard to other tumor cell lines, the 
chromosomal distribution was quite uniform over a comparatively narrow range. 
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Figure 5.4: Chromosomal counts of 
human Kb-V1 cells over various 
passages; the distributions of the 25th (A), 
the 46th (B) and the 54th (C) passage are 
shown. As becomes obvious, the cells are 
predominantly triploid and were relatively 
stable over the observation period. 
 
Due to their growth characteristics and the observed genetic stability, Kb-V1 cells were 
considered suitable to establish a multidrug resistant tumor model in nude mice. 
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5.3.1.4 Immunocytochemical detection of the ABCB1 transporter 
Over-expression of ABCB1 transporters (especially important after discontinuing 
vinblastine exposure) was examined by flow cytometry (cf. section 5.3.1.7) and immuno-
cytochemical methods. 
Figure 5.5 shows the detection of P-glycoprotein in Kb-V1 cells with a primary antibody 
directed against an intracellular amino acid sequence of P-gp. It can be seen from the 
control sample that the staining procedure could not completely eliminate unspecific AB 
binding. Nevertheless, the expression of the relevant efflux transporter is obvious. 
 
 
Figure 5.5: Immunocytochemical detection of ABCB1 transporter in Kb-V1 cells (passage 63; 
primary AB: Mdr C19 (raised in goat); secondary AB: texas red conjugated donkey anti-goat AB, 
1:200; nuclei were stained with DAPI); A) Identically treated control cells without primary AB; 
B) Primary AB in a dilution of 1:500; C) Primary AB in a dilution of 1:50 
 
5.3.1.5 Chemosensitivity against selected cytostatic drugs 
Expression of ATP dependent efflux transporters is the most common cause for acquired 
resistance of tumor cells to a broad variety of anticancer drugs (Gottesman, 2002). 
Therefore, the effect of the known ABC transporter substrates (Szakacs et al., 2008) 
paclitaxel, doxorubicin, topotecan and mitoxantrone (see Figure 5.6) on proliferating 
Kb-V1 cells was investigated. Additionally, for reasons of comparison and control, cisplatin 
(no ABC transporter substrate) was included in the investigations. 
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Figure 5.6: Chemical structures of cytotoxic drugs in clinical use that are substrates of ABC 
transporters 
Cisplatin was cytocidal at a concentration of 1 µM (data not shown), demonstrating that the 
Kb-V1 cells had not developed resistance against this cytostatic. On the contrary, the 
substantial tolerance against anticancer drugs, which are P-gp substrates, becomes 
obvious from Figure 5.7 and Figure 5.8. In the case of doxorubicin and paclitaxel, 
concentrations up to 5 µM and 500 nM, respectively, were tolerated without any effect on 
cell growth. The anthracycline analog mitoxantrone showed a cytostatic effect at 
concentrations of 500 nM and 1 µM. Also the topoisomerase inhibitor topotecan was able 
to exert a cytostatic to cytocidal drug effect at a concentration of 1 µM. 
The fact that such enormous concentrations of anticancer drugs are tolerated indicates the 
presence of ABC transporters. Even after administration of paclitaxel to nude mice at a 
dosage as high as 8 mg/kg (see section 4.3.9), the paclitaxel plasma levels decrease to 
less than 500 nM approximately 4 hours after injection (the levels in tumor tissue are most 
likely lower). Therefore, a clinical relevant effect of paclitaxel mono-therapy on Kb-V1 
tumors should be highly implausible. 
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Figure 5.7: Resistance of Kb-V1 cells (passage 49) against doxorubicin and paclitaxel; vehicle 
(open circles); A) Doxorubicin at various concentrations: 500 nM (filled squares), 1 µM (filled 
triangles), 5 µM (filled diamonds) and 10 µM (filled inverted triangles); B) Paclitaxel at various 
concentrations: 10 nM (filled squares), 50 nM (filled triangles), 100 nM (filled diamonds) and 
500 nM (filled inverted triangles) 
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Figure 5.8: Resistance of Kb-V1 cells (passage 64 (A) and 49 (B)) against mitoxantrone and 
topotecan; vehicle (open circles); A) Mitoxantrone at various concentrations: 50 nM (filled circles) 
100 nM (filled squares), 500 nM (filled triangles) and 1 µM (filled diamonds); B) Topotecan at 
various concentrations: 10 nM (filled circles), 50 nM (filled squares), 100 nM (filled triangles), 
500 nM (filled diamonds) and 1 µM (filled inverted triangles) 
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5.3.1.6 Reversal of P-gp mediated classical multidrug resistance 
Prior to treatment studies in nude mice, it was crucial to assure that P-glycoprotein 
mediated multidrug resistance can be reversed by the combination with ABCB1 
modulators in vitro. 
In Figure 5.9 the cytotoxicities of high concentrations of doxorubicin (or paclitaxel) alone 
are compared to the effect of the respective anticancer drug at lower concentrations in 
combination with a low amount of different ABCB1 modulators. Furthermore, the impact of 
the modulators alone (at a high concentration of 1 µM) was determined to exclude inherent 
toxicity. 
Addition of 100 nM ME30-1 results in a strong cytocidal effect of 500 nM doxorubicin 
(compared to inefficacy of doxorubicin alone at a concentration of 5 µM). When combined 
with ME33-1 (identical doxorubicin concentration), 50 nM of the inhibitor were sufficient to 
produce a cytocidal effect (data not shown). In the case of paclitaxel, even 30 nM were 
sufficient to exert a full cytocidal effect on Kb-V1 cells when 30 nM of ME33-1 were added 
to the culture medium (compared to inefficacy of paclitaxel alone at a concentration of 
500 nM). Both modulators alone had no impact on cell growth up to a concentration of 
1 µM. 
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Figure 5.9: Reversal of P-gp mediated drug resistance of Kb-V1 cells by combination with an 
ABCB1 modulator; A) Doxorubicin [5 µM] (filled squares), ME30-1 [1 µM] (filled triangles), 
doxorubicin [500 nM] + ME30-1 [50 nM] (filled diamonds) and doxorubicin [500 nM] + 
ME30-1 [100 nM] (filled inverted triangles); B) Paclitaxel [500 nM] (filled squares), ME33-1 
[1 µM] (filled triangles) and paclitaxel [30 nM] + ME33-1 [30 nM] (filled diamonds) 
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Nevertheless, incubation with 5 µM of both modulators revealed a modest cytotoxic effect 
on cell growth, indicating inherent toxicity, albeit at very high concentrations (see 
section 3.3.2.2). 
As expected, the combination of 100 nM ME33-1 and cisplatin (investigated in the 
concentration range between 50 nM and 10 µM) showed no increase in toxicity of the 
anticancer agent (data not shown). 
5.3.1.7 Maintenance of the transporter status after discontinued vinblastine 
exposure 
Under in vitro conditions a selection pressure in terms of persistent efflux transporter 
expression is mediated by the P-gp substrate and cytotoxic agent vinblastine. Since 
selection pressure cannot be sustained in vivo, the following approach (see also 
section 5.2.8) was used to investigate if a drastic reduction of ABCB1 transporter function 
has to be expected after discontinuation of vinblastine treatment. Therefore, a 
corresponding reference group was subcultured without vinblastine. After various periods 
of time, the P-gp activity was compared with that of the cells which had been permanently 
exposed to the cytostatic using the flow cytometric calcein-AM efflux assay. 
Figure 5.10 A illustrates the underlying principle. 100 % inhibition of P-gp function was 
achieved by addition of 1 µM of tariquidar. The difference between the geometrical means 
(GeoMeans) in fluorescence intensity of untreated (100 % function) versus tariquidar 
treated cells corresponds to the amount of functional P-glycoprotein. Figure 5.10 B 
reveals that P-gp transport activity was reduced by 35 % within 7 days after 
discontinuation of vinblastine treatment. More important, after that initial reduction, ABCB1 
mediated transport activity did not decrease further during the remaining observation 
period. 
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Figure 5.10: Verification of maintained transporter status after discontinuing vinblastine exposure to 
Kb-V1 cells; A) Schematic illustration of the principle; B) The difference at the beginning of the 
experiment is defined as 100 %. After an initial reduction to approximately 65 %, ABCB1 transport 
activity remains constant over time (mean values ± SEM, n = 5). 
Taken together, the detailed in vitro characterization revealed the suitability of Kb-V1 cells 
to establish an ABCB1 transporter expressing subcutaneous tumor model in nude mice. 
Consequently, further in vivo experiments were initiated and are described in the following. 
 
5.3.2 In vivo characterization of solid Kb-V1 tumors 
5.3.2.1 Tumorigenicity and in vivo growth characteristics 
In order to assure tumorigenicity as well as reproducible growth characteristics in vivo, 
Kb-V1 cells were implanted and resulting tumors were serially transplanted as described in 
section 5.2.9. 
Figure 5.11 shows the in vivo growth kinetics of Kb-V1 xenografts over various passages. 
Tumors in the passages zero, one and two exhibited stable and reproducible growth rates, 
especially within the first 50 days after cell (or tumor tissue) implantation. This is of special 
importance, since the characteristic observation phase during treatment experiments 
coincides with that period. In contrast, in vivo passage 3 shows a pronounced retardation 
of tumor growth. 
Within the first three in vivo passages, tumorigenicity was sufficiently high (above 70 %) to 
provide s.c. xenografts for therapeutic studies in nude mice. Additionally, tumor growth did 
not affect the animals´ general state of health. 
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Figure 5.11: Growth curves of 
subcutaneous human Kb-V1 
xenografts over the in vivo pas-
sages 0 (circles), 1 (squares), 
2 (triangles) and 3 (diamonds); 
a retardation of tumor growth in 
higher passages is obvious 
(mean values ± SEM). 
 
Subsequent treatment studies were performed using tumors in the first in vivo passage. 
5.3.2.2 Histology 
In order to confirm the malignant nature of the xenografts, tissue samples were collected 
and histologically characterized over the various passages (for passage 0 see Figure 
5.12). Criteria of malignancy such as an increased nucleocytoplasmic ratio, largely 
undifferentiated tissue, anisomorphic cells, multiple prominent nucleoli and a 
hyperchromatic cell membrane, are obvious. The mitotic activity is moderate (cf. section 
5.3.1.1). 
Figure 5.12: Histological staining of a subcutaneous Kb-V1 tumor (passage 0); A) Masson-Goldner 
staining (objective 40x) and B) Haematoxylin-eosin staining (objective 63x) 
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5.3.2.3 Maintenance of the ABCB1 transporter status in vivo 
Due to the lack of vinblastine-induced selection pressure in vivo, expression of the ABCB1 
transporter in subcutaneously growing Kb-V1 tumors had to be controlled. A staining 
protocol using paraffin embedded sections of tumor tissue fixed with Bouin´s solution was 
inadequate. Most likely, the harsh fixation and embedding procedure did alter the relevant 
antigenic determinant and/or impeded the AB from reaching its intracellular target (see 
below). A more sophisticated approach (detailed described in section 5.2.7) using an 
in vivo fixation method followed by cryosectioning of tumor tissue and subsequent staining 
of free floating sections was successful. 
Figure 5.13 shows the immunohistochemical detection of P-glycoprotein in a Kb-V1 tumor 
(first passage). Since the primary antibody is directed against an intracellular peptide 
sequence (at the C-terminus of P-gp), permeabilisation of cells prior to AB staining is 
crucial. Due to the staining procedure (free floating sections) and the moderate fixation, the 
highly vulnerable tissue was cut into 50 µm thick sections, which is reflected by the diffuse 
fluorescence of AB-labeled P-glycoprotein. 
 
 
Figure 5.13: Immunohistochemical detection of ABCB1 transporters in a solid Kb-V1 tumor in the 
1st in vivo passage (primary AB: Mdr C19 (raised in goat) directed against an intracellular peptide 
sequence of P-gp; secondary AB: texas red conjugated donkey anti goat-AB; nuclei were stained 
with DAPI); A) Identically treated control section without primary AB; B) Primary AB in a dilution of 
1:25 
Despite the aforementioned problems, the expression of the ABCB1 protein in solid tumors 
was confirmed. Thus, a major requirement was fulfilled with respect to therapeutic studies. 
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5.3.3 Effect of paclitaxel and co-administered ABCB1 modulators on 
subcutaneous multidrug resistant xenografts 
Due to the encouraging in vitro (see chapter 3 and section 5.3.1.6) and in vivo (cf. 
chapter 4) results, the effect of ME30-1, ME33-1 and tariquidar (efficacy was confirmed in 
previous studies (Hubensack et al., 2008)) in combination with paclitaxel was investigated 
on multidrug resistant Kb-V1 tumors. 
Table 5.2 summarizes the major characteristics of the various treatment groups. The 
animals were assigned to groups considering a homogeneous distribution of body weight 
and especially tumor area to avoid inherent bias. Compounds were administered weekly, 
because this treatment regimen has been reported as at least equieffective and less 
hematotoxic, when compared with the licensed 2- or 3-weekly schedule (Green et al., 
2005; Mauri et al., 2010). As the achieved in vivo concentrations were up to 285 times 
higher than the IC50-values obtained in vitro (see chapter 4) and due to limited availability 
of the test compounds, the dosage of the modulator was reduced to 30 mg/kg. 
Table 5.2: Biometric parameters at the day of randomization 
Study 
parameter  
Control 
group  
Modulator 
group  
Paclitaxel 
group  
Paclitaxel + 
Modulator 
group 
M
E
30
-1
 na  8  7  10  10 
Body 
weightb  34.4 ± 0.9  35.3 ± 0.8  36.0 ± 0.9  35.5 ± 1.0 
Tumor 
areac  9.5 ± 2.2  8.1 ± 2.2  8.5 ± 2.5  9.0 ± 3.3 
M
E
33
-1
 na  9  9  11  11 
Body 
weightb  30.9 ± 1.2  30.3 ± 1.3  31.8 ± 1.2  30.7 ± 0.9 
Tumor 
areac  9.6 ± 2.1  10.4 ± 2.1  8.9 ± 2.1  9.5 ± 2.9 
Ta
riq
ui
da
r na  9  8  11  11 
Body 
weightb  30.9 ± 1.2  28.8 ± 1.1  31.8 ± 1.2  30.1 ± 0.6 
Tumor 
areac  9.6 ± 2.1  8.4 ± 3.1  8.9 ± 2.1  9.3 ± 2.8 
a Number of animals per treatment group; b body weight in [g] ± SEM; c tumor area in [mm2] ± SEM 
In order to exclude gender related impact on tumor growth, solely male nude mice at an 
age between 8 and 12 weeks were included in all studies. A group receiving only the 
respective modulator was implemented to detect a possible inherent cytotoxic effect of the 
tariquidar-like compounds. 
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5.3.3.1 Morpholino analog of tariquidar (ME30-1) 
ME30-1 was the first tariquidar-like modulator investigated in therapeutic in vivo studies. 
Consequently, the cytostatic agent was co-administered at a relatively low dosage initially. 
Figure 5.14 shows the effect on tumor progression and body weight of nude mice. While 
paclitaxel mono-therapy had no impact on tumor growth, the combination of ME30-1 and 
paclitaxel resulted in a retardation of the mean tumor area (A). This effect becomes more 
obvious when the median tumor area (less sensitive to outliers) is plotted (B). Additionally, 
no increase in paclitaxel related toxicity (emaciation of the animals) was observed in the 
Pac/Mod-group (most probably because the new modulators do not increase the paclitaxel 
plasma levels) (C). Administration of the modulator alone (also true for ME33-1 and 
tariquidar, see below) did not significantly retard tumor progression. 
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Figure 5.14: Effect of ME30-1 
(30 mg/kg, p.o.) on the activity 
of paclitaxel (i.v.) against 
subcutaneously growing Kb-V1 
tumor xenografts; animals were 
treated on days 15 (2.5 mg/kg), 
21, 29 and 38 (3 mg/kg) post 
tumor implantation. Control 
(open circles), ME30-1 (filled 
squares), paclitaxel + vehicle 
(filled circles), paclitaxel 
+ ME30-1 (filled diamonds); 
effect on mean tumor area 
(± SEM) (A), median tumor 
area (B) and body weight 
(± SEM) (C) 
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Figure 5.15 compares the individual tumor growth curves of animals in the group receiving 
the combination therapy (A) with animals treated with paclitaxel alone (B). Combined 
administration of the modulator led to moderate retardation of tumor progression in the 
Pac/Mod-group, while there was a pronounced effect in five out of ten animals (tumor 
area ≤ 20 mm2 after 52 days). In the paclitaxel group only two tumors were ≤ 20 mm2. In 
the control group the three smallest neoplasms had tumor areas of 35, 40 and 56 mm2. In 
the experiments with the modulators ME33-1 and tariquidar, the tumor areas of the three 
smallest neoplasms in the paclitaxel group (51 days after tumor transplantation) were 
determined to be 35, 36 and 40 mm2. 
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Figure 5.15: Growth curves of individual tumors (n = 10) in the treatment groups of 
paclitaxel + ME30-1 (A) and paclitaxel + vehicle (B); the five tumors of the respective treatment 
group showing slowest growth are represented by filled symbols. As becomes obvious, half of the 
animals (especially those with small tumors at the beginning of the study) show a pronounced 
retardation of tumor growth (or even remission). 
It may be speculated why only a subpopulation of animals benefits substantially from the 
combination therapy. Additional resistance mechanisms (independent of ABCB1 
transporter expression, confer section 5.4) as well as inconsistencies in the vascularization 
of in the individual tumors could play a role in the therapy-refractory animals. 
Additionally, tumors, liver and kidneys of 3 to 4 randomly selected animals per treatment 
group were harvested and histologically investigated for potential (toxic) effects of the 
therapy. None of the investigated tissue samples showed histologically recognizable 
abnormalities (data not shown). 
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5.3.3.2 Ethoxyethyloxy analog of tariquidar (ME33-1) 
The results of the treatment experiments performed with ME33-1 are shown in Figure 
5.16. Though the paclitaxel dose was increased to 4.5 mg/kg (due to the good tolerance of 
the combination with ME30-1) co-administration of ME33-1 resulted only in a slight 
(probably irrelevant) retardation of tumor growth. Also when the median tumor areas were 
compared, no significant differences were detectable (data not shown). Additionally, no 
individual animals in the Pac/Mod-group did benefit above-average (data not shown). 
Interestingly, the comparatively high paclitaxel dosage did not cause toxic side effects. 
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Figure 5.16: Effect of ME33-1 
(30 mg/kg, p.o.) on the activity 
of paclitaxel (4.5 mg/kg, i.v.) 
against subcutaneously grow-
ing Kb-V1 tumor xenografts 
(mean tumor area ± SEM); 
animals were treated on days 
14, 20, 28 and 35 post tumor 
implantation. Control (open 
circles), ME33-1 (filled 
squares), paclitaxel + vehicle 
(filled circles) and paclitaxel 
+ ME331 (filled diamonds) 
 
5.3.3.3 The parent compound tariquidar 
As becomes obvious from Figure 5.17, concomitant application of tariquidar did not result 
in a significant retardation of mean tumor progression or in that of individual animals (data 
not shown). As described for the other modulators, the combination therapy was well 
tolerated by the animals (data not shown). 
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Figure 5.17: Effect of tariquidar 
(30 mg/kg, p.o.) on the activity 
of paclitaxel (4.5 mg/kg, i.v.) 
against subcutaneously grow-
ing Kb-V1 tumor xenografts 
(mean tumor area ± SEM); 
animals were treated on days 
14, 20, 28 and 35 post tumor 
implantation. Control (open 
circles), tariquidar (filled 
squares), paclitaxel + vehicle 
(filled circles) and paclitaxel 
+ tariquidar (filled diamonds) 
 
5.4 Summary and conclusions 
In order to study the suitability of human Kb-V1 cells for a multidrug resistant 
subcutaneous tumor model in nude mice, the cells were characterized in vitro first. 
Therefore, the cells were (among other things) investigated with respect to morphology, 
growth kinetics, chromosome distribution, chemosensitivity and expression of the relevant 
efflux transporter. 
Growth kinetics as well as the number of chromosomes (indicator for genetic stability) did 
not vary significantly over various in vitro passages. As expected, the cells were highly 
resistant against anticancer agents that are known substrates of P-gp such as doxorubicin, 
topotecan and paclitaxel. The ABCB1-mediated multidrug resistance was reversed by 
addition of ABCB1 modulators in vitro. For instance, 30 nM of ME33-1 were sufficient to 
fully restore the sensitivity of Kb-V1 cells against paclitaxel (used at the same 
concentration as the modulator). Additionally, expression of P-gp remained (after a slight 
initial reduction) constant after discontinuation of vinblastine exposure. Taken together, the 
in vitro characterization revealed the suitability of Kb-V1 cells for further in vivo 
experiments. 
The resulting tumors showed stable and reproducible growth rates over multiple passages, 
sufficiently high tumorigenicity (above 70 %) and were well tolerated by the animals. 
Additionally, the expression of ABCB1 transporters at the protein level was confirmed in 
the solid tumors. 
In subsequent treatment experiments, the effect of concomitant administration of paclitaxel 
and various modulators was investigated. Solely the combination of ME30-1 with paclitaxel 
resulted in a significant retardation of tumor progression. However, only a subgroup of 
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tumors responded to combined application of ME30-1 and paclitaxel. The other modulators 
(despite a higher in vitro potency) showed no significant effect in vivo. It may be 
speculated that varying penetration of the modulators in the tumor tissue is responsible for 
that outcome. Another possible explanation is that additional mechanism(s) of resistance 
(independent of ABCB1 transporter expression) could have evolved. It is well know that 
the majority of clinical tumors exhibit intrinsic or acquired resistance to paclitaxel 
(McGrogan et al., 2008; Schmidt et al., 2003). Beside the most important cause of 
resistance, the expression of the ABCB1 transporter, a number of other mechanisms of 
paclitaxel resistance are described. For instance, over-expression of the HER-2/neu 
protein (Ueno et al., 2000; Yu et al., 1996), of β-tubulin (Kavallaris et al., 1997; Mozzetti et 
al., 2005) and of the microtubule function regulating tau proteins (Rouzier et al., 2005). On 
the other hand also deficiencies in the function of the tumor suppressor protein p53 
(Giannakakou et al., 2000; Nielsen et al., 1998) and spindle checkpoint proteins such as 
MAD2 (Kienitz et al., 2005) were reported to confer resistance. Additional mechanisms as 
the expression of other efflux transporters from the ABCC family (Longley and Johnston, 
2005) and the mutation of the target (Berrieman et al., 2004) should also be taken into 
consideration. If only one of the described mechanisms of paclitaxel resistance has 
evolved prior or during therapy, even an effective ABCB1 modulator is unable to positively 
influence tumor growth. The findings are in agreement with a clinical phase I study on 
tariquidar in combination with the ABCB1 substrate vinorelbine in which 26 patients with 
various tumors (renal cell carcinoma, breast cancer, adrenocortical cancer, ovarial cancer 
etc.) were enrolled (Abraham et al., 2009). Although tariquidar increased 99mTc-sestamibi 
retention in most tumors and mediated a long-lasting inhibition of P-gp mediated 
rhodamine efflux from CD56+ cells, only one partial remission (renal carcinoma) was 
reported. 
Another important conclusion can be drawn from experiments with multidrug resistant 
human 2780AD ovarian carcinoma xenografts in nude mice (Mistry et al., 2001). In this 
study, mice tolerated 3 cycles (at a 2-day interval!) of a combination of tariquidar 
(10 mg/kg, i.v.) and 15 mg/kg paclitaxel. That means a higher dosage of paclitaxel should 
be administered in future studies. Moreover, treatment experiments could be more 
successful with tumors in the in vivo passage zero (instead of one) due to lower probability 
of tumors to lose the MDR phenotype or to develop other mechanisms of resistance. 
Considering the fact that cytostatics are generally more active against small tumors, 
therapy could be started 7 to 10 days after cell implantation (without a randomization 
according to tumor area). 
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Chapter 6 
6 Studies on the efficacy of ABCB1 
modulators by optical imaging of intra-
cerebral tumor xenografts in nude mice 
 
6.1 Introduction 
The tremendous technological progress has facilitated a number of non-invasive methods 
for the monitoring of tumor growth and the detection of metastasis (Koo et al., 2006). The 
techniques with the highest significance in clinical use are Magnetic Resonance Imaging 
(MRI), Positron Emission Tomography (PET) and Computer Tomography (CT). Since 
these methods are technically elaborate as well as costly, optical imaging techniques are 
an attractive alternative in preclinical investigations. The two main forms, fluorescence 
imaging (FLI) and bioluminescence imaging (BLI), detect low levels of light (or photons) by 
means of extremely sensitive camera systems. The emission of light follows the excitation 
of fluorophores (see below) by an external light source (FLI) or originates from the 
enzymatic oxygenation of a substrate (BLI) (Day et al., 2004). Due to the correlation 
between light absorption and tissue depth, these imaging modalities are limited to small 
animal research (or to organs close to the surface of the skin). Since solely the amount of 
emitted light is quantified, the anatomic resolution of both methods is low. 
 
6.1.1 Fluorescence imaging 
As indicated above, the presence of a fluorophore, normally a fluorescent protein, in the 
investigated tissue is necessary. Nearly 20 years ago, the first protein of this type (GFP, 
green fluorescent protein) was identified and characterized (Prasher et al., 1992). In the 
following years, improved biomolecules were engineered with regard to fluorescence 
intensity (EGFP, enhanced GFP), emission wavelength (DsRed, red fluorescent protein) 
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and solubility (DsRed2) (Hoffman, 2009). Recently, a red fluorescent protein (termed 
Katushka) with favorable properties for in vivo imaging has been described (Shcherbo et 
al., 2007). Among other advantages, its emission maximum is shifted to 635 nm (better 
tissue penetration) and the extinction coefficient as well as the quantum yield (brighter 
fluorescence emission) has been substantially increased. 
In preclinical oncology, so far especially GFP (Chishima et al., 1997; Peyruchaud et al., 
2001) and DsRed2 (Bouvet et al., 2005; Yang et al., 2005) were utilized to monitor tumor 
growth and metastatic progression. 
 
6.1.2 Bioluminescence imaging 
The main advantage of BLI over FLI is the high sensitivity as there is no “light noise” (Koo 
et al., 2006), i.e. in contrast to FLI, no external light source generates background by auto-
fluorescence of biomolecules (e.g. haemoglobin) in animal tissue. BLI becomes possible 
due to an enzyme-catalysed conversion of chemical energy into light (Wilson and 
Hastings, 1998). The oxidation of substrates (e.g. luciferin or coelenterazine) is mediated 
by a class of different enzymes (subsumed under the term luciferases) that can be found in 
a broad variety of species. Among the most prominent representatives are the North 
American firefly (Photinus pyralis) and the sea pansy (Renilla reniformis). Due to the 
described mechanisms, prior to BLI, the administration of the respective substrate is 
necessary. 
In the literature, various applications of BLI for the monitoring of malignancies (resulting 
from luciferase expressing tumor cells) in the periphery are described (Jenkins et al., 2005; 
Pfost et al., 2009). Due to the high sensitivity, even the detection of small metastases in 
the region of the thorax and the intestine was reported (Scatena et al., 2004; Smakman et 
al., 2004). Furthermore, orthotopic xenograft models were developed, permitting the 
observation of tumor progression and the investigation of the efficiency of chemotherapy 
(Moriyama et al., 2004; Szentirmai et al., 2006). 
The aim of this work was to investigate the therapeutic value of tariquidar and ME33-1 (the 
two ABCB1 modulators out of a small library of tariquidar analogs with the most 
pronounced effect on paclitaxel brain levels; cf. chapter 4) in the adjuvant therapy of 
malignant brain tumors. The in our laboratory established intracerebral human 
glioblastoma model in nude mice (Altenschöpfer, 1998; Fellner et al., 2002) had to be 
adopted to incorporate the aforementioned fluorescence- and bioluminescence-based 
methods. The refined model should enable optical in vivo imaging for the detection of a 
solid tumor at the beginning of the study and monitoring of tumor growth during therapy. 
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Prior to these studies in nude mice, the generated U-118 transfectants had to be 
characterized in vitro with regard to transfection efficiency, chemosensitivity and growth 
kinetics. 
 
6.2 Materials and methods 
6.2.1 Drugs and chemicals 
Stock solutions of puromycin·2 HCl (Sigma, Deisenhofen, Germany) and geniticin disulfate 
(G418, Biochrom AG, Berlin, Germany) were prepared with Millipore filtered water and 
were stored at -20 °C until usage. 
For the in vivo investigations, the potassium salt of D-luciferin (Molecular Imaging Products 
Company, Ann Arbor, MI and SYNCHEM OHG, Felsberg, Germany) was dissolved in PBS 
(8.0 g/L NaCl, 1.0 g/L Na2HPO4·2 H2O, 0.20 g/L KCl, 0.20 g/L KH2PO4 and 0.15 g/L 
NaH2PO4·H2O, pH 7.4) to achieve a concentration of 40 mg/mL. After sterile filtration the 
solution was aliquoted and stored at -78 °C. 
Paclitaxel, doxorubicin as well as the cell culture media EMEM and DMEM were 
purchased from Sigma (Munich, Germany). For tariquidar and ME33-1 please refer to 
section 3.2.1. If not stated otherwise chemicals were obtained from Merck (Darmstadt, 
Germany) in p.a. quality. 
 
6.2.2 Stable transfection of human U-118 MG glioblastoma cells 
U-118 MG glioblastoma cells in passage 459 were transfected with the gene encoding the 
firefly luciferase2 codon optimized for the expression in mammals (pGl4.20 [luc2/Puro] 
vector; Promega, Mannheim, Germany). Additionally, the respective cells were co-
transfected with the gene encoding the red fluorescent protein 2 (the pDsRed2-C1 vector 
(BD Bioscience Clontech, Heidelberg, Germany) was a gift from ACGT ProGenomics 
(Halle a. d. Saale, Germany)). In a third approach, transfection of U-118 MG cells 
(passage 453) was performed with the pTurboFP635-N vector (BioCat, Heidelberg, 
Germany) containing the gene for the far-red fluorescent protein Katushka. All experiments 
were performed using the transfection reagent FUGENE® HD (Roche Diagnostics, 
Mannheim, Germany) according to the following procedure. 
U-118 MG cells were seeded into 12-well plates (BD Biosciences, Heidelberg, Germany) 
at a density of 180 000 cells/well. On the following day, 50 µL of serum-free DMEM 
containing 1 µg of the respective plasmid DNA in combination with 1.5, 3 or 4.5 µL 
FUGENE® HD were added drop-wise to each well. 36 hours after transfection, cells were 
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transferred to 12.5 cm2 culture flasks (BD Biosciences) containing DMEM supplemented 
with the appropriate selection agent (cf. section 6.2.3). 
After successful transfection was assured in the polyclonal cell populations, homogenous 
cell clones were isolated by the following procedure. Transfected cells were seeded at a 
low density (approximately 30 cells/cm2) into petri dishes containing culture medium with 
suitable selection antibiotics. After several resistant colonies had reached a sufficient cell 
number, clones were picked via trypsinization and transferred into 12.5 cm2 culture flasks. 
Subsequently, the various cell clones were characterized in vitro and in vivo. 
 
6.2.3 Cell lines and culture conditions 
The human glioblastoma cell lines U-87 MG and U-118 MG were grown in Eagle´s 
Minimum Essential Medium (EMEM, supplemented with 2.2 g/L NaHCO3, 110 mg/L 
sodium pyruvate and 5 % FCS) and Dulbecco´s Minimum Essential Medium (DMEM, 
supplemented with 3.7 g/L NaHCO3, 110 mg/L sodium pyruvate and 5 % FCS), 
respectively. The various transfectants were maintained in the aforementioned culture 
medium containing the following selection antibiotics (suitable concentrations were 
determined with wild type cells by means of the crystal violet chemosensitivity assay (data 
not shown)). Luciferase2 and DsRed2 co-transfected U-118 MG cells: 1.0 µg/L 
puromycin·2 HCl and 600 µg/L G418; luciferase2 mono-transfectants: 1.0 µg/L 
puromycin·2 HCl; Katushka mono-transfectants: 0.5 µg/L puromycin·2 HCl. 
For further general information concerning the maintenance of cultured cells please refer 
to section 3.2.2. 
 
6.2.4 Determination of chemosensitivity and in vitro growth characteristics 
The assays were performed as described in sections 3.2.5 and 5.2.3. 
 
6.2.5 Intracerebral and subcutaneous implantation of glioblastoma cells 
into nude mice 
The subcutaneous tumor cell implantation is described in section 5.2.9. The intracerebral 
cell implantation was performed with slight modifications as described previously 
(Altenschöpfer, 1998; Hubensack, 2005). In brief: nude mice were anesthetized with 
ketamine/xylazine (cf. section 4.2.5) and the parietal bone was drilled through with a 1 mm 
diameter bit (3 mm on to the right-hand side of the sagittal line and 3 mm rostral of the 
coronal line). Subsequently, 5·104 transfected glioblastoma cells suspended in 10 µL of the 
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appropriate serum-free culture medium (prepared as described in section 5.2.9) were 
injected 3 mm deep into the brain tissue. Finally, the wound was closed with a surgical 
clamp and the pads of the animals were tattooed to make them individually identifiable. 
 
6.2.6 Detection of Katushka- and DsRed2-mediated fluorescence 
6.2.6.1 Fluorescence microscopy 
Microscopic images of Katushka- and DsRed2-mediated fluorescence were acquired on a 
Carl Zeiss Cell Observer (excitation wavelength 545/25 nm, emission wavelength 605/70) 
and a Leica DM-IRB microscope (Texas Red filter cube; excitation wavelength 560/40 nm, 
emission wavelength 645/75), respectively. 
6.2.6.2 MaestroTM imaging system 
The U-118 MG transfectants were additionally investigated by means of fluorescence 
imaging. Cells were seeded at various densities (DMEM without phenolred) into black, flat-
bottomed 96-well plates (Greiner, Frickenhausen, Germany). After an incubation period of 
at least one hour at 37 °C/5 % CO2, Katushka- and DsRed2-mediated fluorescence was 
detected with the MaestroTM in vivo imaging system (500 FL system, Cambridge Research 
& Instrumentation, Woburn, MA). The selected filter settings enabled excitation in the 
range of 503 to 555 nm and detection of emitted light at wavelength higher than 580 nm. 
Data analysis was performed with the Maestro Software 2.6.0B. 
 
6.2.7 Fluorescence imaging of subcutaneous glioblastoma in nude mice 
For the in vivo investigations, mice were immobilized by ketamine/xylazine anesthesia (cf. 
section 4.2.5) and placed on the heated specimen stage (in order to stabilize body 
temperature during narcosis) of the aforementioned imaging system. For relevant 
instrument settings please refer to section 6.3.2.2. 
 
6.2.8 Determination of luciferase2 activity 
6.2.8.1 In cell lysates 
The assays were essentially performed as described previously (Kühnle, 2010). In brief: 
cells were grown in 24-well plates to an approximate confluence of 80 - 100 %. After a 
washing step with PBS, cells were incubated with lysis buffer (25 mM TricineTM (pH 7.8; 
Sigma, Munich, Germany), 10 % (v/v) glycerol, 2 mM EGTA, 1 % (v/v) Triton X-100 
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(Sigma), 5 mM MgSO4·7 H2O, 1 mM dithiotreitol (Sigma)) for 20 min under agitation. 
Aliquots of the lysates were transferred into polystyrene tubes, 100 µL of a 0.2 mg/mL 
D-luciferin solution in assay buffer (25 mM TricineTM (pH 7.8), 5 mM MgSO4·7 H2O, 2 mM 
EGTA, 2 mM ATP (Boehringer, Mannheim, Germany), 100 µM coenzyme A (Sigma)) were 
added and the bioluminescence signal was determined over a period of 10 sec (as relative 
light units, RLU) on a Lumat LB 9501 (Berthold, Bad Wildbad, Germany). 
For reasons of comparison, the obtained RLUs were normalized to the total protein content 
of each sample, which was determined by the method of Bradford (1976). 95 µL of lysis 
buffer were added to 5 µL of the various cell lysates and incubated with 1000 µL 
Bradford´s dye reagent (Bio Rad Laboratories, Munich, Germany) for 10 min. Sub-
sequently, the absorbance at 595 nm was measured with an Uvikon 930 spectro-
photometer (Kontron, Düsseldorf, Germany). The protein concentrations were calculated 
from a standard calibration curve using human serum albumin (Behringwerke, Marburg, 
Germany) in the range of 1 - 12 µg protein per sample. The normalized RLU values were 
expressed as RLU/µgprotein. 
6.2.8.2 In whole cells 
In analogy to the fluorescence based methods, U-118 MG glioblastoma cell transfectants 
were seeded in black 96-well microtiter plates (Greiner) at various densities (in 150 µL of 
phenolred-free culture medium). After an incubation period of at least one hour at 
37 °C/5 % CO2, 50 µL of a D-luciferin solution (680 µg/mL) in PBS was added to each well. 
Bioluminescence imaging was performed after 5 min of incubation by means of a back-
illuminated AndorTM DV887 ECS-BV EMCCD camera installed in the housing of the 
MaestroTM in vivo imaging system. The device as well as additional modifications to reduce 
extraneous light to a minimum are described in detail in the PhD theses of Peter Jarzyna 
and Matthias Kühnle (Jarzyna, 2007; Kühnle, 2010). Data acquisition and analysis was 
performed with the Andor Solis imaging software 4.3. 
 
6.2.9 Bioluminescence imaging of subcutaneous and intracerebral 
glioblastoma in nude mice 
Ketamine/xylazine anesthetized (cf. section 4.2.5) mice received an intraperitoneal 
injection of freshly thawed solution of 40 mg/mL D-luciferin in PBS (100 µL for 
subcutaneous, 200 µL when orthotopic tumors were imaged). After a distribution period of 
5 min, the mice were placed on the heated specimen stage of the imaging system and the 
bioluminescence signal was detected with an AndorTM DV887 ECS-BV EMCCD camera. 
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The relevant instrument settings are specified in the respective paragraphs of the results 
and discussion section. 
 
6.2.10 Histology 
The histological characterization of subcutaneous tumors is described in section 5.2.10. In 
order to detect intracerebral tumor xenografts, excised brains were fixed in Bouin´s 
solution and embedded in paraffin according to a standard procedure. In analogy to 
previous studies (Fellner et al., 2002), 15 serial coronal sections (6 µm) were cut every 
200 µm starting and ending 1.5 mm rostral and caudal to the region of tumor cell injection. 
After deparaffinization and rehydration, samples were stained by the method of Masson-
Goldner (Romeis, 1989). 
 
6.2.11 Therapeutic in vivo studies 
Compound preparation as well as the application of the ABCB1 modulators (tariquidar or 
ME33-1) and paclitaxel was performed essentially as described in section 4.2.5 
and 5.2.11. 
The first bioluminescence in vivo imaging of orthotopic glioblastomas was performed on 
days 14/15 post tumor cell implantation to assure the presence of a solid tumor. 
Subsequently, animals were assigned to the various treatment groups with respect to the 
bioluminescence signal in order to assure a homogeneous distribution of different sized 
brain tumors. 
Mice treated with paclitaxel combined with an ABCB1 modulator (in the following 
designated as Pac/Mod group) received the modulators (50 mg/kg) by gavage into the 
stomach 2.5 hours prior to i.v. paclitaxel injection. Compounds were administered on 
days 16/17, 22/23 (4.0 mg/kg paclitaxel) and 29/30 (3.0 mg/kg paclitaxel) after tumor cell 
implantation. Mice of the control group were not treated whereas animals of a third group 
received the respective modulator. Furthermore, animals dosed with paclitaxel alone (the 
blank solvent of the ABCB1 modulators was additionally administered) were included in 
the study. Subsequently, tumor progression was monitored by means of BLI on days 27/28 
and 34/35 post tumor cell implantation. The instrument settings in all therapeutic in vivo 
investigations were as follows: exposure time 900 s, EM gain 255, no binning, readout rate 
1 MHz at 16 bit, stage height h2c. 
At the end of the study (or earlier if the state of health required a preterm intervention 
(violation of no-go criteria)) animals were killed by cervical dislocation and brains were 
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dissected. The subsequent confirmation of tumorigenicity by histopathology is described in 
section 6.2.10. 
 
6.3 Results and discussion 
6.3.1 In vivo imaging using fluorescent and bioluminescent U-118 MG 
glioblastoma cells 
In order to establish an intracerebral tumor model, which is accessible to in vivo imaging 
methods, human U-118 MG glioblastoma cells were transfected with the codon optimized 
firefly luciferase2. Additionally, the respective cells were co-transfected with gene encoding 
the red fluorescent protein 2. The generated mono- and co-transfectants were designated 
U-118 Luc2 and U-118 Luc2/DsRed2, respectively. 
6.3.1.1 DsRed2-mediated fluorescence of U-118 transfectants 
The success of the transfection procedure was assured in the polyclonal cell populations 
by means of fluorescence microscopy (see Figure 6.1). 
Figure 6.1: DsRed2 fluorescence of 
polyclonal U-118 Luc2/DsRed2 glio-
blastoma cells (Leica DM-IRB 
microscope; Texas Red filter cube: 
excitation wavelength 560/40 nm, 
emission wavelength 645/75 nm) 
 
Since the resulting polyclonal U-118 transfectants showed low transfection efficiency as 
well as variable DsRed2-protein expression, cells were isolated in order to obtain clones 
with homogenous protein expression. The resulting cell populations were classified with 
respect to their fluorescence intensity with the MaestroTM in vivo imaging system. 
Figure 6.2 shows exemplarily the correlation between DsRed2-mediated light emission 
and the cell number of U-118Luc2/DsRed2 clones 3, 11 and 13. 
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Figure 6.2: Fluorescence of 
U-118Luc2/DsRed2 clone 3 
(filled circles), clone 11 (open 
circles) and clone 13 cells 
(open triangles); data acqui-
sition with the MaestroTM 
imaging system; instrument 
settings: exposure time 5 s for 
23 unmixed single images in 
the range from 580 - 800 nm 
(10 nm steps) 
 
As becomes obvious, the expression level the DsRed2 protein differed between the 
investigated clones. Transfectants with a high expression of the red fluorescent protein 2 
were selected for further in vitro investigations (see below). 
6.3.1.2 Luciferase2-mediated bioluminescence of U-118 transfectants 
In order to identify the cell clones with high luciferase activity, the bioluminescence light 
emission was measured after addition of D-luciferin to the lysates of the corresponding cell 
populations. Lysates of the wild type cells served as control (see Figure 6.3). 
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Figure 6.3: Specific luciferase2 activity determined in the lysates of various U-118 Luc2 clones 
1 - 9; wild type cells served as negative control. Mean values ± SEM, n = 3 
In contrast to the wild type U-118 MG cells, all resistant cell colonies and in particular the 
clones 4, 6, 7 and 8 showed substantial luciferase2 activity. The transfectants showing 
paramount bioluminescence were further characterized with the AndorTM EMCCD in vivo 
imaging system (see below). 
By analogy with the mono-transfected cells, the cell lysates of U-118 Luc2/DsRed2 clones 
were investigated with regard to their luciferase2 activity (see Figure 6.4). Also the co-
transfected cell populations exhibited sufficient luciferase2 activity. Nevertheless, 
compared to the mono-transfectants, the bioluminescence-mediated light emission was on 
average lower. Taking the fluorescence intensity into consideration, promising clones were 
selected and subsequently imaged. 
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Figure 6.4: Specific luciferase2 activity determined in the lysates of various U-118 Luc2/DsRed2 
clones; wild type cells served as negative control. Mean values ± SEM, n = 3 
In order to investigate the luciferase2 activity in living cell, the selected transfectants were 
seeded in 96-well plates at various densities. Additionally, the minimal number of cells 
necessary for selective detection with the AndorTM EMCCD camera system should be 
elucidated. 
Figure 6.5 shows exemplarily the bioluminescence-mediated light emission of 
U-118 Luc2 clones 5, 7 and 8. As becomes obvious, the extremely sensitive method 
allowed the detection of very low cell numbers. Whereas 8,000 – 16,000 cells of clone 5 
yielded a passable signal-to-noise ratio, in the case of the clones 7 and 8 the limit of 
detection was lower than 4,000 cells. Wild type cells gave no signal at all investigated 
concentrations (up to 250,000 cells/well; data not shown). 
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Figure 6.5: Specific luciferase2 
activity of the U-118 Luc2 clones 5, 
7 and 8 detected in living cells; 
image acquisition with an AndorTM 
DV887 ECS-BV EMCCD camera; 
instrument settings: exposure time 
30 min, EM gain 255, no binning, 
readout rate 1 MHz at 16 bit 
 
There were hints from the literature that the expression level of luciferase in tumor cells 
can retard growth kinetics of resulting tumors (Brutkiewicz et al., 2007). Consequently, 
clones with a detection limit ranging from 2,000 – 16,000 cells (U-118 Luc2 clones 5, 7, 
and 8 as well as U-118 Luc2/DsRed2 clones 3 and 13) were selected for further in vitro 
and in vivo studies. 
6.3.1.3 Chemosensitivity and in vitro growth characteristics of luciferase2 
and luciferase2/DsRed2 transfected glioblastoma cells 
For a predictive and clinically relevant tumor model it is crucial to exclude an influence of 
the transfection on both, chemosensitivity and growth behavior. Additionally, the procedure 
used to obtain different clones (due to the genetic instability and heterogeneity of tumor 
cells, cf. chapter 5), could promote the selection of a specific subpopulation with 
significantly altered characteristics. Consequently, both features of the transfectants were 
investigated and compared to the wild type cells. 
Figure 6.6 and Figure 6.7 show the chemosensitivity of U-118 MG transfectants and wild 
type cells against doxorubicin and paclitaxel, respectively. The sensitivity of all investigated 
clones against both chemotherapeutic agents was comparable to the wild type cells. 
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Figure 6.6: Chemosensitivity of U-118 MG cells (open circles) (passage 478) and transfectants 
(passage 16 - 18) against 500 nM (A) and 1000 nM (B) doxorubicin; U-118 Luc2 clone 5 (filled 
inverted triangles), U-118 Luc2 clone 7 (filled squares), U-118 Luc2 clone 8 (filled triangles), 
U-118 Luc2/DsRed2 clone 3 (filled circles) and U-118 Luc2/DsRed2 clone 13 (filled diamonds) 
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Figure 6.7: Chemosensitivity of U-118 MG cells (open circles) (passage 478) and transfectants 
against 10 nM (A) and 50 nM (B) paclitaxel; U-118 Luc2 clone 5 (filled inverted triangles), 
U-118 Luc2 clone 7 (filled squares), U-118 Luc2 clone 8 (filled triangles), 
U-118 Luc2/DsRed2 clone 3 (filled circles) and U-118 Luc2/DsRed2 clone 13 (filled diamonds) 
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Additionally, the proliferation of mono- and co-transfected cells was investigated in vitro 
(see Figure 6.8). Similar to the results of the chemosensitivity investigations, within the 
range of experimental errors, there was no difference between wild type and luciferase 
expressing cells with respect to growth kinetics. 
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Figure 6.8: Growth kinetics of U-118 transfectants and wild type cells (open circles) (passage 480); 
A) U-118 Luc2 clone 5 (filled inverted triangles), U-118 Luc2 clone 7 (filled squares) and 
U-118 Luc2 clone 8 (filled triangles); B) U-118 Luc2/DsRed2 clone 3 (filled circles) and 
U-118 Luc2/DsRed2 clone 13 (filled diamonds) 
 
6.3.1.4 Tumorigenicity and bioluminescence of subcutaneously implanted 
transfectants 
In the next step, five clones selected during the in vitro investigations were implanted 
under the thoracic dermis of nude mice to assure stable expression of the transfected 
genes and detectability under in vivo conditions. 
Figure 6.9 and Figure 6.10 show the bright field as well as the bioluminescence images of 
nude mice bearing luciferase2 expressing glioblastomas resulting from U-118 Luc2 clone 7 
and 8 cells. As becomes obvious, both tumors were identifiable by their specific light 
signal. For comparison, the tumor area (U-118 Luc2 clone 7: 5 x 5 mm2, U-118 Luc2 
clone 8: 5 x 5 mm2) was measured with a sliding caliper. 
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Figure 6.9: Bright field (left) and bioluminescence (right) in vivo images of a nude mouse bearing a 
subcutaneous U-118 Luc2 clone 7 xenograft 31 (A) and 38 days (B) after tumor cell implantation; 
image acquisition was performed 300 s after i.p. injection of D-luciferin. Instrument settings: 
exposure time 360 s, EM gain 100, no binning, readout rate 1 MHz at 16 bit 
 
 
 
Figure 6.10: Bright field (left) and bioluminescence (right) in vivo images of a nude mouse bearing 
a subcutaneous U-118 Luc2 clone 8 xenograft 31 (A) and 38 days (B) after tumor cell implantation; 
image acquisition was performed 900 s after i.p. injection of D-luciferin. Instrument settings: 
exposure time 360 s, EM gain 255, no binning, readout rate 1 MHz at 16 bit 
As expected due to the results of the in vitro investigations, xenografts resulting from 
U-118 Luc2 clone 5 cells showed a lower light intensity compared to clone 7 and 8. In 
contrast, U-118 Luc2/DsRed2 clone 3 tumors were not detectable by bioluminescence 
in vivo imaging (data not shown). In the case of clone 13 the tumors regressed before a 
first BLI could be performed (see below). 
For grading of the transfectants, tissue samples were excised and histologically 
characterized. Figure 6.11 shows exemplarily the histology of subcutaneous 
U-118 Luc2/DsRed2 clone 13 and U-118 Luc2 clone 7 xenografts, which did not differ from 
the wild type. Typical for subcutaneous, malignant U-118 MG glioblastoma is a rich stroma 
in which the anisomorphic cells, containing prominent nucleoli, are embedded. 
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Figure 6.11: Masson-Goldner staining of luciferase2 expressing subcutaneous tumors; 
A) U-118 Luc2/DsRed2 clone 13 derived tumor located in the subepidermal adipose tissue 
(objective 10x); B) Detail view of a U-118 Luc2 clone 7 xenograft infiltrated by striated muscle 
(objective 40x) 
In contrast to the encouraging results concerning transfection efficiency, chemosensitivity, 
growth kinetics and detectability, the tumorigenicity was variable and low (cf. Figure 6.12). 
None of the investigated glioblastoma variants showed stable and reproducible growth 
rates as required for the planned preclinical investigations. In general, after an initial phase 
of tumor formation (in ≥ 80 % of the animals), eventually the majority of tumors regressed. 
This behavior was especially pronounced for the co-transfectants (D, E). None of the 
U-118 Luc2 clone 5, 7 and 8 tumors (A - C) reached a tumor area ≥ 40 mm2 within 80 days 
after subcutaneous cell implantation. 
Nevertheless, it was speculated that the tumorigenicity of the glioblastoma cells might be 
higher when growing in their orthotopic localization. Consequently, the two most promising 
cell clones, U-118 Luc2 clone 7 and 8, were implanted into the brain of nude mice. 
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Figure 6.12: Growth curves of individual 
subcutaneous xenografts originating from 
different U-118 transfectants: 
Luc2 clone 5 (A), Luc2 clone 7 (B), 
Luc2 clone 8 (C), Luc2/DsRed2 clone 3 (D) 
and Luc2/DsRed2 clone 13 cells (E) 
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6.3.1.5 Tumorigenicity and bioluminescence of intracerebrally implanted 
transfectants 
By analogy with the investigation of subcutaneous tumors, bioluminescence-mediated light 
emission was detected with the AndorTM EMCCD camera in the living animal. 
Figure 6.13 and Figure 6.14 show at one animal the results obtained with 
U-118 Luc2 clone 7 and 8 xenografts. The tumor “progression” was monitored over a 
period of 3 - 4 weeks. 9 days after orthotopic tumor cell injection, in 3 of 6 mice (both 
subgroups) intracerebral tumors were detectable by their specific light signals. In contrast 
to U-118 Luc2 clone 7 tumors (solely 2 tumors detectable at day 15), the signal emitted by 
clone 8 tumors slightly intensified until day 16 post cell implantation. Since no signal was 
observed in the group of animals transplanted with clone 7 at day 28, the ultimate tumor 
monitoring was brought forward to day 23 in the U-118 Luc2 clone 8 group. Similarly, only 
in one animal a reduced tumor-induced light signal (depicted in Figure 6.14 C) was 
observed. 
 
 
Figure 6.13: Bright field (top) and bioluminescence (bottom) in vivo images of a nude mouse 
bearing an intracerebral U-118 Luc2 clone 7 xenograft; image acquisition was performed 9 (A), 
15 (B) and 28 days (C) after tumor cell implantation. Instrument settings: exposure time 900 s, 
EM gain 255, no binning, readout rate 1 MHz at 16 bit 
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Figure 6.14: Bright field (top) and bioluminescence (bottom) in vivo images of a nude mouse 
bearing an intracerebral U-118 Luc2 clone 8 xenograft; image acquisition was performed 9 (A), 
16 (B) and 23 days (C) after tumor cell implantation. Instrument settings: Exposure time 900 s, 
EM gain 255, no binning, readout rate 1 MHz at 16 bit 
To explore, if the reduced light signal resulted from tumor regression or the loss of 
luciferase2 expression in tumor tissue, the brains were dissected. Serial coronal sections 
(mean distance 200 µm; cf. section 6.2.10) of the brains were prepared and investigated 
by histology. No tumor tissue was found in the brains of nude mice when suspensions of 
U-118 Luc2 clone 7 cells had been injected. In contrast, malignant tissue was detected in 
one section of the brains of U-118 Luc2 clone 8 glioblastoma bearing animals (see Figure 
6.15). 
 
Figure 6.15: Masson-Goldner staining of 
luciferase2 expressing intracerebral U-118 
Luc2 clone 8 xenograft; the transition between 
murine brain tissue and malignant human 
tumor tissue is depicted (objective 40x). 
 
The findings are in agreement with the results of experiments performed with the 
subcutaneous tumors and confirm that the weak bioluminescence resulted from impaired 
tumor cell proliferation in vivo rather than from the loss of luciferase2 expression. 
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Since the luciferase2 and DsRed2 co-expressing U-118 tumors were not detectable in vivo 
(neither by bioluminescence nor by fluorescence imaging, data not shown), a third 
approach was pursued that is presented in the next section. 
 
6.3.2 In vivo imaging of Katushka-mediated fluorescent U-118 MG 
glioblastoma cells 
In a final approach, U-118 MG cells were transfected with the gene encoding the far-red 
fluorescent protein termed Katushka (the generated mono-transfectants were designated 
U-118 Katushka). 
6.3.2.1 Katushka-mediated fluorescence of U-118 transfectants in vitro 
In analogy to the DsRed2 expressing cells, resistant cell populations were isolated from 
the selection medium in order to obtain clones with a high protein expression. The 
subsequent characterization by means of fluorescence microscopy is presented in Figure 
6.16 with clone 6 as an example. Compared to the DsRed2 expressing transfectants, the 
resulting Katushka clones showed higher transfection efficiency as well as brighter 
fluorescence intensity. 
 
Figure 6.16: Katushka-mediated fluorescence (A) and phase contrast (B) image of 
U-118 Katushka clone 6 cells (Carl Zeiss Cell Observer; excitation wavelength 545/25 nm, emission 
wavelength 605/70 nm) 
Subsequently, U-118 Katushka clones 1 - 9 were investigated with respect to their 
fluorescence intensity using the MaestroTM imaging system. As shown in Figure 6.17, the 
Katushka-mediated fluorescence emission correlated with the cell number in a linear 
manner. Especially U-118 Katushka clone 9 cells exhibited a supreme fluorescent intensity 
that was approximately 10-fold higher than observed in the DsRed2 transfectants (cf. 
Figure 6.2). 
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Figure 6.17: Fluorescence of 
U-118 Katushka cells; clone 9 
(filled triangles) showed a 
pronounced higher expression 
of the Katushka protein 
compared to the other 
clones 1 - 8. Data acquisition 
with the MaestroTM imaging 
system; instrument settings: 
exposure time 5 s for 21 
unmixed single images in the 
range from 600 - 800 nm 
(10 nm steps) 
 
The U-118 Katushka clones 2, 6, 8 and 9 were selected for further in vivo studies. 
6.3.2.2 In vivo imaging of subcutaneous tumors 
After subcutaneous implantation of the genetically engineered glioblastoma cells into nude 
mice, only U-118 Katushka clone 2 and 6 cells were tumorigenic. As in the previous exper-
iments, the malignant phenotype was confirmed by histopathology (see Figure 6.18). 
 
 
Figure 6.18: Masson-Goldner staining of a 
subcutaneous U-118 Katushka clone 2 tumor 
(objective 20x) 
 
In contrast to the DsRed2 expressing tumors, U-118 Katushka clone 2 and 3 xenografts 
were detectable under in vivo conditions by means of the MaestroTM imaging device (see 
Figure 6.19). Although the fluorescence intensity was sufficient for subcutaneous 
investigations, the signal-to-noise ratio of these clones was too low for intracerebral 
studies. Unfortunately, clone 9 which was superior in terms of fluorescence intensity and 
thus most promising with respect to intracranial detection, was not tumorigenic. 
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Additionally, the irregular and discontinuous growth behavior (cf. Figure 6.20) did not favor 
elaborate orthotopic experiments. 
 
 
 
 
Figure 6.19: Bright field (left) and fluorescence (right) in vivo images of a nude mouse bearing a 
subcutaneous U-118 Katushka clone 2 xenograft; image acquisition was performed 16 (A) and 
27 days (B) after tumor cell implantation. Instrument settings: exposure time 4 s for 23 unmixed 
single images in the range from 580 - 800 nm (10 nm steps) 
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Figure 6.20: Growth curves of individual subcutaneous tumors originating from 
U-118 Katushka clone 2 (A) and clone 6 (B) cells 
 
Since none of the nine U-118 MG transfectants (genetically engineered by 3 different 
approaches) showed sufficient tumorigenicity and persistent in vivo growth, the wild type 
glioblastoma cells were implanted subcutaneously (see Figure 6.21). Although the cell line 
was tumorigenic in previous studies (Altenschöpfer, 1998; Fellner et al., 2002), problematic 
growth characteristics were observed. Initially, in 6 of 7 mice a small tumor was formed. 4 
xenografts regressed untimely and only two glioblastomas grew very slowly after a lag-
period of approximately two months. It may be speculated that permanent subculturing 
(≥ 450 in vitro passages) or irregularities in the storage conditions (liquid nitrogen) may 
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have accounted for this outcome. In more recent investigations (Müller, 2007) similar 
problems concerning the in vivo growth behavior were reported with U-118 MG cells 
transfected with the gene encoding for EGFP. 
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Figure 6.21: Growth curves of 
individual tumors originating from 
U-118 MG cells 
 
6.3.3 Effect of concomitant application of paclitaxel and ABCB1 
modulators on the growth of intracerebral human glioblastoma 
The efforts to establish an intracerebral tumor model aimed at the evaluation of the 
therapeutic value of new ABCB1 modulators in combination with cytostatics in the 
treatment of malignant brain tumors. As presented above, these efforts failed due to 
insufficient tumorigenicity of the genetically engineered U-118 glioblastoma cells (the same 
holds for the wild type). Fortunately, Matthias Kühnle was successful in analogous 
attempts using highly tumorigenic U-87 MG cells (Kühnle, 2010). Subsequently, the 
U-87 Luc2 clone 3 xenografts (engineered and characterized as part of his PhD thesis) 
were utilized for treatment experiments investigating the effect of concomitant application 
of paclitaxel and ABCB1 modulators on intracerebral tumor growth. The extensive 
transplantation and in vivo imaging procedures were done in collaboration with Matthias 
Kühnle. 
6.3.3.1 Chemosensitivity of luciferase2 expressing human U-87 MG 
glioblastoma cells 
In a proof of principle study demonstrating the therapeutic value of ABCB1 inhibition at the 
BBB, it is crucial to exclude two possibilities. Firstly, increased paclitaxel toxicity due to 
inhibition of ABCB1 transporters in the cell membrane of glioblastoma cells (as seen for 
MDR Kb-V1 cells; cf. chapter 5); secondly, inherent toxicity of the P-gp modulator on the 
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utilized cells. Figure 6.22 shows that tariquidar and ME33-1 neither increased the toxicity 
of paclitaxel (A - C) nor affected cell growth significantly when used alone (D). 
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Figure 6.22: Chemosensitivity of U-87 Luc2 clone 3 (passage 5); vehicle (open circles); 
A) Paclitaxel at various concentrations: 5 nM (filled circles), 10 nM (filled square), 50 nM (filled 
triangles), 100 nM (filled diamonds) and 500 nM (filled inverted triangles); respective concentrations 
of paclitaxel combined with 100 nM of ME33-1 (B) or tariquidar (C); D) ABCB1 modulator alone: 
100 nM (filled circles) and 500 nM (filled squares) of ME33-1; 100 nM (filled triangles) and 500 nM 
(filled diamonds) of tariquidar; 100 nM of vinblastine served as positive control (filled inverted 
triangles). 
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6.3.3.2 Confirmation of tumorigenicity by bioluminescence imaging 
A central objective of the new study design was to assure definitely the presence of a solid 
tumor at the beginning of treatment. 
Figure 6.23 shows a characteristic example of the initial tumor monitoring. Up to 4 
anesthetized mice (individually identifiable via tattooed pads) were placed on the specimen 
stage (segregated by a cross-shaped shield to eliminate falsification of the results by stray 
light) of the in vivo imaging system. In this case, the tumors were exemplarily classified 
into the categories small, medium and large (in the following order: upper left, lower right 
and lower left quadrant; the animal in the upper right corner was excluded due to the 
diffuse and undefined signal). Accordingly, the animals were assigned to the various 
treatment groups guaranteeing a homogeneous distribution with respect to the intensities 
of the tumor signal. 
 
 
Figure 6.23: Confirmation of solid intracerebral U-87 Luc2 clone 3 tumors by means of 
bioluminescence in vivo imaging 14 days after cell implantation; bright field (A), bioluminescence 
(B) and background image (C); in all subsequent investigations, the instrument settings were kept 
constant: exposure time 900 s, EM gain 255, no binning, readout rate 1 MHz at 16 bit, stage height 
h2c 
 
6.3.3.3 Observation of tumor growth by bioluminescence imaging 
After the allocation to the respective treatment groups, the different test compounds were 
administered three times on a weekly schedule as described in detail in section 6.2.11. 
Untreated animals served as control. 
Tumor progression was monitored by means of bioluminescence imaging on the 
days 27/28 and 34/35 after tumor cell implantation (see Figure 6.24). As becomes 
obvious, final image acquisition was impossible in the majority of the untreated mice. The 
rapid tumor progression resulted in a pronounced loss of body weight and required 
intervention (killing of the animals in order to avoid a violation of no-go criteria) in a number 
of animals. Additionally, debilitated animals were prone to demise during anesthesia. Since 
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intact blood circulation is necessary for the distribution of D-luciferin, the respective 
imaging data were useless. As expected, also the animals that received tariquidar, ME33-1 
and paclitaxel showed strong luminescent signals already on days 27/28 after cell 
implantation. Consequently, an impact of these compounds on tumor progression is highly 
unlikely. In contrast, in the group treated with paclitaxel and tariquidar, final imaging was 
possible in 7 of 8 animals. Additionally, in three mice only a moderate light signal was 
detected that in turn indicates a retarded tumor progression. Similar results were observed 
when mice were dosed with paclitaxel and ME33-1. One tumor stagnated while in two 
animals a regression of the light signals was detected (cf. also section 6.3.3.4). In general, 
the mice in the Pac/Mod groups were in a better state of health compared to the other 
subgroups.
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 Untreated mice  
Days after tumor cell implantation  Days after tumor cell implantation 
14/15 27/28 34/35  14/15 27/28 34/35 
  
n.p.  
 
  
n.p.  
 
n.p 
  
n.p.  
 
n.p 
  
    
 Tariquidar group  
14/15 27/28 34/35  14/15 27/28 34/35 
  
 
 
n.p. 
  
 
 
  
n.p.  
 
n.p. 
  
n.p.  
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 ME33-1 group  
14/15 27/28 34/35  14/15 27/28 34/35 
  
 
 
  
n.p.  
 
n.p. 
  
n.p.  
 
n.p. 
  
n.p.  
 
n.p. 
 Paclitaxel group  
14/15 27/28 34/35  14/15 27/28 34/35 
  
n.p.  
 
  
n.p.  
 
n.p. 
  
n.p.  
 
  
n.p.  
 
n.p. 
  
n.p.  
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n.p.  
 
n.p. 
 Paclitaxel + Tariquidar group  
14/15 27/28 34/35  14/15 27/28 34/35 
  
 
 
  
 
 
  
 
 
  
 
 
n.p. 
 Paclitaxel + ME33-1 group  
14/15 27/28 34/35  14/15 27/28 34/35 
  
 
 
  
 
 
  
n.p.  
 
  
n.p.  
 
n.p. 
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Figure 6.24: Specific light signals of intracerebral U-87 Luc2 clone 3 tumors in the various treat-
ment groups detected by means of bioluminescence in vivo imaging; n.p.: it was not possible to 
perform the final image acquisition procedure successfully due to preterm death of an animal (e.g. 
during anesthesia or if the state of health (rapid tumor progression) required intervention (violation 
of no-go criteria)). 
 
6.3.3.4 Comparison of bioluminescence signals with histological serial 
sections 
Finally, serial coronal sections of the various brains were prepared and 10 selected 
samples were investigated histologically in order to verify tumorigenicity as well as to 
compare tumor area and the obtained specific light signals. Since the majority of tumors 
expanded beyond the prepared 15 serial sections, a quantitative determination was 
impossible. Figure 6.25 shows the characteristic morphology of high grade human 
glioblastoma grown in mouse brain. Additionally, two excised brains are depicted in order 
to demonstrate that the resulting tumors were even macroscopically visible. 
 
Figure 6.25: Mason-Goldner staining of 
luciferase2 expressing intracerebral 
U-87 Luc2 clone 3 xenograft (A/B); the respec-
tive solid tumors were already macroscopically 
recognizable in the excised brains (C/D). 
 
As examples, Figure 6.26 shows serial sections of two brains of nude mice and the 
respective bioluminescence image. A voluminous tumor (dark tissue) in the brain sections 
of an untreated control animal yielded a strong specific light signal. In contrast, the small 
tumor in brain sections of a mouse treated with paclitaxel combined with ME33-1 produced 
only a moderate signal. 
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Figure 6.26: Serial coronal section of two representative brains of nude mice (mean distance 
200 µm, starting and ending 1.5 mm rostral and caudal to the region of tumor cell injection) and the 
respective bioluminescence image; a tumor of substantial size is detected in the brain sections of 
an untreated control animal (grey background) whereas only little tumor tissue is visible in the serial 
brain sections of a mouse treated with paclitaxel combined with the ABCB1 modulator ME33-1 (blue 
background). 
In general, the bioluminescence signals correlated to the histologically detected tumor 
area. Nevertheless, in one of the two brains in which a regression of the light signal 
(paclitaxel + ME33-1 group) was observed, a tumor of extensive size was found (data not 
shown). As mentioned earlier, a supply of D-luciferin into the tumor tissue (via an intact 
blood circulation) is a prerequisite for successful detection by means of BLI. Additionally, 
the light signal correlates with the amount of the substrate present in the respective tissue. 
It may be speculated that inadequate distribution of D-luciferin may have caused the poor 
signal intensity. 
 
6.4 Summary and conclusions 
The present study aimed at the evaluation of the therapeutic value of new ABCB1 
modulators in the chemotherapy of malignant brain tumors. Therefore, an existing 
intracerebral model in nude mice was modified to facilitate non-invasive determination of 
tumor burden and progression by means of optical in vivo imaging. 
Consequently, human U-118 MG glioblastoma cells were transfected with the genes 
encoding for fluorescent proteins (DsRed2 and Katushka) or the luciferase2 enzyme. The 
in vitro characterization of the obtained transfectants revealed a low detection limit of both 
methods, BLI and FLI. Additionally, the chemosensitivity and the growth kinetics were 
similar to those of the wild type cells. 
In subsequent in vivo investigations, the resulting luciferase2 expressing tumors were 
detectable subcutaneously as well as in the brain of the living animal. Additionally, the 
respective bioluminescence signal allowed a semi-quantitative evaluation of tumor size. In 
contrast to the encouraging results so far, none of the engineered U-118 glioblastoma 
variants proved to be suitable for preclinical investigations due to dissatisfying in vivo 
growth. 
Since the efforts to establish an intracerebral U-118 glioblastoma model failed owing to 
inadequate tumorigenicity, highly tumorigenic U-87 Luc2 clone 3 xenografts were utilized 
for subsequent treatment experiments. The aim of these investigations was to elucidate, if 
the potential of tariquidar and ME33-1 in increasing the concentration of paclitaxel in the 
CNS (cf. chapter 4) is sufficient to improve brain cancer chemotherapy. Subsequent BLI 
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studies revealed a modest retardation of tumor progression with respect to the specific 
light signals. Additionally, a moderate survival benefit by co-administration of paclitaxel and 
ABCB1 modulators compared to the other treatment groups was observed. 
Finally, selected brains were subjected to histopathological investigations and compared to 
the light signals obtained by in vivo imaging. In general, the bioluminescence signals were 
in good agreement with the histologically determined tumor area. Nevertheless, 
inconsistencies between the results obtained with both methods were observed as well. 
For example it may be difficult to quantitate very small tumors or xenografts located in the 
extramenigeal space by histological serial section. Additionally, the timely BLI process 
(approximately 40 min, background images included) requires a comparatively long 
immobilization of the tumor bearing mouse by anesthesia. This increases the risk that the 
animal awakes or eventually dies during anesthesia leading to false negative results. 
Additionally, the exact location of the tumor (deep in the brain tissue or at the surface) as 
well as the positioning of the scull may to some extent influence the detected light signal. 
In summary, the accuracy of optical in vivo imaging was sufficient for a semi-quantitative 
evaluation of tumor progression. That enabled the confirmation of both, the existence as 
well as the homogeneous distribution of solid brain tumors at the beginning of the 
treatment experiments. Moreover, the combination of paclitaxel with tariquidar or ME33-1 
revealed a moderate retardation of tumor progression combined with a modest survival 
benefit. With slight modifications in the study design (earlier onset of chemotherapy, 
increased concentration of the cytotoxic agent, no background acquisition) future trials 
may reveal the full potential of ABCB1 modulators in the adjuvant therapy of malignant 
brain tumors. 
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Chapter 7 
7 Identification of putative binding modes 
of tariquidar-like modulators at 
P-glycoprotein 
 
7.1 Introduction 
34 years ago it was discovered that a glycosylated 170 kDa surface protein is responsible 
for reduced drug permeation (therefore designated P-glycoprotein) in colchicine resistant 
chinese hamster ovary cells (Juliano and Ling, 1976). Due to its relevance in MDR tumors, 
substantial efforts have been made to investigate the nature of this protein so that P-gp 
became the first cloned human ABC transporter (Chen et al., 1986). However, until 
recently there was a lack of structural information concerning mammalian ABC 
transporters at the atomic level, and structures obtained by electron microscopy, albeit at a 
low resolution of approximately 8 Å, were the best data available (Lee et al., 2008; 
Rosenberg et al., 2005). With a resolution of up to 3.8 Å, the recently published x-ray data 
of the murine Abcb1a transporter (Aller et al., 2009) allow detailed insights into the 
morphology of the protein (see Figure 7.1), thereby facilitating structure-based 
approaches. 
In order to enable crystallization and improve resolution, the authors had to perform some 
structural modifications. Among others, three glycosylation sites in the first extracellular 
loop were removed and six cysteines were labeled with a mercury(II) complex. Crystals 
were grown using detergent solubilized protein in a nucleotide and magnesium free 
medium. Due to high flexibility, the N-terminus (amino acids 1-33) and the linker region 
(amino acids 627-683) connecting the first nucleotide binding domain with the second 
transmembrane domain (TMD2) could not be visualized. Importantly, the modified protein 
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showed almost full functionality and only minor differences between the structures 
obtained from the three different crystals were observed. 
Among the essential topological features is the pseudo two-fold symmetry of the 
transporter, which becomes obvious by the front and back views presented in Figure 7.1. 
Furthermore, each topological half of the protein comprises TMs from the C- and the 
N-terminal side of the polypeptide chain to stabilize the Λ-shaped topology (the interlacing 
TMs are 4/5 and 10/11, respectively). Inside the transporter, at the interface of the two 
TMDs, an internal cavity is formed where the co-crystallized cyclic inhibitors QZ59-RRR 
and QZ59-SSS bind to the protein. Both QZ59-isomers inhibited calcein-AM efflux in the 
low micromolar range and decrease ATP hydrolysis, indicating that they (as tariquidar) are 
not transported by P-glycoprotein. At the intracellular face of Abcb1a, two nucleotide 
binding domains, NBD1 and NBD2, are separated by a distance of ~30 Å. NBD1 follows 
TM6 and is linked to the second TMD. NBD2 begins after TM12 and extends to the C-
terminus of the protein. 
 
Figure 7.1: Ribbon-tube model of the murine Abcb1a transporter (multidrug resistance protein 3) on 
the basis of the 3.8 angstrom resolution x-ray structure (PDB ID 3g5u) (Aller et al., 2009) after 
energy minimization; transmembrane and nucleotide binding domains are labeled and colored in 
yellow (TM1 - TM6 (=TMD1); NBD1) and violet (TM7 - TM12 (=TMD2); NBD2), respectively. A) 
Front and B) back view of the protein backbone; as becomes obvious, TMs4 and 5 as well as 
TMs10 and 11 cross over to the diametrical bundle of TMs. This topology is crucial to stabilize the 
Λ-shaped conformation and to enable the large motional ranges required for substrate transport. 
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The detailed information provided by the x-ray structure served as basis for the docking 
studies presented in this chapter. 
 
7.1.1 Mechanism of transport 
A growing number of results from the literature coincide with the “hydrophobic vacuum 
cleaner”-model of substrate transport first described by Raviv et al. (1990). This model 
suggests that hydrophobic substrates enter the binding site directly from the plasma 
membrane and are exported by P-glycoprotein without reaching the cytosol. Moreover, 
there is substantial evidence that substrates are preferentially extracted from the 
cytoplasmic leaflet of the plasma membrane (Chen et al., 2001; Gatlik-Landwojtowicz et 
al., 2006; Shapiro and Ling, 1997). 
The highly lipophilic character of substrates and inhibitors indicates accumulation within 
the bilayer. If there is direct access from the membrane (with a higher ligand concentration 
compared to the cytoplasm), inhibitory activity should, among other things, depend on the 
lipophilicity of the modulators. A correlation between lipophilicity and inhibitory activity was 
shown for propafenone-type modulators of P-glycoprotein (Schmid et al., 1999). Moreover, 
it could also be shown that the affinity of vinblastine, daunorubicin and verapamil to 
purified protein increased in the presence of more lipophilic phospholipids (Romsicki and 
Sharom, 1999). 
Further evidence in favor of this transport mechanism is provided by the recently published 
x-ray structure of murine P-gp (Aller et al., 2009). Considering the approximate location of 
the plasma membrane, the Λ-shaped inward facing conformation forms a gate, which 
allows entry of lipophilic compounds directly from the inner (cytoplasmatic) leaflet of the 
bilayer (see Figure 7.2). This up to 9 Å wide gate is formed by TMs 4/6 on one and 
TMs 10/12 on the other side, respectively. After passing the portals, the compounds are 
located in the internal cavity of the transporter. This cavity with a volume of approximately 
6000 Å3 contains the binding site for substrates and inhibitors. 
The subsequent mechanism of transport is assumed to resemble that described for the 
bacterial ABC transporter MsbA (Ward et al., 2007). ATP binding induces a packing 
rearrangement of the TMs and results in the dimerization of the NBDs. The concomitant 
twisting motion opens the protein to the extracellular space (associated with a decrease in 
substrate binding affinity) and enables unidirectional transport of the substrate. After 
nucleotide hydrolysis and release, the transporter returns to the inactive, inward-facing 
conformation. This transport mechanism is in accord with the influence of lipophilicity on 
the inhibitory activity of modulators and reasonable also with respect to evolutionary 
aspects (Higgins, 2007). Since many substrates of P-gp are toxic secondary metabolites of 
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plants (e.g. taxanes, vinca alkaloids and colchicine) or microorganisms (e.g. anthracyclines 
and cyclosporines), the ability of an organism to extrude those toxins, before they reach 
their intracellular targets, is a major evolutionary advantage. 
Figure 7.2: Approximate position of 
P-glycoprotein within the lipid bilayer; 
after entering the cell membrane, 
substrates accumulate dependent on their 
lipophilicity and are able to reach the 
internal cavity via an open gate in the 
inner leaflet. 
 
7.1.2 Location of the binding region 
The identification of the binding site of P-glycoprotein is a crucial step in understanding the 
mechanisms of drug transport (Globisch et al., 2008). Additionally, information about the 
interacting residues could facilitate structure-based design of inhibitors as well as structural 
optimization of drugs with respect to impeded efflux (Perego et al., 2001; Szakacs et al., 
2006). 
According to the probable transport mechanism (cf. section 7.1.1), it is reasonable to 
suppose that the binding site(s) is (are) located in the internal cavity within the plasma 
membrane (Higgins, 2007). Indeed, numerous experimental studies using diverse 
biochemical methods provided evidence that substrates and inhibitors bind in this region 
and helped to specify interaction sites (McDevitt and Callaghan, 2007). 
Cross-linking experiments with the thiol-reactive substrate tris-(2-maleimidoethyl)amine 
(TMEA) on the human P-glycoprotein identified L339 (L335 in murine P-glycoprotein) and 
V982 (V978) to be important for substrate binding (Loo and Clarke, 2001a). ATPase 
activity of mutants containing cysteine in the respective amino acid positions was 
significantly decreased by cross-linking with TMEA. Additionally, cross-linking was reduced 
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by pre-incubation with P-gp substrates such as colchicine, vinblastine or verapamil. The 
importance of L339 for inhibiting transport function is also documented by studies with 
other thiol-reactive substrates. The covalent attachment of coumarin-maleimide to L339C 
significantly decreased ATP hydrolysis by P-glycoprotein (Rothnie et al., 2005). The 
mutant L339C was protected from covalent modification with thiol-reactive 
methanethiosulfonate-verapamil (MTS-verapamil) by pre-incubation with verapamil (Loo 
and Clarke, 2001b). In contrast, MTS-rhodamine (a derivative of another P-gp substrate) 
labeled F343C (murine F339) increased ATPase activity 5.8-fold (Loo et al., 2003a). 
Furthermore, addition of verapamil to the MTS-rhodamine labeled mutant further enhanced 
ATP hydrolysis (not observed with substrates like colchicine or calcein-AM). Therefore, the 
binding site of MTS-rhodamine seems to overlap with that of colchicines and calcein-AM, 
but not with that of verapamil. Among findings from other studies (Loo et al., 2003b), this 
indicates that various substrates bind to different sites within the same common 
drug-binding region. 
In a different study (Loo et al., 2006), F728C mutation of the human protein (murine F724) 
resulted in a 4-fold decrease in the apparent verapamil affinity. Moreover, labeling of 
F728C with MTS-verapamil elevated ATPase activity 11.5-fold. In addition to verapamil, 
other ABCB1 substrates and inhibitors as cyclosporine A protected F728C from labeling 
with MTS-verapamil. All these experiments with verapamil and its derivatives are of special 
interest due to their similarity to tariquidar (see Figure 7.3). 
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Figure 7.3: Similarity between the structures of tariquidar (dark gray) and verapamil (green) 
visualized by superposition; the structural formulas (left panel) indicate the common structural 
features (two dimethoxyphenyl moieties, the tertiary amine and the hydrophobic linker). 
The recently disclosed crystal structures of the murine Abcb1a transporter, co-crystallized 
with two stereoisomers of a cyclic hexapeptide inhibitor (Aller et al., 2009), confirmed the 
participation of the above mentioned amino acids in binding. The two stereoisomers 
(QZ59-RRR and QZ59-SSS) bind in three (the SSS-isomer can occupy two sites) different 
locations and orientations to P-glycoprotein, showing that P-gp is able to interact with 
138 Chapter 7 
different ligands via various and partially overlapping binding sites (Sheps, 2009). These 
findings are in agreement with the observed multispecifity of P-gp and other multidrug 
resistance transporters (Higgins, 2007). That the binding sites partially overlap may also 
explain inconsistent data in the literature about their number (Neyfakh, 2002). Additionally, 
the three polar amino acids Q721, Q986 and S989 are of particular importance in the 
“lower” binding site of the QZ59-SSS inhibitor (Aller et al., 2009) and were considered in 
the initial steps of the docking investigations (see below). 
 
7.1.3 Genetic docking algorithm of FlexiDockTM 
The following explanations outline the main features of the applied genetic docking 
algorithm of FlexiDockTM and can be found in detail in the manual provided from TriposTM 
(Tripos, 2006). All calculations were performed with the Molecular Modeling suite Sybyl 7.3 
(Tripos, L.P., St. Louis, MO) on an SGI Octane Workstation. 
Methodology and terminology of genetic docking algorithms are based on Darwinian 
evolution. Each member of a population is represented by a chromosome (potential 
solution) consisting of a collection of genes. Genes encode defined torsion angles 
(rotatable bonds) of the ligand and amino acid side chains as well as rigid body rotations 
and translations of the ligand in x-, y- and z-direction. In each generation, evolution occurs 
by mutation of genes (e.g. for a torsional gene: rotation about a specific bond) and 
crossover between chromosomes (exchange of genes). 
For every chromosome, a fitness (or scoring) function (energy of all moving atoms in the 
protein-ligand complex, an additional term optionally weights H-bonds) based on a subset 
of the Tripos force field is calculated. Chromosomes with a high fitness function (well fitting 
ligand orientations and conformations) have a higher probability (selection pressure) of 
surviving to the next generation. Due to this "elitism", these solutions have the best chance 
to propagate into future generations and the quality of the solutions will increase with time. 
Additionally, checking for duplicates ensures the solution´s diversity over various 
generations. 
The evolution process can be influenced by customizing the FlexiDockTM parameters. 
Among the most important ones are the number of seeds (population size), the definition 
of putative H-bond sites (corresponding solutions have a higher scoring function), the 
probability level (and the allowed range) of mutations and the number of generations to 
run. The last parameter is highly dependent on the number of rotatable bonds in both, the 
ligand and the binding site. Selecting the number of generations too small can result in no 
plausible solution. In contrast, choosing a too high number of generations will result in low 
diversity of the results since all genes have converged. 
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Additionally, it should be kept in mind that FlexiDockTM operates only in the torsional, 
rotational and transformational space. As a consequence, during the optimization process, 
bond lengths and angles remain constant. 
 
7.2 Materials and methods 
7.2.1 Selected ABCB1 modulators 
In order to investigate the putative binding mode of tariquidar-like modulators at 
P-glycoprotein, five compounds were chosen for docking experiments (see Figure 7.4). 
Tariquidar, ME30-1 and ME5-7 have a common basic structure. Modifications in 
positions 4 and 5 of the benzamide moiety lead to substantial differences of the in vitro 
activity. Additionally, ME25-3, an inhibitor with a relative selectivity for the ABCG2 
transporter (due to a shift of the quinoline-3-carbonylamino moiety to position 3 (meta)) 
was considered. Furthermore, the dual ABCB1/ABCG2 inhibitor elacridar with the 
benzamide moiety as part of an acridine ring was included in the docking experiments. 
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Figure 7.4: Chemical structures of compounds selected for docking experiments; ABCB1 inhibitory 
activity at human P-gp was determined on Kb-V1 cells with the calcein efflux assay by flow 
cytometry. 
Under physiological conditions, the protonated species of tariquidar-like modulators 
predominates (> 73 %, calculated by ACD/Labs 12). Consequently, in all further 
investigations, the nitrogen in the tetrahydroisoquinoline moiety was regarded as being 
protonated. 
 
7.2.2 Determination of IC50- and log D-values 
All tariquidar analogs were provided by the laboratory of Prof. Dr. König (University of 
Regensburg, Germany) and ABCB1 inhibitory activity was determined by means of the 
calcein efflux assay on the flow cytometer and in the micro-plate format. The assays on 
human Kb-V1 cells were performed according to Müller et al. (2007) and as described in 
chapter 3, respectively. Log D-values at pH 7.4 were calculated with ACD/Labs 12 
software (Toronto, Canada). 
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7.2.3 Conformational analysis 
Due to the high degree of flexibility inherent in the tariquidar-like modulators, the number of 
possible solutions had to be constrained by conformational analyses. Compound ME30-1 
was split into two fragments (see Figure 7.5) which were separately analyzed by grid 
searches. 
 
Figure 7.5: Flexible bonds of ME30-1 included in the conformational analysis are indicated in bold. 
In a first attempt the molecule was split and a grid search was performed for each moiety. Only 
preferred torsion angles were incorporated into subsequent conformational analyses of the whole 
structure. 
A subsequent systematic search of the whole structure was restricted to energetically 
favored torsion angles resulting from the previous step. All conformations obtained by the 
systematic search were minimized. Every structure with an RMS distance to all other 
conformations of > 0.5 Å was regarded as individual local minimum. The energetically 
most favored extended conformer was used as starting conformation for docking 
experiments. 
 
7.2.4 Preparation of the transporter 
The 3.8 Å resolution x-ray structure (Aller et al., 2009) of the murine Abcb1a transporter 
(PDB ID Code: 3G5U) was obtained from the Protein Data Bank (Research Collaboratory 
for Structural Bioinformatics (RCSB), Rutgers University, NJ) and processed with the 
structure preparation tool implemented in Sybyl 7.3. The main modifications in brief: 
removal of mercury atoms; addition of hydrogens; addition of acetyl (N-termini of the 
polypeptide chain) and methylamino (C-termini of the polypeptide chain) groups; addition 
of AMBER7 FF99 charges; if necessary, correction of side chain conformations (with 
rotamer states from the Lovell library (Lovell et al., 2000)) to remove steric bumps. 
Subsequently, the protein was minimized with the AMBER7 FF99 force field (dielectric 
constant 4). This first minimization steps were performed by the steepest descent method. 
In a second minimization approach with the Powell conjugation gradient method, the 
transporter was allowed to relax to a total energy of approximately -4000 kcal mol-1. 
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7.2.5 Docking of ABCB1 modulators 
Results from labeling (Loo and Clarke, 2001b), cross-linking (Loo and Clarke, 2001a) and 
mutational experiments (Loo et al., 2006) as well as the location of the co-crystallized, 
cyclic inhibitors (Aller et al., 2009) were considered to localize the binding region. In a first 
attempt, the energetically favored conformations of the modulators were manually docked 
in this region, suggesting interactions with the essential amino acids described in 
section 7.1.2. In a second step, the FlexiDockTM module implemented in Sybyl 7.3 was 
used for refinement. All flexible bonds of the modulators and all side chains of amino acids 
in proximity to the pre-positioned ligand were defined as rotatable. In general, several runs 
using different starting seeds and a minimum of 750 generations per rotatable bond were 
performed. The obtained docking results were analyzed by visual inspection and used for 
further FlexiDockTM runs with marked H-bond donor and acceptor sites in the protein and 
the ligand. 
In the resulting docking solutions, the modulators and amino acids within a radius of 6 Å 
around them were minimized with the Tripos force field (dielectric constant 1; ligand: 
Gasteiger-Hückel charges, protein: AMBER FF99 charges; range constraints of detected 
H-bonds: 1.7 Å to 2.2 Å) using the steepest descent method. Afterwards, the ligand was 
fixed, and the protein was minimized with the AMBER FF99 force field (dielectric 
constant 4; minimization method: Powell) until an RMS gradient of < 0.05 kcal mol-1 Å-1 
was achieved. 
 
7.2.6 Sequence alignment 
The primary amino acid sequences of the Abcb1a (P21447), the Abcb1b (P06795) and the 
ABCB1 transporters (P08183) were downloaded from the UniProt knowledgebase, and the 
sequence alignment was performed with CLUSTAL W2 (Larkin et al., 2007). 
 
7.3 Results and discussion 
7.3.1 Correlation between lipophilicity and inhibitory activity 
Due to evolutionary aspects, the topology of the transporters and experimental evidence, 
substrates and modulators are most likely extracted directly from the lipid bilayer. The 
concentration of a particular compound in a lipophilic compartment is a function of its 
octanol-water partition coefficient. Thus, IC50-values should not depend only on binding 
affinities, but also on the lipophilicity of the modulators. 
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In order to investigate this assumption, pIC50-values of 23 selected tariquidar-like ABCB1 
modulators (Müller, 2007) are correlated with their calculated log D-values. Figure 7.6 
shows a significant correlation between the inhibitory potency and lipophilicity. Tariquidar 
as well as the analogs investigated in more detail in the previous chapters appear above 
the regression line in the upper right corner of the graph. Accordingly, the “additional 
potency” of these compounds is caused by high affinity to the target and not only 
dependent on the concentration in the lipophilic compartment. However, hydrophobicity 
has a certain influence on activity due to membrane penetration and possibly hydrophobic 
interactions with the target.  
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Figure 7.6: The pIC50-values 
(determined with calcein efflux 
assay at the plate reader) of 23 
selected tariquidar-like ABCB1 
modulators are correlated with 
calculated log D-values. 
Regression equation: 
pIC50 = 0.39 log D + 3.31 
r = 0.56, s = 0.66, p = 0.005 
r: coefficient of correlation 
s: standard error of estimate 
p: level of significance 
 
By contrast, there are several compounds with poor affinity in spite of high hydrophobicity 
(lower right corner). The lack of hydrophilic compounds with high activity (upper left corner) 
may be due to low concentrations at the target. This complicates the design of potent 
hydrophilic, well soluble P-glycoprotein modulators with drug-like properties. Possibly, a 
prodrug concept could solve this problem (see section 7.4). 
 
7.3.2 Conformational analysis of compound ME30-1 
Since no crystallographic data of tariquidar or related structures were available from the 
Cambridge Structural Database (Cambridge Crystallographic Data Center, Cambridge, 
United Kingdom), representative conformational searches were performed for compound 
ME30-1 as described in section 7.2.3. 
The resulting low-energy solutions were analyzed by visual inspection and could be 
grouped into two categories, “folded conformers” with a high contribution of intramolecular 
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interactions and “extended conformers”. Figure 7.7 shows two distinctive representatives 
for the first category with low energy in consequence of intramolecular interactions. 
 
 
Figure 7.7: Two characteristic examples of energetically favored folded conformers of ME30-1. 
A) Spacefill and capped sticks illustration of a conformer stabilized by hydrophobic interactions. 
B) Side- and top view of a molecular conformation resulting from distinctive π-π stacking 
interactions 
It is a common rule that minimization of the free, not target-bound compound overesti-
mates intramolecular contacts as H-bonds and hydrophobic interactions which are 
probably not relevant for the conformation in the binding pocket (Klebe, 2009). Additionally, 
a molecular axis longer than 18 atoms appears to be favorable for effective inhibition of 
P-gp function (Wang et al., 2003). 
Consequently, the energetically favored extended conformers were regarded to represent 
the receptor bound conformations. Figure 7.8 shows low-energy conformers of compound 
ME30-1 from this group. 
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Figure 7.8: Superposition (side view) of 34 extended conformations of ME30-1 with calculated 
energies lower than 32 kcal/mol (A) and after rotation of 90° (B); the lowest energy conformer, 
colored in green, was used for further docking experiments. 
For all further docking experiments the energetically most favored extended conformer 
was used as starting conformation. 
 
7.3.3 Analysis of binding modes of ABCB1 modulators 
Five modulators with different structural features covering a sufficient range of IC50-values 
(see section 7.2.1) were selected for docking experiments. All investigated modulators 
share a similar binding position (see Figure 7.9 for ME30-1) in the C-terminal half of the 
transporter in the region of the plasma membrane. This location corresponds to the “lower” 
binding site of QZ59-SSS in the x-ray structure (Aller et al., 2009). Additionally, this 
location is in accordance with the suggested transport mechanism and with results from 
labeling, cross-linking and mutational experiments. 
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Figure 7.9: Overall front (A) 
and side view (B) of the 
ABCB1 transporter backbone 
with ME30-1 (in green) 
illustrating the approximate 
position of ligand binding; the 
modulator interacts at the level 
of the inner leaflet with 
residues in the C-terminal half 
(predominantly TM5, TM7 and 
TM12) of P-glycoprotein. 
 
7.3.3.1 Binding modes of tariquidar and ME30-1 
The binding mode of tariquidar, the best characterized and the most potent of the 
investigated modulators, is shown in Figure 7.10. The binding site consists of 
predominantly non-polar amino acids in TMs 5-9 and 12, which enable hydrophobic 
interactions. Additionally, polar amino acids in TM5 (Y303), TM7 (N717 and Q721) and 
TM12 (Q986 and S988) form hydrogen bonds with the molecule. An interaction found for 
all investigated modulators is the strong charge-assisted H-bond between the side chain of 
S988 and the protonated tertiary amine. As reported previously (Seelig and 
Landwojtowicz, 2000), a basic, tertiary amino group is an important structural feature of 
most ABCB1 inhibitors and substrates. Among other things (see section 7.4), the obvious 
steric freedom in the region around the tetrahydroisoquinoline moiety could be responsible 
for the broad variety of drugs interacting with P-gp. 
In contrast, there is very limited space in position 3 (meta) and to some extent in position 4 
(para) of the benzamide moiety. This fact is of special importance for the binding affinity of 
compounds with sterically discriminating moieties (e.g. ME25-3 and ME5-7) in these 
positions. 
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Figure 7.10: A) Model of the putative Abcb1a binding site for tariquidar; shown are residues within 
3 Å around the ligand, except (for clarity) F724 (TM7), F766 (TM8), V978 and F990 (TM12). The 
orientation of tariquidar allows the formation of H-bonds (depicted as yellow dotted lines) with the 
side chains of Y303 (TM5), N717 (TM7), Q721 (TM7) and Q986 (TM12). Additionally, a strong 
charge-assisted H-bond between the hydroxy group of S988 (TM12) and the protonated tertiary 
amine is possible. B) Connolly surface (cross-sectional slice) of the binding site colored by the 
lipophilic potential (brown - lipophilic, green/blue - hydrophilic); in this representation, the limited 
space in position 3 and 4 of the benzamide moiety and, in contrast, a high degree of steric freedom 
around the dimethoxy-tetrahydroisoquinoline moiety becomes obvious. 
The less potent analog ME30-1, bearing a morpholine substituent in position 5 of the 
benzamide moiety, showed a similar binding mode as tariquidar (see Figure 7.11). As a 
result of the lacking 4-methoxy group, the H-bond to Y303 in TM5 is not possible. 
Furthermore, the modulator is slightly shifted compared to tariquidar probably in order to fit 
the morpholine group to a hydrophobic pocket. This shift might also be responsible for the 
loss of the H-bond between the carbonyl oxygen of the benzamide moiety and Q986 in 
TM12. Nevertheless, the remaining H-bonds as well as the hydrophobic interactions may 
account for an effective inhibition of P-glycoprotein. 
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Figure 7.11: A) Model of the supposed Abcb1a binding site for ME30-1; shown are residues within 
3 Å around the ligand, except (for clarity) F332 (TM6), F766 (TM8), V978 and M982 (TM12). As in 
the case of tariquidar, H-bonds with the side chains of N717 (TM7), Q721 (TM7) and S988 (TM12) 
are possible. In contrast, the interaction with Y303 (TM5) is lacking. The morpholine moiety fits to a 
hydrophobic pocket resulting in a slight shift of the molecule which possibly eliminates the H-bond 
to Q986 observed with tariquidar. B) Connolly surface (cross-sectional slice) of the binding site 
colored by the lipophilic potential (brown - lipophilic, green/blue - hydrophilic); also in the binding 
orientation of ME30-1, the limited space in meta- and para-position of the central aromatic ring is 
obvious. 
 
7.3.3.2 Binding modes of ME25-3 and ME5-7 
Compounds such as ME25-3, with the quinoline-3-carbonylamino substituent in position 3 
of the benzamide moiety, are weak inhibitors of the ABCB1 transporter, but turned out to 
be ABCG2 selective modulators. This modification of the substitution pattern paved the 
way to discriminate between ABCB1 and ABCG2 modulators derived from tariquidar. The 
replacement of the methoxy group in position 4 with the sterically more demanding 
methoxycarbonyl moiety further reduced the affinity against P-gp and resulted in the most 
potent and selective ABCG2 modulators known so far (Kühnle et al., 2009). 
Figure 7.10 A shows the orientation of ME25-3 in the binding pocket of P-gp in relation to 
tariquidar. As a consequence of the limited space for substituents in position 3 of the 
benzamide moiety (see above), the quinoline-3-carbonylamino substituent is suggested to 
fit to the hydrophobic pocket occupied by the morpholino group of ME30-1. This results in 
a loss of the H-bonds with N717 and Q721 (both in TM7). Since the interactions with Y303 
in TM5 and S988 are still possible, at least low inhibitory activity at P-gp is retained. 
In the case of ME5-7 a completely different binding mode compared to tariquidar must be 
assumed (Figure 7.12 B), although the quinoline-3-carbonylamino substituent is in the 
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“correct” position 2 of the benzamide moiety. In consequence of the steric bulk of the 
sulfonamide moiety, the entire molecule has to re-orientate. Apart from the H-bond of the 
tertiary amine with S988, all specific interactions observed for the other compounds are 
lost. Additionally, in this orientation only weak hydrophobic interactions of the quinoline 
moiety are possible. Probably, also the decrease in lipophilicity (poor accumulation in the 
membrane) due to the introduction of the sulfonamide moiety contributes to the total loss 
of apparent inhibitory activity at the ABCB1 transporter. 
 
 
Figure 7.12: Orientation of ME25-3 (orange) and ME5-7 (green) in relation to tariquidar (dark grey) 
in the binding pocket of P-gp; A) The quinoline-3-carbonylamino moiety in meta-position is 
suggested to fit to the hydrophobic pocket (similarly like the morpholine moiety of ME30-1). Thus, 
the H-bonds of the quinoline-3-carbonylamino group with N717 and Q721 (seen with tariquidar and 
ME30-1) are impossible. Nevertheless, the H-bonds to Y303, S988 and potentially Q986 can still be 
formed and guarantee an at least low inhibitory activity. B) Due to the bulk of the sulfonamide 
group, the entire molecule has to re-orientate. At this position, all specific interactions (except for 
that of the tertiary amine) observed for tariquidar, ME30-1 and ME25-3 are lost. Combined with 
reduced hydrophobic interactions of the quinoline moiety in this orientation, the loss of affinity is 
comprehensible. 
 
7.3.3.3 Binding mode of elacridar 
Elacridar, a potent dual ABCB1/ABCG2 inhibitor with the benzamide moiety included in an 
acridine ring (mimicking a cyclic substitution in the ortho- and meta-position) was also 
investigated. Due to the lower bulk of the ring system compared to the meta-
quinoline-3-carbonylamino group of ME25-3, an orientation of the benzamide moiety like in 
the case of tariquidar is still possible. 
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From Figure 7.13 it becomes obvious that elacridar addresses the same binding region as 
the other modulators, but in a unique and slightly different manner. Y303 (TM5) interacts 
with the carbonyl group at the acridine ring (like the 4-methoxy group in tariquidar and 
ME25-3) and Q986 (TM12) contacts the 10-methoxy substituent instead of the carbonyl 
function in the benzamide moiety of tariquidar. This results in a shift of the molecular axis 
towards TM6 and fits the ring system in the narrow part of the binding pocket. Additionally, 
a dual charge-assisted hydrogen bond between the protonated tertiary amine and both, 
the backbone and the side chain oxygen of S988 is possible. 
 
 
Figure 7.13: A) Model of the assumed Abcb1a binding site for elacridar; shown are residues within 
3 Å around the ligand, except (for clarity) A981, V984 and D993 (TM12). Formation of H-bonds is 
possible with Y303 (TM5), Q986 (TM12) and both, the backbone and the side chain oxygen of 
S988 (TM12). B) Connolly surface (cross-sectional slice) of the binding site colored by the lipophilic 
potential (brown - lipophilic, green/blue - hydrophilic); a minor twist of the acridine ring enables the 
accommodation in the binding pocket and H-bonds with Y303 and Q986. 
A further cause for the high activity of elacridar might be favored entropy driven binding 
due to the reduced flexibility in contrast to the tariquidar-like modulators. 
 
7.4 Summary and conclusions 
In the following, items associated with species differences of the transporters and 
conclusions with respect to the design of optimized modulators (regarding solubility, affinity 
and verification of binding modes) will be addressed. 
Abcb1a and Abcb1b are results of a gene duplication in rodents (Dean and Annilo, 2005). 
Our docking studies were based on the x-ray structure of the murine Abcb1a transporter. 
The binding mode at human P-glycoprotein may be more or less different (Gottesman et 
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al., 2009). Indeed, substrate patterns and inhibitory potencies of modulators differ among 
the two murine isoforms themselves and the human transporter (Schwab et al., 2003; 
Tang-Wai et al., 1995). Nevertheless, the sequence identity between Abcb1a and the 
human transporter of 87.3 % is high (93.3 % similarity), even higher than the identity 
between the two murine isoforms (83.9 % identity, 92.1 % similarity). With regard to the 
proposed binding modes of tariquidar-like modulators, mainly residues in close proximity to 
the ligands are relevant. Table 7.1 shows the high degree of conserved residues 
especially between the human and the murine Abcb1a transporter. Only F833 in TM9 is 
replaced by a threonin residue. With respect to the second rodent transporter, five amino 
acids are different. In this case, especially the replacement of Q986 by asparagine could 
affect the inhibitory potency. 
Accordingly, all tariquidar-like modulators investigated in chapter 3 on murine P388D1Doxo 
cells showed nearly the same affinity increase (IC50-ratios) compared to the assay on 
human Kb-V1 cells. This can be explained with the specific experimental set-up and the 
utilized cell species. Valspodar with a unique structure (and a presumably distinct binding 
region) exhibited a significantly greater IC50-ratio. 
Table 7.1: Comparison of residues forming the binding pocket of tariquidar in docking studies on 
the murine transporter Abcb1a with the corresponding residues of the human (ABCB1) and the 
second murine analog (Abcb1b)a,b 
Abcb1a L 300 
Y 
303 
Y 
306 
F 
332
L 
335
I 
336
F 
339
Q 
343
P 
346
N 
717 
Q 
721 
F 
724 
 
ABCB1 * * * * * * * * * * * *  
Abcb1b * * * * * L * H * * * *  
TM 5 6 7  
Abcb1a L 758 
S 
762 
F 
766 
A 
830
F 
833
F 
974
V 
978
A 
981
M 
982
G 
985 
Q 
986 
S 
988 
S 
989
ABCB1 * * * * T * * * * * * * * 
Abcb1b M * * * T * * * * * N * * 
TM 8 9 12 
a In order to consider different orientations of the various ligands, amino acids within 6 Å of the 
modulator are listed. 
b Stars indicate sequence identity of the corresponding residue with the murine Abcb1a transporter. 
Our results might be helpful in the design of P-gp modulators. Structural modifications 
increasing solubility are not appropriate due to the influence of lipophilicity on inhibitory 
activity. The modulators require a certain amount of hydrophobicity to accumulate in the 
membrane and approach the binding site. A prodrug concept could help to solve this 
problem. 
Structural modifications of tariquidar with probably positive influence on the P-gp affinity of 
the modulators are summarized in Figure 7.14. Targeting Q343 in TM6 with an H-bond 
152 Chapter 7 
donor or acceptor group could stimulate binding by an additional specific interaction. 
Rigidisations of the ligand could increase inhibitory activity due to enhanced entropy driven 
binding. Considering the substantial size of the binding pocket, also bivalent compounds 
are conceivable. The second pharmacophore could bind to residues in the upper region of 
the internal cavity (occupied by the QZ59-isomers). 
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Figure 7.14: Suggested structural modifications of tariquidar to increase affinity to the ABCB1 
transporter. 
Furthermore, it would be helpful to verify the "lipophilicity hypothesis" and the proposed 
binding modes with a series of structurally altered compounds.  
Table 7.2 summarizes possible modifications, the anticipated effect and the rationale 
based on the proposed binding modes. In particular, alkylation of the tertiary amine should 
be probed, because the interaction with S988 is suggested to be crucial for all investigated 
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modulators. Nevertheless, due to multispecifity of P-gp, it is also conceivable, that such 
compounds are able to bind with an altered binding mode at a different binding site. 
Table 7.2: Overview about recommended structural modifications to verify the suggested binding 
modes; additionally, the predicted effects on the inhibitory potency and the underlying mechanisms 
are listed. 
Recommended 
structural 
modification 
 
Predicted 
effect on  
potency 
Rationale 
mono- and dichlorinated 
derivatives at the central 
aromatic ring system 
 increase higher lipophilicity increases concentration in membrane 
replacement of dimethoxy-
tetrahydroisoquinoline moiety 
with piperidine 
 unaltered no distinct interactions of the dimethoxybenzyl moiety 
alkylation of the tertiary amine  pronounced decrease 
loss of charge-assisted 
H-bond(s) with S988 
replacement of isoquinoline 
moiety with 2-naphthyl moiety  decrease 
loss of specific interaction with 
N717 
removal of the 4,5-dimethoxy 
groups of the benzamide moiety  decrease loss of H-bond with Y303 
 
Additionally, the limited sterical freedom in meta- and para-position of the benzamide 
moiety is in agreement with the observed selectivity of meta- and para-substituted tariqui-
dar analogs for the ABCG2 transporter. The exact knowledge of the binding region at P-gp 
can also facilitate an anti-target based design of selective ABCG2 modulators. 
In summary, the molecular modeling investigations facilitate a unique insight into the 
structure and function of P-glycoprotein. The location of the proposed binding region is in 
accordance with the suggested transport mechanism and with results from labeling, cross-
linking, mutational and x-ray crystallographic experiments. The proposed binding modes 
largely agree with the inhibitory potencies of tariquidar-like modulators and can explain the 
selectivity of the meta- and para-substituted analogs for the ABCG2 transporter. Further-
more, the putative binding site with six polar residues distributed over 4 TMs in a highly 
lipophilic environment provides the necessary selectivity, flexibility and multispecificity P-
glycoprotein is notorious for. 
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8 Summary 
 
The ABCB1 transporter (P-glycoprotein), an ATP-driven efflux protein, strongly influences 
the absorption, distribution and excretion of various drugs. As an essential component of 
the blood-brain barrier, P-glycoprotein limits the penetration of potent cytostatic agents 
(e.g. paclitaxel) into the central nervous system (CNS). Furthermore, over-expression of 
ABCB1 transporters in tumor cells is one of the major mechanisms of classical multidrug 
resistance (MDR) in cancer. Hence, inhibition of P-glycoprotein is an attractive strategy to 
improve the therapy of both, tumors in the CNS and MDR malignancies in the periphery. 
Accordingly, a series of potent inhibitors derived from the 3rd generation P-glycoprotein 
modulator tariquidar was investigated in vitro. A fluorescence-based efflux-assay using 
human Kb-V1 cells was established at the microtiter plate format. The obtained data were 
in good agreement with the validated flow cytometric method while throughput was 
substantially increased. Additionally, cells expressing the murine transporter were 
generated to assure activity at rodent P-glycoprotein. Further biopharmaceutical 
investigations (concerning toxicity, stability, plasma albumin binding and inhibition of 
cytochrome P450 isoenzymes) confirmed the suitability of tariquidar and the three most 
promising derivatives (bearing polar residues such as a methoxyethoxyethylamino 
(ME27-4), a morpholino (ME30-1) or an ethoxyethyloxy (ME33-1) moiety) for further in vivo 
studies. 
In order to determine the concentration of the selected modulators in brain and plasma 
samples, a solid-phase extraction procedure followed by RP-HPLC analysis was validated. 
The method yielded reproducible high recoveries, a low limit of quantification as well as 
high accuracy and precision. The concomitant administration of paclitaxel in successive 
bio-distribution studies in NMRI mice revealed favorable bioavailability and high metabolic 
stability of the tariquidar-like compounds. As desired, the modulators significantly 
increased the brain AUC of paclitaxel. The observed increase by a factor of two to four 
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correlated with the previously determined in vitro potency of the various inhibitors. In 
contrast to the co-administration of the 2nd generation modulator valspodar, the plasma 
AUC of paclitaxel was unaffected, indicating lower systemic toxicity. 
To investigate if the increased paclitaxel brain concentration is of relevance for the therapy 
of malignant brain tumors, an intracerebral xenograft model in nude mice was refined. 
Human U-118 MG glioblastoma cells were transfected with the genes encoding for the far-
red fluorescent protein or the luciferase2 (Luc2) enzyme to facilitate non-invasive 
determination of tumor burden by means of fluorescence or bioluminescence imaging 
(BLI). Tumors originating from intracranial injection of luciferase2 expressing cells were 
detectable in the living animal. Unfortunately, the growth behavior was unsuitable for the 
intended in vivo investigations. Alternatively, highly tumorigenic U-87 Luc2 xenografts were 
utilized for subsequent treatment experiments evaluating the combination of paclitaxel with 
the most potent modulators ME33-1 or tariquidar. Since the obtained light signals largely 
correlated with the histological determined tumor burden, BLI revealed a moderate 
retardation of tumor progression when paclitaxel was combined with an ABCB1 modulator. 
Furthermore, the therapeutic value of the co-administration of ABCB1 modulators with 
paclitaxel in the treatment of MDR tumors was investigated. For this purpose, ABCB1 
transporter over-expressing Kb-V1 cells were extensively characterized in vitro followed by 
subcutaneous implantation into nude mice. The resulting malignancies showed high 
tumorigenicity, reproducible growth kinetics and maintained transporter expression in vivo. 
In subsequent treatment experiments ME30-1, ME33-1 and tariquidar were investigated. In 
contrast to the other modulators, only the combination of ME30-1 with paclitaxel 
significantly slowed down the growth of Kb-V1 tumors compared to paclitaxel mono-
therapy. 
Additionally, molecular modeling investigations were performed based on the very recently 
published x-ray structure of the murine Abcb1a transporter. Conformational analysis of the 
tariquidar-like modulators provided the starting conformation for successive docking 
experiments. The location of the subsequently identified binding region is in accordance 
with the suggested transport mechanism and experimental data from the literature. The 
proposed binding modes largely agree with the inhibitory potencies of the investigated 
ABCB1 modulators and explain the negligible ABCB1 activity of tariquidar-derived, 
selective ABCG2 modulators. The findings facilitate the structure based design of 
optimized ABCB1 modulators and may contribute to improve the adjuvant cancer 
chemotherapy of glioblastomas and MDR tumors. 
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A Appendix 1: In vitro activity of epothilones 
against human glioblastoma cells and 
interaction with ABC transporters 
 
A.1 Introduction 
Due to the crucial role of microtubules in cell transport, signaling and mitosis, drugs which 
destabilize (e.g. vinca alkaloids) or stabilize (e.g. taxanes) microtubules are among the 
most commonly prescribed anticancer agents (Goodin et al., 2004). Although taxanes are 
active against a broad range of solid malignancies, their clinical use is limited. The most 
important issues are the risk of hypersensitivity reactions, toxicity (first and foremost on 
hematopoiesis (dose limiting) and the nervous system (cumulative)) and tumor resistance 
(Morris and Fornier, 2008). 
The epothilones, a new class of microtubule-stabilizing agents (Bollag et al., 1995) are 
naturally occurring 16-membered macrocyclic polyketides with no structural relation to the 
taxanes (see Figure A.1). 
 
Figure A.1: Chemical structures of the two investigated epothilones. This compound class was 
initially discovered as cytotoxic metabolites from the myxobacterium Sorangium cellulosum. 
Beside their impressive intracellular accumulation (Wartmann and Altmann, 2002), the 
epothilones are of special interest because of their activity against both, multidrug resistant 
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cancer cells (Kowalski et al., 1997) and tumors (Altmann et al., 2000). Since the 
expression of P-glycoprotein is one of the major mechanisms of MDR in cancer (Szakacs 
et al., 2006), the epothilones are considered to be not or at least less susceptible to ABC 
transporter mediated chemoresistance and hence superior to established cytostatic drugs 
such as vinblastine and paclitaxel (Aghajanian et al., 2007). 
Due to the fact that epothilones are able to displace [3H]-paclitaxel from microtubules, an 
overlapping or even identical binding site was postulated (Bollag et al., 1995; Wartmann 
and Altmann, 2002). The proposed common binding pocket on β-tubulin has (despite the 
above mentioned poor structural similarity to paclitaxel) encouraged speculations about a 
common pharmacophore (Giannakakou et al., 2000). 
The publication of the structure of epothilone A (Epo A) bound to tubulin determined by 
electron crystallography and nuclear magnetic resonance spectroscopy (Nettles et al., 
2004) revealed that Epo A and paclitaxel indeed occupy a rather expansive common 
binding site (see Figure A.2). However, since side chains and all functional groups (except 
C7-OH) exploit distinctly different regions of the binding pocket, the speculations about a 
common pharmacophore turned out to be wrong. 
Figure A.2: Superposition of 
Epo A (blue) and paclitaxel 
(gold) in ß-tubulin. The single 
common center (C7-OH) is 
indicated by blue arrows. The 
image in (A) relates to a 90° 
rotation of the image in (B). 
Reprinted from Nettles et al. 
(2004) with permission from 
The American Association for 
the Advancement of Science. 
 
Nevertheless, the fact that such structurally diverse compounds1 (Kar et al., 2003) bind 
with low nanomolar affinity to the same promiscuous binding pocket in totally different 
orientations by interacting with an optimal subset of residues raises the question whether 
this is also possible for the multispecific binding region of P-glycoprotein. And indeed, 
there is evidence that epothilones have a certain susceptibility for the ABCB1 transporter 
and that there are differences in affinity depending on the structure of the particular 
epothilones (Chou et al., 1998; Goodin et al., 2004; Wartmann and Altmann, 2002). 
                                                
1 In all probability the endogenous neuronal tau protein also interacts with the same binding site at 
β-tubulin 
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Consequently, the major aim of this investigation was the further elucidation of interactions 
between epothilones and ABC transporters as well as their activity against different human 
glioblastoma cell lines. 
 
A.2 Materials and methods 
A.2.1 Drugs and chemicals 
Epothilone B and epothilone D were kindly provided by the Helmholtz Zentrum für 
Infektionsforschung (Braunschweig, Germany). Mitoxantrone stocks were obtained by 
diluting Novantron® (Wyeth Pharma, Münster, Germany) in 70 % ethanol. A 10 mM stock 
solution of Ko143 in DMSO was a gift from Dr. A. H. Schinkel (Netherlands Cancer 
Institute). Rotenone and mitoxantrone were purchased from Sigma (Munich, Germany). 
Tariquidar and the tariquidar-like modulators were synthesized according to the literature 
(Egger et al., 2007; Hubensack, 2005). Murine serum was isolated from mature CD-1 mice 
and stored at -78 °C until usage. 
 
A.2.2 Cell lines and culture conditions 
Cells were maintained as described in section 3.2.2. 
 
A.2.3 Chemosensitivity assay 
The assays were performed as described in section 3.2.5. 
 
A.2.4 Calcein-AM efflux assay 
The assays were performed as described in section 3.2.3.1.1. 
 
A.2.5 Confocal laser-scanning microscopy 
The assays were performed as described in section 3.2.7. 
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A.3 Results and discussion 
A.3.1 Antiproliferative activity against human glioblastoma cells 
The susceptibility of the tumor to the selected cytostatic drug is a major prerequisite for the 
co-administration of anticancer agents and ABCB1 modulators in brain cancer 
chemotherapy. Consequently, in a first step the sensitivity of U-87 MG, U-118 MG and 
U-373 MG glioblastoma cells against epothilone B (Epo B) and epothilone D (Epo D) was 
investigated by means of the crystal violet chemosensitivity assay. 
A.3.1.1 Effect of permanent exposure 
The impact of permanent incubation with Epo B and D on proliferating U-87 MG and 
U-118 MG cells is presented in Figure A.3 and Figure A.4. Epo B shows cytostatic effects 
at a concentration of 0.5 nM and no cytocidal effects up to 10 nM. In the case of Epo D 
approximately 10-fold higher concentrations were required for equal drug action. 
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Figure A.3: Effect of Epo B and Epo D on proliferating U-87 MG cells (passage 180) during 
permanent incubation; vehicle (open circles); A) Epo B at different concentrations: 0.1 nM (filled 
inverted triangles), 0.5 nM (filled squares), 1 nM (filled triangles), 5 nM (filled circles) and 10 nM 
(filled diamonds); B) Epo D at different concentrations: 0.5 nM (filled inverted triangles), 1 nM (filled 
squares), 5 nM (filled triangles), 10 nM (filled circle) and 50 nM (filled diamonds) 
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Figure A.4: Effect of Epo B and Epo D on proliferating U-118 MG cells (passage 495) during 
permanent incubation; vehicle (open circles); A) Epo B at different concentrations: 0.1 nM (filled 
inverted triangles), 0.5 nM (filled squares), 1 nM (filled triangles), 5 nM (filled circles) and 10 nM 
(filled diamonds); B) Epo D at different concentrations: 0.5 nM (filled inverted triangles), 1 nM (filled 
squares), 5 nM (filled triangles), 10 nM (filled circle) and 50 nM (filled diamonds) 
When results obtained with U-373 MG cells (data not shown) are considered, the 
sensitivity of the selected glioblastoma cells against Epo B and D decreases according to 
the following order: U-373 MG cells > U-118 MG > U-87 MG. Taken together, impact on 
the growth of glioblastoma cells was already achieved at very low (sub-nanomolar to single 
digit nanomolar) concentrations. 
A.3.1.2 Effect of short-term exposure 
In order to investigate the cytotoxic activity at conditions (concerning exposure time and 
concentration) achievable in vivo, Epo B and D were removed from the culture medium 
after different exposure times. 
Figure A.5 illustrates that a concentration of 20 nM Epo B for one hour was sufficient to 
reach a cytostatic drug effect. The prolongation of the exposure period did not enhance 
activity. This indicates that an initial damage is responsible for the antiproliferative activity. 
The same correlation was observed for Epo D (at a higher concentration of 100 nM). 
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Figure A.5: Effect of Epo B and Epo D on proliferating U-118 MG cells (passage 499) during short 
term exposure; vehicle (open circles); 100 nM VBL, permanent exposure (filled inverted triangles); 
A) Epo B, 20 nM with different exposure times: 1 h (filled squares), 3 h (filled triangles), 5 h (filled 
circles) and permanent (filled diamonds); B) Epo D, 100 nM with different exposure times: 1 h (filled 
squares), 3 h (filled triangles), 5 h (filled circles) and permanent (filled diamonds) 
 
A.3.2 Influence of murine serum on stability and activity of epothilones 
The previous results showed that the investigated epothilones are active in vitro. However, 
these experiments do not consider problems such as plasma protein binding and 
enzymatic degradation. Consequently, Epo B and D were incubated in murine serum prior 
to the experiment. 
As becomes obvious from Figure A.6, pre-incubation of Epo B decreased its activity five to 
ten-fold (this effect was also observed with U-87 MG and U-373 MG cells; data not 
shown). Since the decrease in activity did not correlate with the pre-incubation period, a 
high plasma protein binding may be assumed. 
In contrast, exposure of Epo D to murine serum resulted in total loss of activity regardless 
of pre-incubation period and concentration (results confirmed by analogous experiments 
with U-87 MG and U-373 MG cells; data not shown). 
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Figure A.6: Effect of Epo B and Epo D (pre-incubated with murine serum) on proliferating 
U-118 MG cells (passage 499); vehicle (open circles), 100 nM VBL without pre-incubation period 
(filled inverted triangles); A) Epo B at different concentrations and pre-incubation periods: 2 nM and 
1 h (filled squares), 5 nM and 1 h (filled triangles), 2 nM and 3 h (filled circles), 5 nM and 3 h (filled 
diamonds); B) Epo D at different concentrations and pre-incubation periods: 5 nM and 1 h (filled 
squares), 20 nM and 1 h (filled triangles), 5 nM and 3 h (filled circles), 20 nM and 3 h (filled 
diamonds) 
The observed instability in murine serum is in agreement with hints from the literature and 
is probably caused by serum esterases (Chou et al., 2001). A lower susceptibility to murine 
enzymes is also described for Epo B (Blum et al., 2001). In all three main metabolites, the 
macrocyclic lactone ring was opened to the acid. 
 
A.3.3 Effect on quiescent U-373 MG cells 
In order to study whether the antiproliferative effect of the compounds is caused by specific 
interference during cell cycle, confluent U-373 MG glioblastoma cells were incubated with 
Epo B and D at high concentrations (see Figure A.7). Rotenone, an inhibitor of NADH 
ubiquinone oxidoreductase served as positive control for unspecific toxicity. 
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Figure A.7: Effect of Epo B and Epo D on resting U-373 MG cells (passage 240) during permanent 
incubation; vehicle (open circles), rotenone 1 µM (filled inverted triangles); A) Epo B at different 
concentrations: 5 nM (filled circles) and 50 nM (filled squares); B) Epo D at different concentrations: 
10 nM (filled circles) and 100 nM (filled squares) 
As becomes obvious from the depicted results, Epo B as well as Epo D exerted (beyond 
their specific interference during cell cycle) no additional, unspecific cytocidal effect on 
quiescent cells. 
 
A.3.4 Interactions with the ABCB1 transporter 
For the applicability in the chemotherapy of malignant brain tumors it is important that the 
cytostatic drug is no substrate of transporters expressed at the BBB (in particular ABCB1 
and ABCG2). Consequently, ABCB1 transporter (over)expressing Kb-V1 cells were 
incubated with various concentrations of Epo B and D. Additionally, cells were exposed to 
100 nM of the selective P-gp modulator ME33-1. In the investigated concentration, the 
modulator alone had no impact on the growth of Kb-V1 cells (data not shown). The results 
of the chemosensitivity assays are illustrated in Figure A.8 and Figure A.9. 
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Figure A.8: A) Effect of Epo B on proliferating Kb-V1 cells (passage 61) during permanent 
incubation; B) Epo B in combination with 100 nM ME33-1; vehicle (open circles), Epo D at different 
concentrations: 0.1 nM (filled inverted triangles), 0.5 nM (filled squares), 1 nM (filled triangles), 5 nM 
(filled circles) and 10 nM (filled diamonds) 
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Figure A.9: A) Effect of Epo D on proliferating Kb-V1 cells (passage 61) during permanent 
incubation; B) Epo D in combination with 100 nM ME33-1; vehicle (open circles), Epo D at different 
concentrations: 0.5 nM (filled inverted triangles), 1 nM (filled squares), 5 nM (filled triangles), 10 nM 
(filled circles) and 50 nM (filled diamonds) 
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The chemosensitivity of Kb-V1 cells against Epo B as well as Epo D was increased 
5 to 10 times by addition of ME33-1. These results militate in favor of a week interaction of 
the respective epothilones with the ABCB1 transporter. 
Since inhibitors of P-gp are often poorly transported substrates, Epo B and Epo D were 
further investigated by means of the calcein-AM efflux assay (see Figure A.10). 
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Figure A.10: ABCB1 inhibition by Epo B (open 
circles) and Epo D (filled circles) in dependence 
of their concentration determined with the 
calcein-AM efflux assay at the flow cytometer 
 
Indeed, Epo D showed in concentrations ≥ 10 µM inhibition of ABCB1 transporter activity. 
 
A.3.5 Interactions with the ABCG2 transporter 
For selectivity reasons, Epo B and D were also investigated (in cooperation with Matthias 
Kühnle) concerning the affinity to BCRP. By analogy to the investigations described in 
section A.3.4, ABCG2 transporter (over)expressing MCF-7/Topo cells were used. Instead 
of ME33-1 the selective BCRP modulator Ko143 was chosen for the co-incubation 
experiments. 
Figure A.11 shows that the sensitivity of MCF-7/Topo cells against Epo D was not 
increased by addition of Ko143. The results of analogous experiments with Epo B were 
identical (data not shown). In addition, no inhibition of the ABCG2 transporter at 
concentrations up to 50 µM was detected by means of the flow cytometric mitoxantrone 
efflux assay (data not shown). 
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Figure A.11: A) Effect of Epo D on proliferating MCF-7/Topo cells (passage 150) during permanent 
incubation; B) Epo D in combination with 100 nM Ko143; Vehicle (open circles), 10 nM VBL (filled 
diamonds) and Epo D at different concentrations: 0.5 nM (filled inverted triangles), 1.0 nM (filled 
squares), 5.0 nM (filled triangles) and 10 nM (filled circles) 
 
A.3.6 Effect of epothilones on the tubulin architecture of Kb-V1 cells 
Confocal laser-scanning microscopy was performed to investigate the effect of 
Epo B and D on the tubulin architecture. It can be seen from Figure A.12 that Kb-V1 cells 
incubated with Epo B or D showed no abnormalities in the morphology of the cytoskeleton. 
 
 
Control Epo B Epo D 
Figure A.12: Kb-V1 cells were incubated with 0.5 nM Epo B and 1 nM Epo D for 3 hours. The 
tubulin architecture was not visibly changed. 
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A.4 Summary 
Epo B and D inhibited the growth of different glioblastoma cells at very low (sub-nanomolar 
to single digit nanomolar) concentrations. At higher concentrations (20 nM of Epo B or 
100 nM of Epo D, respectively) even an exposure time of one hour was sufficient for 
cytostatic drug effects. 
Issues associated with plasma protein binding and enzymatic degradation were 
investigated by pre-incubation of epothilones with murine serum. These experiments 
showed that only Epo B is sufficiently stable for further in vivo studies in rodents. 
Moreover, investigations on quiescent glioblastoma cells revealed no unspecific toxicity in 
the investigated concentration range. 
Taken together, the experiments showed that Epo B and D were active against human 
glioblastoma cells under conditions mimicking the situation in vivo. In addition, the 
calcein-AM efflux assay disclosed a certain impact on ABCB1 transporters. The results 
were confirmed by co-incubation experiments with P-gp expressing cells that revealed an 
increased chemosensitivity of Kb-V1 cells when combined with an ABCB1 modulator. 
In summary, epothilone B is a candidate for further preclinical tumor-pharmacological 
studies in combination with ABCB1 modulators. 
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B Appendix 2: Development of an automated 
cryopreservation procedure for solid 
tumors 
 
B.1 Introduction 
This work focused on the development of a standardized and automated freezing 
procedure for the cryopreservation of human cancer xenografts and was done in 
collaboration with Matthias Kühnle. For further information concerning the technical 
assembly of the freezing device and other applications of the developed cryopreservation 
procedure please refer to his PhD thesis (Kühnle, 2010). Additionally, the tumorigenicity 
and the growth kinetics of re-thawed tumor tissue were investigated. 
 
B.2 Materials and methods 
B.2.1 Chemicals, culture media and technical devices 
All chemicals were purchased from Merck (Darmstadt, Germany). Eagle`s Minimum 
Essential Medium (Sigma, Deisenhofen, Germany) was supplemented with 110 mg/L 
sodium pyruvate (Serva, Heidelberg, Germany) and 2.2 g/L sodium hydrogen carbonate. A 
computer controlled rate freezer IceCube 14S from SYLAB Geräte GmbH 
(Neupurkersdorf, Austria) was used for the experiments. 
 
B.2.2 Freezing and procedure 
DMSO was added to Eagle´s Minimum Essential Medium to reach a final concentration of 
10 % and was subsequently sterile filtered into cryo-tubes (Greiner Bio-One, Fricken-
hausen, Germany). 6-10 tumor samples, generated as described in (section 5.2.9), were 
transferred into the cryo-tubes and stored on ice for transport. 
Approximately 10 minutes before microprocessor controlled freezing according to the 
previously optimized protocol, samples were taken from ice. This protocol guaranteed that 
the increase in temperature at the point of crystallization was counteracted by extensive 
and rapid cooling of the freezing chamber (see Figure B.1). Therefore, a constant cooling 
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rate of the sample was regained approximately 50 % earlier what in turn minimized tissue 
damage (due to reduced ice crystal growth and crystallization heat). 
 
Chamber 
temp. 
 
[°C] 
 Δ Temp. 
per 
minute 
[°C/min] 
 Runtime 
current 
step 
[min] 
 Runtime 
total 
 
[min] 
 
Table B.1: Parameters of 
the optimized cryopreser-
vation protocol. After 
30.4 minutes (at the 
lowest chamber tem-
perature of -70 °C) the 
crystallization was ad-
ditionally triggered by 
controlled autoseeding 
for 25 seconds. 
20.0  0  0  0  
0  -2.0  10.0  10.0  
0  0  5.0  15.0  
-14.5  -1.0  14.5  29.5  
-70.0  -59.5  0.9  30.4  
-70.0  0  0.5  30.9  
-27.0  20.0  2.2  33.1  
-22.0  2.0  2.5  35.6  
-40.0  -1.0  18.0  53.6  
-140.0  -2.0  50  103.6  
 
 
 
Figure B.1: A) Details of the temperature gradient of the optimized freezing protocol at different 
positions of the freezing chamber. The turquoise curve represents the programmed temperature 
profile whereas the blue curve shows the actual temperature of the sample in the cryo-tubes. In 
comparison to the starting protocol (with a linear cooling rate of 1 °C/min, depicted in B), the 
observed rise in temperature at the time of crystallization is considerably lower and shorter 
(approximately 50 % each). 
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After 104 minutes, the samples had reached a final, uncritical temperature of -140 °C and 
a constant cooling rate was no longer necessary. Subsequently, the cryo-tubes were 
transferred into a Dewar container for long range storing over liquid nitrogen. 
 
B.2.3 Thawing procedure and subcutaneous xenograft implantation 
Immediately before transplantation, cryopreserved tumor tissue samples were thawed 
rapidly by swiveling the cryo-tubes in 37 °C warm water. Afterwards, the samples were 
washed with sterile PBS. The subsequent tissue implantation procedure was performed as 
described in section 5.2.9. 
 
B.3 Results and discussion 
B.3.1 Effect of freezing and thawing on tumorigenicity and growth kinetics 
of Kb-V1 tumors 
After approximately 3 month of storage over liquid nitrogen, Kb-V1 tissue samples 
maintained tumorigenicity and generated solid tumors in nude mice. Growth kinetics were 
determined and compared to the growth characteristics of non-frozen control tumors of the 
respective in vivo passage (see Figure B.2). 
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Figure B.2: The in vivo growth curves of subcutaneously growing Kb-V1 tumors are depicted 
(mean values ± SEM). Growth kinetics of tumors obtained by implantation of frozen and re-thawed 
tumor pieces (filled circles) are compared to serially transplanted control tumors (open squares) 
over various passages. A) In vivo passage 1; take rate investigational group 78 %, control mice 
88 %; B) In vivo passage 2; take rate investigational group 100 %, control mice 75 %; C) In vivo 
passage 3; take rate investigational group 71 %, control mice 50 % 
Tumors originating from frozen tissue samples showed growth characteristics and take 
rates comparable to serially transplanted xenografts. In Figure B.3, a retardation of tumor 
growth in higher passages (cf. section 5.3.2.1) is obvious. 
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Figure B.3: Comparison of the growth kinetics 
(mean values ± SEM) of malignancies obtained 
by implantation of frozen and re-thawed tumor 
pieces over various in vivo passages: first (filled 
circles), second (filled squares) and third 
passage (filled triangles) 
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In summary, an automated cryopreservation protocol was established and refined. The 
optimized procedure minimizes heat-related tissue damage and enables long-term storage 
of solid tumor samples. Since further investigations with Kb-V1 tumors revealed sustained 
tumorigenicity as well as comparable growth kinetics, cryopreserved tissue samples can 
replace serial transplantation of the respective tumor. Consequently, the established 
procedures can reduce the number of animals required to establish tumor-pharmacological 
models in nude mice and will be of high benefit for future preclinical studies. 
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